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ABSTRACT
MENTAL HEALTH AND SUBSTANCE USE DISORDERS AND TREATMENT
RECEIPT AMONG PREGNANT WOMEN IN THE UNITED STATES, 2008-2014:
TREND ANALYSIS, LIKELIHOOD OF TREATMENT RECEIPT, AND ETHNIC
DISPARITIES IN MENTAL HEALTH TREATMENT
Taghreed Salameh
July 21, 2017
Pregnant women and their children are at risk for devastating health consequences
when pregnancy is associated with poor mental health and substance use problems. Yet,
most of what is known about these significant issues in pregnant women came from
clinical samples which limits the generalizability of the findings to the national
population. Therefore, the purposes of this dissertation were to examine trends from 2008
to 2014 in mental health and substance use disorders and treatment receipt, and explore
factors associated with treatment receipt in pregnant women aged 18-44 years in the
United States. This dissertations contains three manuscripts: (1) a systematic review of
trend and population-based studies on mental health and substance use disorders and
treatment receipt in pregnant women in the United States; (2) a trend study on mental
health and substance use disorders and treatment receipt among pregnant and
nonpregnant women in the United States from 2008 to 2014; and (3) a population-based
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study of factors associated with mental health and substance use treatment receipt in
pregnant women.
The review of trend studies showed that illicit drug use disorder increased in
pregnant women over the past decade, particularly opioid and marijuana use disorders.
Despite the increase in treatment admissions for these disorders from 1992 to 2012, the
overall treatment admission rate for pregnant women remained relatively stable at 4%.
Although antidepressant use increased from 1995 to 2010 in pregnant women, there is a
lack of trend studies addressing the changes in mental health disorders over the same time
period. A review of population-based studies revealed that White ethnicity, older
reproductive age, college education, and health insurance coverage are associated with
mental health and substance use treatment receipt.
In the second manuscript, trends in mental health and substance use disorders and
treatment receipt were compared across one-to-two pairs of matched groups of pregnant
(n = 5,520) and non-pregnant women (n = 11,040) who participated in the 2008-2014
National Survey on Drug Use and Health (NSDUH). There was no difference in these
trends by pregnancy status from 2008 to 2014. Yet, past-year anxiety disorder, pastmonth psychological distress, and illicit drug use disorder increased in the total sample of
pregnant and nonpregnant women from 2008 to 2014, whereas trends in mental health
treatment receipt and unmet need for substance use treatment did not change over the
same time period.
In the final manuscript, secondary analysis of the 2008-2014 NSDUH was
conducted with data from 5,520 pregnant women (1,106 with mental health problems and
521 with substance use disorders) who were 18-44 years old. The best predictors of
vii

receipt of mental health treatment included: past-year anxiety disorder, major depressive
episode, serious psychological distress, college education, health insurance coverage, and
White ethnicity. Predictors of substance use treatment receipt were: illicit drug abuse and
dependence, alcohol dependence, comorbid anxiety/depression, White ethnicity, and
urban residency. Compared to Whites, nonWhite pregnant women with major depressive
episode, serious psychological distress, substance use disorders, and/or comorbid mental
health and substance use disorders had lower odds of receiving mental health treatment.
The findings of this dissertation indicate that there is a gap between the need and
the receipt of mental health and substance use treatment in pregnant women. Improved
recognition and access to treatment for mental health and substance use disorders in this
vulnerable population is critical. Preventive and interventional strategies are required to
address the mental health needs of ethnic minority pregnant women with mental health
and/or substance use disorders.
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CHAPTER I
INTRODUCTION

Mental health and substance use disorders are significant public health issues that
have deleterious effects on the mother and her child. However, there is hope to improve
maternal mental health and promote better futures for mothers and their children. This
message of hope for women is created and advanced by researchers, policy makers,
healthcare providers, and women themselves (United States Department of Health and
Human Services [USDHHS], 2009). In response to this message of hope, the purposes of
this dissertation were to examine trends in mental health and substance use disorders and
treatment receipt, and explore factors associated with treatment receipt in pregnant
women aged 18-44 years in the United States.
This dissertation consists of an introduction, three manuscripts, and a discussion
chapter in which the findings of the three chapters are integrated. First, a systematic
review of trend and population-based studies was conducted to describe mental health
and substance use disorders and treatment receipt among pregnant women in the United
States. Second, trends from 2008 to 2014 in mental health and substance use disorders
and treatment receipt among pregnant and nonpregnant women in the United States were
examined. Third, the Behavioral Model of Health Services Use (Andersen, 1995) was
used to examine factors associated with the receipt of treatment for mental health and
substance use disorders among pregnant women in the United States.
1

Serious mental health conditions disproportionately affect women (Hasin,
Goodwin, Stinson, & Grant, 2005; Kessler, Berglund, et al., 2003) and are common
among women of childbearing age (Farr, Bitsko, Hayes, & Dietz, 2010; Ko, Farr, Dietz,
& Robbins, 2012). In the United States, up to 12.4% of pregnant women suffer from
depression (Ko et al., 2012; Le Strat, Dubertret, & Le Foll, 2011; Melville, Gavin, Guo,
Fan, & Katon, 2010; Vesga-Lopez et al., 2008), and anxiety often occurs with depression
(Bowen et al., 2014; Le Strat et al., 2011). These serious mental health conditions are
associated with substance use problems (Connelly, Hazen, Baker-Ericzen, Landsverk, &
Horwitz, 2013; Le Strat et al., 2011) and increase the risk for developing chronic
disorders such as diabetes (Farr, Hayes, Bitsko, Bansil, & Dietz, 2011).
Prenatal mental illness takes a toll on maternal-child health. Maternal
complications associated with poor mental health during pregnancy include preterm
delivery (Accortt, Cheadle, & Dunkel Schetter, 2015; Grigoriadis et al., 2013), low birth
weight (Accortt et al., 2015), and postpartum depression (Goodman, Chenausky, &
Freeman, 2014). The mother-child relationship also is negatively affected (Grigoriadis et
al., 2013; Rossen et al., 2016), and children of depressed mothers are at risk for
behavioral and cognitive disorders (Csaszar, Melichercikova, & Dubovicky, 2014;
Kingston, Tough, & Whitfield, 2012). Substance use disorders comorbid with mental
health problems (Connelly et al., 2013), and children of substance using mothers are also
at risk for mental disorders and harmful substance use, even after controlling for other
childhood experiences (Jaaskelainen, Holmila, Notkola, & Raitasalo, 2016).
The Substance Abuse and Mental Health Services Administration (SAMHSA,
2014b) reported that 5.4% of pregnant women used illicit drugs in the past month and a
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higher percentage of them (9.4%) used alcohol in 2012 and 2013. Alcohol use during
pregnancy can cause fetal alcohol syndrome (Lehikoinen, Orden, Heinonen, &
Voutilainen, 2016). Prenatal marijuana use is also associated with intrauterine growth
restriction (IUGR) (Metz & Stickrath, 2015) and may adversely affect children’s
neurodevelopment (Jaques et al., 2014). In addition, cocaine-using women are at risk for
placental abruption, preterm birth, IUGR, and impaired neurodevelopment in exposed
infants (Lambert & Bauer, 2012).
Prenatal exposure to psychotherapeutic drugs, particularly opioids, is associated
with preterm birth and Neonatal Abstinence Syndrome (NAS) (Narkowicz, Plotka,
Polkowska, Biziuk, & Namiesnik, 2013). NAS is characterized by extreme irritability,
tremors, seizures, vomiting, diarrhea, and inconsolability from drug withdrawal (Hudak
& Tan, 2012). Infants with NAS stayed in the hospital for an average of 16.9 days with a
mean hospitalization cost of $66,700 in 2012 (Patrick, Davis, Lehmann, & Cooper,
2015). Hence, prenatal substance use is an ongoing public health problem (Narkowicz et
al., 2013) representing burden to society because of costs associated with health care for
substance-exposed infants (Patrick et al., 2015) and child protective services
interventions (Ondersma, Simpson, Brestan, & Ward, 2000).
Despite ongoing medical recommendations (American College of Obstetricians
and Gynecologists [ACOG], 2015b) and state screening initiatives (Agency for
Healthcare Research and Quality, 2016), maternal depression is rarely diagnosed (Ko et
al., 2012) or treated (Glasheen, Colpe, Hoffman, & Warren, 2015; Ko et al., 2012; VesgaLopez et al., 2008); anxiety also is more often ignored than screened or studied
(Fairbrother, Janssen, Antony, Tucker, & Young, 2016; Fairbrother, Young, Janssen,
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Antony, & Tucker, 2015). Moreover, pregnant women with substance use disorders are
rarely screened and referred to treatment by health care providers (McCabe & Arndt,
2012; Terplan, Smith, Kozloski, & Pollack, 2010). Unfortunately, numerous obstacles
(e.g., stigma and cost) impede pregnant women from receiving treatment for mental
health (Ko et al., 2012) and substance use problems (Jackson & Shannon, 2012a). In
addition, there are scant drug treatment programs targeting these women (Guttmacher
Institute, 2017). This is of critical concern in the presence of health care disparities
experienced by ethnic and racial minorities of pregnant women with mental health
problems (Chang, Tabet, Elder, Kiel, & Flick, 2016).
Given the vulnerability of pregnant women and the complexity of mental health
and substance use disorders, understanding the seriousness of these disorders and the
pattern of treatment receipt among pregnant women over time is warranted. Such
information is critical for proper allocation of prevention and treatment resources
nationwide. Yet, there is a paucity of review studies that shed the light on recent trends in
mental health and substance use disorders and treatment receipt among pregnant women
in the United States. The majority of review studies focused on the screening of
depression during pregnancy or postpartum (Lancaster et al., 2010; O’Connor, Rossom,
Henninger, Groom, & Burda, 2016; Thombs et al., 2014; van der Zee-van den Berg,
Boere-Boonekamp, Haasnoot-Smallegange, & Reijneveld, 2017), while a few addressed
barriers and facilitators to depression care during pregnancy (Byatt, Levin, Ziedonis,
Simas, & Allison, 2015; Byatt, Simas, Lundquist, Johnson, & Ziedonis, 2012).
Chapter Two presents a systematic review of the literature on mental health and
substance use disorders and treatment receipt among pregnant women in the United
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States. The purpose of this review was to synthesize findings of trend and populationbased studies on mental health and substance use disorders and treatment receipt among
pregnant women in the United States. Trend and population-based studies were selected
for this systematic review to inform policy makers, healthcare providers, researchers, and
others about the seriousness of maternal mental health and substance use disorders and
what factors influencing access to treatment among pregnant women. The hope is to
inspire future research and spur a change in maternal mental health through developing
preventive and intervention strategies.
The passage of the Mental Health Parity and Addiction Equity Act (MHPAEA)
(2008) and the Patient Protection and Affordable Care Act (PPACA) (2010) indicates
major implications to enhance women’s access to health care such as health coverage
expansion and integrating mental health and substance use treatment services with
primary medical care. However, there is limited literature addressing recent trends in
mental health and substance use disorders and receipt of treatment in the United States
(Mojtabai & Jorm, 2015), particularly among pregnant women. It is crucial to examine
the difference in these patterns between pregnant and nonpregnant women. Such
information will help in designing unique preventive strategies and program interventions
according to the specific needs of pregnant women.
Chapter Three presents a trend study of mental health and substance use disorders
and treatment receipt among pregnant and nonpregnant women in the United States.
Secondary analysis of the 2008-2014 National Survey on Drug Use and Health (NSDUH)
was conducted to compare trends in mental health and substance use disorders and
treatment receipt by pregnancy status. One-to-two pairs of pregnant (n = 5,520) and non-
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pregnant women (n = 11,040) were matched using propensity score matching. Pregnancy
status was regressed onto age, ethnicity, marital status, education level, employment
status, income, health insurance, and county urbanicity. A series of logistic regression
models was conducted to examine potential interactions between pregnancy status and
time in predicting: past-year major depressive episode (MDE); anxiety disorder; pastmonth serious psychological distress; past-year any mental illness; past-year alcohol use
disorder; illicit drug use disorder; mental health treatment receipt; and unmet need in the
receipt of substance use treatment. This study also compared trends in mental health
treatment receipt by pregnancy status among women with past-year any mental illness.
Furthermore, barriers to mental health and substance use treatment were compared
among women of childbearing age across two time periods, 2008-2010 and 2011-2014.
Although prenatal mental health has been given little attention compared to
postpartum depression, most of what is known is about factors associated with poor
mental health during pregnancy (Fairbrother et al., 2016; Fairbrother et al., 2015; Le Strat
et al., 2011; Vesga-Lopez et al., 2008) rather than factors related to mental health
treatment receipt. Likewise, there is sparse evidence about factors associated with the
receipt of substance use treatment among pregnant women. In Chapter Four, the
Behavioral Model of Health Services Use (Andersen, 1995) was used to examine factors
associated with mental health and substance use treatment among pregnant women with
mental health and substance use disorders in the United States. This model was chosen
because it integrates individual and contextual determinants of health services use: (a)
predisposing characteristics (e.g., ethnicity); (b) enabling factors (e.g., health insurance
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coverage); and (c) need factors (e.g., MDE, substance use disorders, and perceived need
for treatment).
Secondary analysis of the 2008-2014 NSDUH was conducted. A sample of 1,106
pregnant women with mental health problems (i.e., past-year MDE, anxiety disorder, or
serious psychological distress) and 521 pregnant women with substance use disorders
(i.e., alcohol use disorder or illicit drug use disorder) were included in this study. A series
of logistic regression models was used to identify predictors of mental health/substance
use treatment receipt as well as ethnic disparities in the receipt of mental health treatment
among pregnant women with mental health and/or substance use disorders. In addition,
barriers to mental health treatment were compared and contrasted across types of mental
health and/or substance use disorders and ethnicity.
Finally, Chapter Five is an integration of the findings of Chapters Two, Three,
and Four. Research, practice, and policy implications generated from the three
manuscripts were summarized and discussed.
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CHAPTER II
MENTAL HEALTH AND SUBSTANCE USE DISORDERS AND TREATMENT
RECEIPT AMONG PREGNANT WOMEN IN THE UNITED STATES: A
SYSTEMATIC REVIEW OF TREND AND POPULATION-BASED STUDIES
Introduction
Mental health problems affect 8.2% to 13.0% of pregnant women (Cook et al.,
2010; Le Strat, Dubertret, & Le Foll, 2011, 2011; Vesga-Lopez et al., 2008) and have
devastating health consequences on the mother and her child (Csaszar, Melichercikova,
& Dubovicky, 2014; Goodman, Chenausky, & Freeman, 2014; Grigoriadis et al., 2013;
Rossen et al., 2016). Prenatal substance use is common among pregnant women with
mental health issues (Connelly, Hazen, Baker-Ericzen, Landsverk, & Horwitz, 2013) and
represents a perennial public health concern (Narkowicz, Plotka, Polkowska, Biziuk, &
Namiesnik, 2013). In 2012 and 2013, 5.4% of pregnant women reported past-month use
of illicit drugs and 9.4% of them drank alcohol (Substance Abuse and Mental Health
Services Administration [SAMHSA], 2014b).
Alcohol consumed during pregnancy is associated with fetal alcohol syndrome
(Lehikoinen, Orden, Heinonen, & Voutilainen, 2016) and low birth weight (Irner,
Teasdale, Nielsen, Vedal, & Olofsson, 2012). Prenatal illicit drug use is associated with
medical and obstetric complications (Lambert & Bauer, 2012; Metz & Stickrath, 2015),
impaired neurodevelopment in prenatally exposed infants (Jaques et al., 2014), and costs
related to their prolonged hospitalization (Patrick, Davis, Lehmann, & Cooper, 2015),
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and child protective services (Ondersma, Simpson, Brestan, & Ward, 2000). Yet, mental
health and substance use disorders continue to be unrecognized and undertreated in
pregnant women (Connelly et al., 2013; Glasheen, Colpe, Hoffman, & Warren, 2015; Ko,
Farr, Dietz, & Robbins, 2012; Vesga-Lopez et al., 2008), irrespective of ongoing
screening initiatives (Agency for Healthcare Research and Quality, 2016), legislation
(Mental Health Parity and Addiction Equity Act [MHPAEA], 2008; Patient Protection
and Affordable Care Act [PPACA], 2010), and available effective treatment modalities
(Baker et al., 2010; Marais et al., 2011; May et al., 2013; Meyer, Johnston, Crocker, &
Heil, 2015).
Although pregnancy represents an ideal time to screen and intervene with
substance and mental health issues (Connelly et al., 2013), pregnant women face
numerous obstacles to access mental health and substance use treatment (United States
Department of Health and Human Services [USDHHS], 2009; Center for Substance
Abuse Treatment [CSAT], 2009). Proper distribution of prevention and treatment
resources requires an understanding of the significance of mental health and substance
use disorders during pregnancy nationwide. Hence, a review of trend studies on mental
health and substance use problems and treatment receipt among pregnant women in the
United States is warranted to understand the changes in these disorders over time.
Prior and recent review studies focused on clinical studies addressing screening of
depression in pregnant or postpartum women (Lancaster et al., 2010; O’Connor, Rossom,
Henninger, Groom, & Burda, 2016; Thombs et al., 2014; van der Zee-van den Berg,
Boere-Boonekamp, Haasnoot-Smallegange, & Reijneveld, 2017). Two recent systematic
reviews focused on studies addressing barriers and facilitators to depression care during

9

pregnancy (Byatt, Levin, Ziedonis, Simas, & Allison, 2015; Byatt, Simas, Lundquist,
Johnson, & Ziedonis, 2012). To our knowledge, no prior review studies examined factors
related to mental health and substance use treatment receipt among pregnant women from
trend and population-based studies in the United States. Understanding these factors from
population-based samples rather than clinical samples is important to inform health
policy so that strategies can be implemented to improve access to mental health and
substance use treatment. Therefore, the purpose of this systematic review was to
synthesize findings from trend and population-based studies to describe mental health
and substance use disorders and treatment receipt in pregnant women of childbearing age
in the United States.
Method
This review was performed using the Preferred Reporting Items Systematic
Review and Meta-analysis (PRISMA) guidelines (Moher, Liberati, Tetzlaff, & Altman,
2009). To decrease the risk of bias (Riesenberg & Justice, 2014), three databases were
searched: CINAHL, PubMed, and PsychINFO. The search strategy was developed and
vetted by a master’s prepared medical librarian. The search terms used in this review
included subject headings and MeSH terms according to the requirements of each
database (see Table 1).
Only peer-reviewed research articles published between 2007 and 2017 were
included. Eligible studies were limited to population-based and trend studies on mental
health or substance use disorders or treatment receipt for these disorders in pregnant
women published in the last 10 years. The search was limited to English language
publications, human subjects, and adults aged 18 years and older. This review was
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limited to trend studies addressing mental health or substance use disorders or treatment
receipt over time among pregnant women in the United States. If multiple trend studies
used overlapping data sources or time points, the most recent study that reported national
estimates was included. Studies that examined trends over less than five years and those
that did not specifically address substance abuse or dependence during pregnancy were
excluded from the review.
This review also focused on population-based studies of treatment receipt for
mental health and substance use disorders. Population-based studies were included if they
reported national/statewide data on mental health or substance use disorders or treatment
receipt irrespective of the study design. Hence, population-based studies of randomly
selected participants as well as population-based prospective/retrospective cohort studies
were included in this review. Large national surveys comparing pregnant and
nonpregnant women in regards treatment receipt for mental health and substance use
disorders were also included.
Data Extraction and Analysis
All primary studies were retrieved through the selected databases and screened for
the eligibility based on the inclusion criteria. The references in each database were
screened for duplication. Then the references list was compared between databases to
eliminate duplicate articles. Next, the titles and abstracts were reviewed to identify
articles that met the inclusion criteria. If this was not clear, the full text was reviewed.
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Results
Study Selection
The initial search resulted in 1,620 articles that were further screened for
duplication. Eliminating the duplicating articles within and between databases resulted in
1,209 articles. After removing articles with obviously irrelevant titles, a total of 450
articles were reviewed at the abstract level. Of these, 402 articles were eliminated due to
lack of relevance to the present review. In addition, full text review resulted in
eliminating another 22 articles. After screening based on the inclusion criteria, 26
research articles were included in the final review. Two additional articles identified from
a review of reference lists of the selected articles were included (see Figure 1).
Trends in Mental Health and Substance Use Disorders and Treatment Receipt
Table 2 shows the characteristics of nine trend studies addressing changes in
mental health and substance use disorders and treatment receipt in pregnant women over
time. Among these studies, three studies addressed trends in antidepressant use during
pregnancy (Andrade et al., 2008; Bobo et al., 2014; Meunier, Bennett, & Coco, 2013),
and only one study focused on examining trends in psychotropic medications (Hanley &
Mintzes, 2014). Overall, these studies showed an increase in antidepressant use during
pregnancy from 1995 to 2010 (Andrade et al., 2008; Bobo et al., 2014; Meunier et al.,
2013). However, one study showed an inconsistent trend in antidepressant use as it
increased from 1995 to 2004 then declined in 2007 (Bobo et al., 2014). Hanley and
Mintzes (2014) found that the rate of psychotropic medication use was relatively stable
between 2006 and 2011, while antidepressant use decreased slightly between 2010 and
2011. No trend studies were found that addressed patterns of mental health treatment
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receipt other than prescription medications over time as well as there is a lack of trend
studies that examined changes of mental health problems in pregnant women over time.
Among trend studies addressing substance use disorders and treatment among
pregnant women, one study examined trends in maternal abuse of various substances
(Pan & Yi, 2013) and another one focused on opioid dependence or abuse during
pregnancy (Maeda, Bateman, Clancy, Creanga, & Leffert, 2014). Three studies addressed
trends in treatment admission for different types of substances using the Treatment
Episode Data Set (TEDS) (Martin, Longinaker, Mark, Chisolm, & Terplan, 2015; Martin,
Longinaker, & Terplan, 2015; McCabe & Arndt, 2012).
Based on the 1999-2008 Nationwide Inpatient Sample dataset, Pan and Yi (2013)
reported an increase in opioid, cannabis and hallucinogens, and methamphetamine abuse
during pregnancy over time. However, cocaine abuse declined significantly while alcohol
abuse decreased slightly. From 1998 to 2011, the prevalence of opioid use disorders
increased from 0.17% to 0.39% among pregnant women (Maeda et al., 2014).
Studies of trends in substance use treatment showed an increase in admission rates
for drug abuse whereas a decrease in alcohol-related abuse admissions occurred from
1998 to 2008 (McCabe & Arndt, 2012). From 1992 to 2012, the rate of treatment
admissions for marijuana as a primary substance of use increased; however, treatment
admission for cocaine and alcohol use decreased over the same time period (Martin,
Longinaker, Mark, et al., 2015). One study focused specifically on opioid use treatment
and showed an increase in admission rate from 1% in 1992 to 19% in 2012 (Martin,
Longinaker, & Terplan, 2015).
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Mental Health and Substance Use Treatment Receipt
Table 3 shows the characteristics of 19 population-based studies addressing
mental health and substance use treatment receipt among pregnant women in the United
States. Among these studies, 11 studies addressed mental health treatment receipt, three
studies addressed substance use treatment receipt, one study focused on mental health
treatment receipt in substance use treatment setting, and four studies discussed barriers to
mental health treatment.
The rate of mental health treatment receipt ranged from 6.3% to 49.6% among
pregnant women (Byatt, Xiao, Dinh, & Waring, 2016; Chang, Tabet, Elder, Kiel, &
Flick, 2016; Cook et al., 2010; Glasheen et al., 2015; Ko et al., 2012; Le Strat et al.,
2011; Roberson et al., 2016). Four studies focused specifically on estimating the rate of
antidepressant use and indicated that 2.2% to 27% of pregnant women used
antidepressant during prenatal period (Bennett, Marcus, Palmer, & Coyne, 2010; Geier,
Hills, Gonzales, Tum, & Finley, 2015; Wu & Davis-Ajami, 2014; Yamamoto,
McCormick, & Burris, 2015). Two studies addressed pharmacotherapy for mental health
problems in pregnant women; 1.4% of women used anxiolytic or antidepressant
medications (Roberson et al., 2016), whereas 39.6% of women used prescription
medications for any emotion, nerve, or mental health problems (Ko et al., 2012). Ko et al.
(2012) also reported that 7.2% of pregnant women required inpatient treatment for any
mental health problem.
Data based on two national survey studies showed that pregnant women are less
likely to receive mental health treatment compared to nonpregnant women even after
adjusting for confounding variables (Glasheen et al., 2015; Vesga-Lopez et al., 2008).
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However, two other national surveys did not show any difference between pregnant and
nonpregnant women in the receipt of mental health treatment (Ko et al., 2012; Le Strat et
al., 2011). Yet, a cohort study based on California State Medicaid program 2006-2009
showed that pregnant women had a lower odds of depression diagnosis or treatment
(Geier et al., 2015). Three studies reported the adjusted association between pregnancy
status and mental health receipt without highlighting the contribution of other sociodemographic characteristics (Ko et al., 2012; Le Strat et al., 2011; Vesga-Lopez et al.,
2008). Yet, Glasheen et al. (2015) found that mental health treatment receipt among
women of childbearing age was related to White ethnicity, older reproductive age,
college education, having a history of depression or anxiety. Likewise, Geier et al. (2015)
reported that White ethnicity, age of 25 years or older, and urban residence were
associated with depression treatment.
Of studies conducted solely among pregnant women, factors associated with
mental health treatment receipt included White ethnicity (Bennett et al., 2010; Byatt et
al., 2016; Chang et al., 2016), older reproductive age, college education, marital status,
tobacco use, physical or psychological abuse (Chang et al., 2016), having
assistance/insurance coverage (Bennett et al., 2010; Chang et al., 2016), having a current
(Byatt et al., 2016) or past mental health problem (Roberson et al., 2016), and urban
residency (Cook et al., 2010). Among these studies, there was only one study conducted
among a nationally representative sample of pregnant women (Byatt et al., 2016).
Three studies explicitly addressed ethnic care disparities among pregnant women.
A study based on the Florida Healthy Start prenatal screening program indicated that the
rate of life-time mental health treatment receipt was highest among White pregnant
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women, while the rate was lowest among Mexicans and other Hispanics (Chang et al.,
2016). Another study based on the 2006-2010 National Ambulatory Medical Care Survey
and the National Hospital Ambulatory Medical Care Survey revealed that nonWhite
pregnant women had lower odds of antidepressant use even after controlling for maternal
age, insurance type, region of the country, and survey type (Yamamoto et al., 2015).
Interestingly, Coleman-Cowger (2012) examined disparities in mental health treatment
based on the 2008 Global Appraisal of Individual Needs Data among past-year pregnant
women who entered substance use treatment. This study showed that higher proportions
of Hispanics and African Americans had not received mental health treatment compared
to Mixed or White women.
Four studies addressed barriers to mental health treatment among pregnant
women. One compared barriers to mental health treatment between pregnant and
nonpregnant women using the 2005-2009 National Survey on Drug Use and Health
(NSDUH) (Ko et al., 2012). The most common barriers were cost, opposition to
treatment, stigma, time/transportation limitation, and not knowing where to go. These
perceived barriers did not differ by pregnancy status. Two studies examined factors
associated with provider-patient conversation regarding depression based on state (Liu &
Tronick, 2012) and national-level data (Farr, Ko, Burley, & Gupta, 2016). These factors
included age of less than 35 years (versus > 35 years), Medicaid coverage, White
ethnicity (Farr et al., 2016; Liu & Tronick, 2012), and being unmarried (Farr et al., 2016).
In addition, non-US born pregnant women and those who visited a private doctor had
lower odds of having a conversation about depressed mood with health care providers
(Liu & Tronick, 2012). From the healthcare providers’ perception, the 2008-2009

16

Virginia Department of Health Data showed that common barriers to treatment/referrals
of pregnant women with depression included the lack of time, available treatment
services, reimbursement, and provider knowledge/skills (Price, Corder-Mabe, & Austin,
2012).
Three studies addressed substance use treatment receipt. A study based on the
2002-2006 NSDUH indicated that less than 20% of women of childbearing age with
substance use disorders received substance use treatment; however, pregnant women did
not have a lower odds of receipt of substance use treatment compared to nonpregnant
women (Terplan, McNamara, & Chisolm, 2012). Yet, women of childbearing age who
were employed, aged 21-25 (versus less than 20 years), had high school education or
equivalent, and those who did not have governmental assistance had a lower odds of
substance use treatment receipt compared to their counterpart group. A population-based
study in Massachusetts 2003–2007 showed that pregnant women who received substance
use treatment were more likely to be age of 30 or older, have some college education, be
married, and have private insurance and fewer health or psychiatric conditions, and less
likely to be Black or Hispanic compared to those who did not receive treatment
(Kotelchuck et al., 2017).
A study based on the 2013 TEDS compared characteristics of pregnant women
who received treatment for opioid use disorder by United States census regions (Hand,
Short, & Abatemarco, 2017). Compared to the South, pregnant women who received
substance use treatment in other regions were more likely to be admitted to medication
assisted treatment, and use heroin and injection drugs. Pregnant women with opioid use
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disorder in the South were less likely to have health insurance coverage, have more than a
high school education level, and be married.
Discussion
Trend Studies on Mental Health and Substance Use Disorder and Treatment
Receipt
The findings of this review demonstrated an increase from 1995 to 2010 in
antidepressant use during pregnancy (Andrade et al., 2008; Bobo et al., 2014; Meunier et
al., 2013). Although antidepressants were the most common psychotropic medications
used among pregnant women, the rate of psychotropic medication use from 2006 to 2011
was stable and antidepressant use slightly decreased between 2010 and 2011 (Hanley &
Mintzes, 2014). Although this suggests a shift in antidepressant use, a careful
interpretation of the pattern of antidepressant use across studies is required. For instance,
Hanley and Mintzes (2014) used a large private insurance claims database, the Truven
Health Market Scan Database, to examine trends in psychotropic medications and this
limits the generalizability of trend findings to women covered by Medicaid. The only
trend study that used a nationally representative sample of women in prenatal care
showed an increase in antidepressant use from 2002 to 2010 (Meunier et al., 2013). Yet,
trend studies of antidepressant use did not report medication use disparities among
pregnant women over time. In addition, this review did not find any trend studies that
specifically examined changes in mental health problems among pregnant women over
time.
Changes in the type of substance use disorders among pregnant women over the
past decade were revealed in this review. Findings from the 1999-2008 Nationwide
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Inpatient Sample dataset showed an increase in opioid, cannabis and hallucinogens, and
methamphetamine related disorders over time, and a decrease in cocaine and alcohol use
disorders among pregnant women (Pan & Yi, 2013). The highest increase in substance
use issues was for cannabis and opioids. Congruently, marijuana was the most common
illicit drug used in the United States among adults aged 12 or older (SAMHSA, 2014b).
The rate of prenatal opioid use disorder also corresponds with the epidemic increase in
opioid abuse among the general population (Centers for Disease Control and Prevention
[CDC], 2013).
The decrease in cocaine use disorder among pregnant women can be related to the
increase in public awareness regarding the cocaine effects (United States Department of
Justice, National Drug Intelligence center, 2011). However, the slight decrease in the
national estimate of alcohol use disorder in pregnant women should be reviewed with the
consideration that pregnant women may continue to consume low to moderate levels of
alcohol that cannot be classified as alcohol use disorder (Pan & Yi, 2013). Yet, the
overall decrease in alcohol use disorder can be due to the tremendous efforts in publically
informing pregnant women about the risks of alcohol consumption on the mother and her
infant (McCabe & Arndt, 2012).
Notably, there were very few trend studies on national estimates of maternal
substance use disorders, and no studies addressed recent trends of these disorders. Yet,
ongoing trend studies show an epidemic increase in Neonatal Abstinence Syndrome
(NAS) in the United States (Patrick, Davis, Lehman, & Cooper, 2012; Patrick et al.,
2015; Tolia et al., 2015), reflecting an increase in maternal substance use issues,
especially opioids. Tolia et al. (2015) reported an increase in Neonatal Intensives Care
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Unit (NICU) admissions for infants with NAS in the United States from seven cases per
1,000 admissions in 2004 to 27 cases per 1,000 admissions in 2013. Opioid pain relievers
were the most commonly used medications among pregnant women from 2012 through
2013.
Interestingly, this review revealed that trends in substance use treatment
admissions are congruent with the trends in substance use disorders. McCabe and Arndt
(2012) reported an increase in drug abuse admissions and a decrease in alcohol abuse
admissions from 1998 to 2008. Other studies based on the 1992-2012 TEDS also showed
an increase in treatment admissions for marijuana, methamphetamine, and opioids, and in
contrast, a decrease in treatment admissions for cocaine and alcohol (Martin, Longinaker,
Mark, et al., 2015; Martin, Longinaker, & Terplan, 2015). Although these patterns are
promising, a majority of pregnant women with substance use disorders do not receive
treatment (Terplan et al., 2012), and their rate of admission for substance use treatment
remained relatively stable at 4% from 1992 to 2012 (Martin, Longinaker, Mark, et al.,
2015). Pregnant women continue to face obstacles to access treatment such as the lack of
availability of treatment programs and stigma (CSAT, 2009). Hence, understanding the
characteristics of women who received treatment over time can also help to identify
disparities and tailor intervention strategies to enhance treatment utilization.
This review indicated that admissions for substance use treatment among pregnant
women who were younger (Martin, Longinaker, Mark, et al., 2015; McCabe & Arndt,
2012), White, had comorbid psychiatric illness (Martin, Longinaker, Mark, et al., 2015;
Martin, Longinaker, & Terplan, 2015), and live in the South (Martin, Longinaker, &
Terplan, 2015) increased over time. Unfortunately, the majority of admission referrals of
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these women have been continued to be through criminal justice systems from 1992 to
2012 (Martin, Longinaker, Mark, et al., 2015; Martin, Longinaker, & Terplan, 2015;
McCabe & Arndt, 2012), suggesting that most health care providers did not screen
women for substance use issues during prenatal care (McCabe & Arndt, 2012). This
review included only trend studies of substance use treatment admission based on the
TEDS which draws data from publically funded facilities in the United States
(SAMHSA, Center for Behavioral Health Statistics and Quality [CBHSQ], 2017); this
may bias the trend findings, as private funded facilities are excluded. In addition, TEDS
does not distinguish new admissions from readmissions which may also affect the
estimation of the rate of treatment receipt for each individual.
Population-based Studies on Mental Health and Substance Use Treatment Receipt
This review of findings from national surveys revealed mixed results regarding
the association between pregnancy status and the receipt of mental health treatment. This
may be due to the heterogeneity of the samples and measures of mental health problems.
For instance, studies based on National Epidemiologic Survey on Alcohol and Related
Conditions (NESARC) measured psychiatric disorders using structured clinical
interviews. Based on this dataset, Vesga-lopez et al. (2008) studied women with any
psychiatric disorder while Le Start et al. (2011) only included women with major
depression. On the other hand, the NSDUH measured mental health problems using selfreport questions operationalizing the Diagnostic and Statistical Manual of Mental
Disorders: DSM-IV (American Psychiatric Association [APA], 1994) and included the
Kessler Distress Scale (Kessler, Barker, et al., 2003). Glasheen et al. (2015) studied
women of childbearing age with past-month psychological distress using data from the
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NSDUH, while Ko et al. (2012) included women with past-year major depressive
episode.
Overall, a majority of pregnant women who need mental health and substance use
treatment do not receive it which has critical implications. First, there is a need to focus
on socio-economically disadvantaged women and to increase health insurance coverage
to improve treatment receipt. Further intervention strategies are also required to help
rural, younger, and low educated women access mental health treatment. However, very
few population-based studies identified factors associated with treatment receipt among a
nationally representative sample of pregnant women.
Second, ethnic health care disparities in the receipt of mental health treatment still
exist among pregnant women and even extend to those with substance use disorders. This
finding is congruent with the presence of healthcare disparities among the general
population (Snowden, 2012). Disparities in antidepressant use are also of particular
concern, especially since the rate of antidepressant use is lower than rate of counseling
among pregnant women (Ko et al., 2012). Both the American Psychiatric Association
(APA) and American College of Obstetricians and Gynecologists (ACOG) recommend
antidepressant use during pregnancy if the benefits to the mother with possible risks to
the fetus and newborn are balanced (Yonkers et al., 2009). Yet, there is a lack of
nationally representative studies on disparities in mental health treatment receipt among
pregnant women.
Third, barriers to mental health treatment receipt are complex and involve patientlevel obstacles (i.e., opposition to treatment and stigma), logistic barriers (i.e., cost and
lack of time/transportation), and provider-level barriers (i.e., patient-provider
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communication, providers’ competency in treatment/referrals, and inadequate available
services). These findings are congruent with a systematic review of 49 studies on barriers
and facilitators to perinatal depression treatment (Byatt et al., 2015).
Fourth, although one study based on the NSDUH did not find a difference
between pregnant and nonpregnant women in substance use treatment receipt, trend
findings based on the TEDS showed that the rate of treatment admissions among
pregnant females was stable from 1992 to 2012 at only 4% (Martin, Longinaker, Mark, et
al., 2015). Notably, there is a paucity of studies that specifically differentiate the
characteristics of pregnant substance use treatment recipients and nonrecipients. Yet, this
review suggested that health insurance coverage is necessary to increase treatment
receipt. Further intervention strategies are also warranted to increase access to substance
use treatment among ethnic minority pregnant women and other vulnerable segments
including those with a low education level.
Fifth, there was no population-based study that specifically addressed barriers to
substance use treatment among pregnant women. However, using data from the 2013
TEDS, Hand et al. (2017) reported that pregnant women in the South who have opioid
use disorder are less likely to receive medication assisted treatment compared to pregnant
women in other regions. In addition, the proportion of pregnant women who received
medication assisted treatment declined nationally from 44% in 1992 to 37% in 2012
(Martin, Longinaker, & Terplan, 2015). This may be due to a lack of health insurance
coverage and available treatment services (Hand et al., 2017).
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Limitations
There are some limitations to this systematic review. Unpublished studies (e.g.,
dissertations) and articles of studies solely conducted among pregnant women under age
18 years were not included in this review. This review included population-based studies
and trend studies on mental health and substance use disorders among pregnant women
and was not a meta-analysis; therefore, the effect sizes of the various studies were not
calculated and compared. There is a lack of trend studies on mental health problems
among pregnant women, and there is a paucity of nationally representative studies on
recent trends in substance use disorders among pregnant women in the United States.
Hence, a clear conclusion regarding the trend in these disorders cannot be drawn.
Relatively few studies examined trends in antidepressant use among pregnant
women, and no studies were found in which trends in the receipt of any treatment
modalities (i.e., prescription medications, outpatient counseling, or inpatient treatment)
were examined. All studies included in this review reported trends in substance use
treatment receipt based on the TEDS which limits the true estimation of treatment receipt
among pregnant women as privately funded treatments were not included. The paucity of
studies conducted among nationally representative samples of pregnant women limits any
conclusions regarding barriers to and factors influencing the receipt of mental health and
substance use treatment in the United States. Finally, studies in this review were
restricted to population-based and trend studies in the United States and may not be
representative of mental health and substance use disorders and treatment receipt among
pregnant women globally.
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Conclusions
This review indicates that the rates of antidepressant use have increased from
1995 to 2010 among pregnant women in the United States. However, there was no study
that examined trend in the receipt of any mental health treatment over time among
pregnant women. Overall, illicit drug use has increased while alcohol use disorder
decreased over the past decade among pregnant women. Marijuana and prescription
opioid use disorders are ongoing public health concerns in pregnant women. Despite the
increase in treatment admissions for these disorders from 1992 to 2012, the overall
admission rate for pregnant women remained relatively stable at 4%.
There is a critical need for innovative preventive interventions for mental health
and substance use disorders, especially for vulnerable pregnant women including ethnic
minorities and those with a low education level. There is a need for policies and treatment
programs to increase access to health insurance and utilization of mental health and
substance use treatment services among pregnant women. Further research is needed to
address ethnic care disparities, barriers to, and factors associated with treatment receipt
among a nationally representative sample of pregnant women. Future systematic reviews
need to include studies from different countries to compare trend data and findings
regarding factors associated with treatment receipt for mental health and substance use
disorders across various health systems.
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Table 1
Search Terms Addressing Mental Health and Substance Use Disorders in Pregnant
Women in the United Stated in Three Databases
Database
CINAHL

Search Terms
(MH "Depression") OR (MH "Anxiety") OR (MH "Symptom
Distress") OR (MH "Substance Use Disorders") OR (MH
"Substance Abuse") OR (MH "Alcohol-Related Disorders")
OR (MH "Inhalant Abuse") OR (MH "Substance Abuse,
Intravenous") OR (MH "Substance Abuse, Perinatal") OR (MH
"Substance Dependence") AND (MH "Pregnancy") AND (MH
"United States+")

PubMed

(((((((((((("Depression"[Mesh] OR "Depressive
Disorder"[Mesh])) OR ("Anxiety"[Mesh] OR "Anxiety
Disorders"[Mesh])) OR "Alcoholism"[Mesh]) OR "Binge
Drinking"[Mesh]) OR "Amphetamine-Related
Disorders"[Mesh]) OR "Cocaine-Related Disorders"[Mesh])
OR "Marijuana Abuse"[Mesh]) OR "Opioid-Related
Disorders"[Mesh])) AND (("Pregnant Women"[Mesh]) OR
"Pregnancy"[Mesh]))) AND "United States"[Mesh]

PsychInfo

((DE "Pregnancy") AND ((DE "Major Depression" OR DE
"Depression (Emotion)") OR (DE "Anxiety" OR DE "Anxiety
Disorders") OR (DE "Distress") OR (DE "Drug Dependency")
OR (DE "Alcoholism") OR (DE "Drug Abuse") OR (DE
"Alcohol Abuse") OR (DE "Substance Use Disorder"))) AND
(United States OR US OR U.S OR USA)
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Table 2
Trend Studies on Mental Health and Substance Use Disorders and Treatment Receipt in Pregnant Women of Childbearing Age in
the United States, 2008-2017
Authors,
Year
Andrade et
al., 2008

Purpose
Examine the
prevalence of
antidepressant drugs
use among pregnant
women in the United
States

Data source, Sample
 Health Maintenance
Organization Research
Network Center for
Education and
Research on
Therapeutics, 20012005
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Findings
Rates of antidepressant drug
use increased from 2.0% in
1996 to 7.6% in 2004 and
2005

Comments
 Seven health plans were
included across the United
States
 No description of women’s
characteristics

Rates per 1,000 increased
steadily from 1995 (66.0) to
2001 (182.8), sharply
increased from 2002 (290.8)
to 2004 (397.6), then
declined post-warning
release to 195.4 in 2007

Antidepressant users tended
to be mostly: Caucasian,
married, rural residents,
smokers, and with substance
abuse diagnoses and medical
comorbidity

 n = 118,935 deliveries
(2001-2005)
 n = 148,107 deliveries
(1996-2000)
Bobo et al.,
2014

Examine if the
 Tennessee Medicaid,
antidepressant
1995–2007
prescription declined
 N = 228,876 singleton
in pregnant women
pregnancies among
after the
women
announcement of the
U.S. and Canadian
advisory warning
about the risks of
antidepressant in 2004

Authors,
Year
Hanley &
Mintzes,
2014

Data source, Sample
 Truven Health Market
Scan database, 20062011

Examine trends in
opioid abuse or
dependence during
pregnancy in the
United Stated from
1998 to 2011
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Purpose
Examine the rate of
psychotropic
medication use during
pregnancy from 2006
to 2011

Maeda,
Batema,
Clancy,
Creanga, &
Leffert,
2014

 N = 343,299 women
who had a live birth

Findings
 The rate of psychotropic
medicines use was
relatively stable between
2006 and 2011(10.3%).
 A slight decrease in
antidepressant use between
2010 (6.7%) and
2011(6.4%)
 The use of stimulants
increased from 0.4% in
2007 to 0.9% in 2011.

Comments
 The most common types:
antidepressants (6.5%),
anxiolytics (4.2%),
antipsychotics (1.1%) and
stimulants (0.6%).
 Rates of use of
psychotropic medicines
were higher before
pregnancy than in first and
second pregnancy
trimesters

 Nationwide Inpatient
Sample of the
Healthcare Cost and
Utilization Project,
1998-2011

The prevalence of opioid use
disorder during pregnancy
increased from 1.7 per 1,000
delivery admissions in 1998
to 3.9 per 1,000 in 2011

The most significant increase
in opioid use disorder (from
1.8 per 1,000 delivery
admissions in 1998 to 4.5 per
1,000 deliveries in 2011)
occurred within the age
group of 20 to 34 years

 N = 56,900,512
delivery admissions

Authors,
Year
Martin,
Longinaker,
Mark,
Chisolm, &
Terplan,
2015

Purpose
Examine recent
trends in substance
use treatment
admissions of
pregnant women for
marijuana use
in the United States

Data source, Sample

Examine recent trends
in substance abuse
treatment admissions
of pregnant women
for prescription
opioids

 Treatment Episodes
Data Set, 1992-2012

Findings

Comments

 Treatment Episodes
Data Set, 1992-2012

 The rate of admissions
 The rate of treatment
for marijuana increased
admissions of pregnant
from 6% to 20% The rate of
women stayed stable at 4%
 N = 420,665 substance admission for other primary  Rates of admissions of
substance of use: Decreased
abuse treatment
whites and those with
for cocaine (40% to 6%)
admissions of
comorbid psychiatric
and alcohol (28% to 12%);
pregnant women
illness increased overtime
Increased for methamphet-  Rates of admissions of
amines (4% to 13%), heroin
non–high school graduates,
(4% to 9%), and opioids
homeless and married
(<1% to 11% )
women decreased over time

29
Martin,
Longinaker,
& Terplan,
2015

 The rate reporting any
prescription opioid abuse
increased from 2% in 1992
to 28% in 2012
 N = 420,665 substance
abuse treatment
 The rate opioids use as the
admissions of
primary substance of abuse
pregnant women
increased from 1% to 19%

 The rate of admissions
increased overtime among:
whites, those aged 21-29
years, with comorbid
psychiatric illness, and live
in the South
 Criminal justice referrals
increased from 11% to 17%

Authors,
Year
McCabe &
Arndt, 2012

Purpose

Data source, Sample

To examine trends in
substance abuse and
demographic from
1998 to 2008 among
pregnant women
admitted into
substance abuse
treatment

 Treatment Episode
Datasets, 1998-2008

Determine national
rates of antidepressant
prescription during
pregnancy and
examine the trends in
the use of prenatal
antidepressants

Findings

 N = 1,724,479 women
aged 18-44
 n = 81,818 pregnant
women

 Decrease in alcohol-related
abuse rates: from 49.3% to
37.6% of pregnant women
 Increase in drug abuse in
pregnant women from
47.8% to 60.9%
 Trends were more
pronounced in pregnant
women compared to
nonpregnant women

 Characteristics of pregnant
women entering treatment
compared to nonpregnant
women: younger,
unmarried, homeless, less
than high school education,
on public assistance or with
no source of income
 Rates of ages 21–24
increased from 22.8% to
31.3%; Referrals from the
criminal justice system
increased over time

 National Ambulatory
Medical Care Survey
and National Hospital
Ambulatory Medical
Care Survey, 20022010

The rate of visits by pregnant
women who received a
prescription for an
antidepressant increased
from .7% in 2002–2006 to
2.1% in 2007–2010

Characteristics of the women
(majority): aged 21 or older
and were Whites
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Meunier,
Bennett, &
Coco, 2013

Comments

 N = 27,328 prenatal
visits

Authors,
Year
Pan & Yi,
2013

Purpose
Examine trends in
hospitalization of
infants prenatally
exposed to alcohol or
drugs

Data source, Sample
 Nationwide Inpatient
Sample dataset, 19992008
 n = 3,842,837
hospitalized live birth
in 1999
 n = 4,253,656
hospitalized live birth
in 2008

Findings
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 Rates of maternal
substance use-related
problems per 10,000
liveborn deliveries from
1999 to 2008:
 Cocaine decreased from
38.9 to 23.8
 Alcohol decreased from
10.6 to 9.4
 Opioids increased from
13.7 to 22.0
 Cannabis and
hallucinogens: increased
from 30.2 to 52.1
 Methamphetamines
increased from 6.9 to 11.2

Comments

Table 3
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Population-based Studies on Mental Health and Substance Use Treatment Receipt in Pregnant Women of Childbearing Age
Authors,
Survey Design,
Screening/Treatment
Rates/Factors Associated with Treatment
Year
Purpose
Sample
Measurement
Receipt
Bennett,
Examine if
Rates of depression care:
 Descriptive
 Depression:
Marcus,
pregnancy is related
comparative cohort
International
 Antidepressants: 27% pregnant women,
Palmer, &
to the
study, Medicaid
Classification of
62% nonpregnant women
Coyne,
discontinuation of
claims data from
Diseases, Ninth Revision  Care visits: 31% pregnant women, 49%
2010
depression care in
all 50 states 1999(ICD-9) codes
nonpregnant women
low-income women
2000
 Depression treatment:
Factors related to treatment receipt:
antidepressant
 White women had fewer depression
medications or a
 N = 6,474 women
care visits during the pregnancy period
aged 15–45 years
depression care visit
compared to nonWhites
(n = 3,237
 Nonwhite pregnant women had fewer
pregnant women;
antidepressant use in postpartum period
n = 3,237 matched
compared to Whites
control cohort of
nonpregnant
 Pregnant women not receiving
women)
assistance had fewer depression care
Byatt, Xiao,
Dinh, &
Waring,
2016

Examine the
relationship between
mental health care
use and depressive
symptoms among
pregnant women

Rate of mental health care use:
 National Health
 Depressive symptoms:
and Nutrition
Patient Health
 12% of women with depressive
Examination
Questionnaire
symptoms; 4% of non-depressed
Survey, 2005–2012  Mental health care use:
 Women with depressive symptoms had
self-report of seeing or
higher adjusted odds ratio of care use
talking to a mental
compared to those without depressive
 N = 463 pregnant
women aged 20-44
health professional about
symptoms
years
mental health
 Only multiracial and other ethnicity
had lower adjusted odds of care use
compared to whites

Authors,
Year
Chang,
Tabet,
Elder, Kiel,
& Flick,
2016

Purpose
Examine lifetime
mental health
services use in
relation to ethnicity
among pregnant
women

Survey Design,
Sample
 Cross-sectional
population-based
study: Florida
Healthy Start
prenatal screening
program, 2008–
2012
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 N = 81,910
pregnant women
with depressive
disorder
ColemanCowger,
2012

Determine if
disparity
in mental health
treatment exist in
pregnant women
entered substance
use treatment across
ethnicity and age
groups

 Global Appraisal
of Individual
Needs Data, 2008
 N = 502 past-year
pregnant women
aged 12-43 years

Screening/Treatment
Rates/Factors Associated with Treatment
Measurement
Receipt
 Depressive symptoms:
 Rates of mental health services use: 26
one question addressed
% all sample, 42.5 % Whites, 11.5%
feeling down, depressed,
Mexican and other Hispanics
or hopeless in the last
month
Predictors of mental health care:
 Mental health treatment:  Tobacco use, physical or psychological
self-report of lifetime
abuse, and illness across ethnic groups
use of mental health
 Demographics (age of 30 years or
services or counseling
older, college education, unmarried
status among non-Hispanic
Asian/Pacific Islander, insurance
coverage )
 Mental health: Internal
Mental Distress Scale,
Behavioral Complexity
Scale, or endorsing
suicidal thoughts
 Treatment receipt: selfreport of treatment
receipt for mental or
psychological problem

 Rate of mental health treatment need
vs. receipt: 78.3% vs. 38.3%
 Treatment disparities: Hispanic and
African American had higher
proportions of no treatment receipt than
the Mixed or Whites
 No difference in treatment receipt by
age groups among those who needed
treatment

Authors,
Year
Cook et al.,
2010

Purpose
Estimate the rate of
12-month and
lifetime psychiatric
disorders in lowincome pregnant
women and the rate
of treatment receipt
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Farr, Ko,
Examine the
Burley, &
prevalence and
Gupta, 2016 predictors
of discussing
depression with a
prenatal care
provider
Geier, Hills,
Gonzales,
Tum, &
Finley,
2015

Survey Design,
Sample

Screening/Treatment
Measurement

Rates/Factors Associated with Treatment
Receipt
Prevalence of treatment in pregnant
 Cross-sectional
 Diagnostic and
women:
Statistical Manual of
Mental
Disorders:
DSM
28.9% for any anxiety disorder
 N = 744 low
IV
income pregnant,
 37.7% for major depressive episode
Special
 Broad definition of
 22.2% for any substance use disorder
Supplement
treatment: speaking with  26.2% for any psychiatric disorder
Nutrition Program
a doctor or other
excluding nicotine
for Women, Infants
professionals about
 Rural women with a psychiatric
and Children,
psychiatric symptoms.
disorder were less likely to receive
Missouri 2000treatment than urban women (20.7%
2001
vs. 29.5%)
 A secondary
 Prenatal education: self-  Rate of prenatal education: 71.9 %
analysis of 2011
report of whether a
Predictors of discussing depressive
data from the
health care provider
symptoms (higher adjusted odds):
Pregnancy Risk
talked with the women
 Demographics (age < 35 years vs. > 35
assessment
about her depressive
years, unmarried status, Medicaid
Monitoring System
feeling during pregnancy
recipients, Hispanic Whites vs.
or after birth.
Asians/Pacific Islanders)
 N = 32,827

Determine rates and  Retrospective
 Depression: ICD-9 code
predictors of
longitudinal cohort
for any depressive
depression detection
study, California
illness
and treatment of new
State Medicaid
 Treatment: receipt of
mothers in
(Medi-Cal)
antidepressant
comparison of
program 2006prescription and/or
nonpregnant women
2009N = 76,493
psychotherapy services

 Rate of antidepressant use: 2.7%
pregnant, 10.8% nonpregnant
Predictors of depression diagnosis/
treatment (higher adjusted odds)
 Pregnant women had lower odds
 Demographics (Age of 25 years or
older, White/African/Asian vs.
Hispanics, urban vs. rural women)

Authors,
Year
Glasheen,
Colpe,
Hoffman, &
Warren,
2015
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Hand,
Short, &
Abatemarco
2017

Purpose
Examine the rates
and correlates of
mental health
treatment receipt
among pregnant and
postpartum women
with serious
psychological
distress

Survey Design,
Sample
 NSDUH 20082012: crosssectional survey
 N ~ 4,600
pregnant, 8,000
postpartum, and
80,400 not
pregnant or
postpartum of
childbearing age
(18-44 years).

Screening/Treatment
Rates/Factors Associated with Treatment
Measurement
Receipt
 Serious psychological
Prevalence of past-year mental health
distress: Kessler Distress
treatment receipt:
6 Scale (past-month)
 38.5% pregnant women; 49.5%
postpartum women; 51.5%
 Mental health treatment:
self-report of the receipt
nonpregnant women
of treatment for
Predictors of mental health treatment
emotions, nerves, and
(sample included childbearing-aged
mental health problems
women):
 Pregnancy status (pregnant women had
lower odds of treatment receipt)
 Demographics (white ethnicity, older
age, college graduates, health
insurance, history of depression/
anxiety) (higher odds)

Compare data related  Treatment
 Substance use: selfto substances used,
Episodes Databasereport by the individual
characteristics of
Admissions, 2013  Treatment modalities for
treatment, and
the current admission:
demographics
methadone-assisted
 N = 8,656 pregnant
of pregnant women
women with opioid
treatment and
entering treatment
use disorder
detoxification.
for opioid use
disorder between
geographical regions

 Pregnant women received treatment in
the South were less likely to: have
health insurance, be married, and have
an education level of more than high
school
 Compared to the South, pregnant
women entering treatment in other
regions were more likely to: be
admitted to medication assisted
treatment, use heroin, and inject drugs

Authors,
Year
Ko, Farr,
Dietz, &
Robbins,
2012
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Survey Design,
Purpose
Sample
Estimate the
 NSDUH 2005prevalence and
2009: crosspredictors of
sectional survey
undiagnosed
depression, treatment  N = 9,032
prevalence and
reproductive-aged
barriers among
(18-44) women
reproductive-aged
with major
women
depressive episode
 n = 375 pregnant
women
 n = 8,657
nonpregnant
women)

Screening/Treatment
Measurement
 Major depressive
episode: nine questions
based on the DSM-IV
criteria
 Mental health treatment:
self-report of the receipt
of treatment for
emotions, nerves, and
mental health problems.

Rates/Factors Associated with Treatment
Receipt
 Past-year mental health treatment
receipt rates in women with major
depressive episode:
49.6% pregnant women; 53.7%
nonpregnant women
 Rates by treatment modality in
pregnant vs. nonpregnant women:
39.6% vs. 47.4% for prescription
medication;
36.3% vs. 35.5% for counseling;
7.2% vs.4.7% for inpatient treatment
(No difference by pregnancy status in
the receipt of any treatment, after
adjusting for socio-demographic
characteristics)
 Barriers to treatment in women:
cost, opposition to treatment, stigma
concerns, time or transportation
limitations, and not knowing where to
go for treatment

Authors,
Year
Kotelchuck
et al., 2017

Purpose
Examine prevalence
of substance use
disorders and
substance use
treatment prior to
delivery (by maternal
characteristics)

37

Survey Design,
Sample
 2003-2007
population-based
data in
Massachusetts:
(a) Massachusetts
Center for Health
Information and
Analysis case mix
data;
(b) Pregnancy to
Early Life
Longitudinal data
system;
(c) Bureau of
Substance Abuse
Services (BSAS)
 N = 375,851

Screening/Treatment
Measurement
 Substance use disorders:
(a) positive neonatal
toxicology screen or
fetal alcohol syndrome;
(b) BSAS treatment
system admission
record; or
(c) ICD-9
 Substance use treatment:
professional services
received in a treatment
facility or hospital-based
program or
detoxification.

Rates/Factors Associated with
Treatment Receipt
 Rate of treatment receipt: 66.3%
Factor associated with treatment
receipt:
 Demographics (age of 30 or older,
some college education, married health
status, private insurance)
 Having fewer health or psychiatric
conditions

Authors,
Year
Le Strat,
Dubertre, &
Le Foll,
2011

Purpose
Examine the
prevalence
and correlates of
Major Depressive
Episode in pregnant
and postpartum
women

38
Liu &
Tronick,
2012

Examine social
determinants of
provider-patient
conversations
regarding depressed
mood during the
perinatal period

Survey Design,
Sample
 2001–2002
National
Epidemiological
Survey on Alcohol
and Related
Conditions: crosssectional survey

Screening/Treatment
Measurement
 DSM-IV
 Receiving treatment for
anxiety or mood in
health professional
clinic, hospital,
emergency room, or
prescribed medication

Rates/Factors Associated with
Treatment Receipt
Rates of treatment receipt in pregnant
vs. nonpregnant women with major
depression:
 36.98% vs. 44.83% for any disorder
 23.76% vs. 33.77% for depression
 26.55% vs. 31.68% for anxiety
 12.85% vs. 9.80% for alcohol/drug use

 N = 1,524 pregnant  Receiving treatment for
women (current or
substance use in
past-12 months
hospital, outpatient
pregnant women)
clinic, detoxification,
methadone maintenance
program, or 12-steps
meeting

Differences in treatment receipt:
 Pregnant women with depression had
higher adjusted odds of treatment
receipt compared to pregnant women
without depression
 Pregnant women with depression had
lower odds of the receipt of treatment
compared to nonpregnant women (but
not significant after adjusting for
socio-demographics)

Conversation about mood:
 New York City
self-report if a health
Pregnancy Risk
care provider talked with
Assessment
respondents about blues
Monitoring System
or depression during
data, 2004–2007
pregnancy or after.
 N = 3,597

 About 50% of women had conversation
 Predictors of having conversation
(lower odds): age of 35 years or above,
non-US born women, and private
doctor, and no prenatal assistance,
Asian/Pacific Islander vs. Whites (less
likely).

Authors,
Year
Price,
CorderMabe, &
Austin,
2012
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Roberson et
al., 2016

Survey Design,
Screening/Treatment
Purpose
Sample
Measurement
Examine perceptions  Virginia
 36-item survey
of healthcare
Department of
instrument: demoproviders’ about
Health Data, 2008graphics, self-reported
depression screening
2009
attitudes and beliefs
and confidence in
regarding perinatal
screening, treatment,  N = 1,498
depression, barriers and
and referring of
facilitators to treatment,
healthcare
women
and satisfaction with
providers
training

Examine the
prevalence of
depression, anxiety,
pharmacotherapy,
and health-seeking
behaviors during
perinatal period in
multiethnic women
in Hawaii

Rates/Factors Associated with Treatment
Receipt
Rate of treatment/referral
 51.6% routine treatment/referral
 33.5% occasional treatment/referral
 12.7% rare or no treatment/referral
 Common barriers: Inadequate time
(41.4%), inadequate available treatment
services (24.4%), inadequate
reimbursement (17.8%), and
inadequate provider’s skills (15.8%).

Rate of mental health care:
 Hawaii Pregnancy  Anxiety/depression
Risk Assessment
symptoms: Self-report of  7.3 % for visiting a healthcare worker
Monitoring System
having depression or
 1.4 % for antianxiety or antidepression
Data, 2009-2011
anxiety, feeling of
prescription
sadness
Factors associated with prescription
 N = 4,735 women
drugs use:
 Treatment: self-report of
receiving treatment for
 Pre-pregnancy depression or anxiety
anxiety or depression or
taking prescription drugs

Authors,
Year
Terplan,
McNamara, &
Chisolm,
2012

Survey Design,
Purpose
Sample
Examine substance
 2002-2006
use, treatment need,
National Survey on
and treatment receipt
Drug Use and
in pregnant and
Health: crossnonpregnant women.
sectional survey

Screening/Treatment
Measurement
 Operationalization of
substance abuse or
dependence based on
DSM-IV criteria
 Substance use treatment
receipt: self-report of
receiving substance use
treatment

Rates/Factors Associated with
Treatment Receipt
 Rate of treatment receipt < 20%
Factors associated with substance use
treatment receipt in women of
childbearing age (after adjusting for
other variables in regression model)
 Pregnant had lower odds of treatment
receipt (but not significant)
 Demographics (employed women, age
of 21-25 compared to < 20, high school
or equivalent) (lower odds)

Vesga-lopez Examine prevalence  2001–2002
 DSM-IV criteria
et al., 2008 of psychiatric
National
 Mental health treatment
disorders and
Epidemiologic
receipt questions are
estimate lifetime and
Survey on Alcohol
disorder-specific
12-month rates of
and Related
addressing if
treatment utilization
Conditions: crossrespondents required
among pregnant and
sectional survey
hospitalizatio, visiting
non-pregnant women
emergency room, or
with psychiatric
asked help from a
 N = 14,895 women
disorders
of childbearing age
therapist or doctor, or
(18-50 years)
needed prescribed
medication.

Rates of past-year treatment seeking in
pregnant, postpartum, and nonpregnant
women:
 10.5%, 11.1%, 16.5% for any
psychiatric disorder
 14.3%, 15.0%, 25.5% for mood
disorder
 6.1%, 7.5%, 11.6% for anxiety disorder
 9.9%, 8.3%, 6.0% for alcohol use
disorder
 30.3%, 17.0%, 34.6% for illicit drug
use

 N = 140,000
women of
childbearing age
(12-44 years)
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 Pregnant women had lower odds of
treatment receipt for mood disorders
but not for anxiety after adjusting
socio-demographic characteristics

Authors,
Year
Wu &
DavisAjami, 2014

41

Yamamoto,
McCormick, & Burris,
2015

Survey Design,
Purpose
Sample
Determine antenatal  Retrospective
antidepressant
cohort study using
treatment persistence
South Carolina
and factors
Medicaid claims
associated with that
data 2004-2009
in low-income,
insured pregnant
 N = 804 pregnant
women
women aged 18
years or older

Screening/Treatment
Measurement
 Major depression:
ICD-9

Determine the rate of  2006–2010
antidepressants use
National
in pregnant women
Ambulatory
during outpatient
Medical Care
care visits and if
Survey and the
these rates varied by
National Hospital
ethnicity
Ambulatory
Medical Care
Survey

 Depression: ICD-9
 Antidepressants use and
cognitive behavioral
therapy

 N = average of
37.8 million visits
per year for
pregnant women

 Antidepressant
medications use:
pharmacy claims

Rates/Factors Associated with
Treatment Receipt
Rate of antenatal depressants use
behaviors:
 20% used more than one antidepressant
 45% treatment nonpersistence
 Predictors of treatment nonpersistence:
Nonwhite ethnicity, previous antenatal
depressant use before pregnancy
(higher odds)
Rate of mental health care:
 2.2% of all visits, antidepressants use
 .2% of all visits, cognitive behavioral
therapy
 Compared to visits for White women,
Non-White women had lower odds of
antidepressant use while depressed
controlling maternal age, insurance
type, region of the country, and survey
type

Identification

PubMed (n = 449)

CINAHL (n = 267)

PsychINFO (n = 904)

Records after duplicates removed
(n = 1,209)

Screening

Records screened at the
title level
(n = 1,205)

Titles clearly irrelevant
(n = 755)

Records excluded
(n = 402)

Eligibility

Records screened at the
abstract level
(n = 450)

Included

Full-text articles
assessed for eligibility
(n = 48)

Manual search
(n = 2)

Studies included in
synthesis
(n = 28)

Full-text articles excluded,
with reasons (n = 22)
4 clinical-based studies
1 population-based study: not
address pregnancy status
5 population-based studies:
not address treatment
receipt
4 population-based studies:
not examine factors related
to treatment receipt
1 trend study: not specify
pregnancy status
3 trend studies: focused on
any substance use
1 trend study: examined
trend over three years
3 trend studies: overlapping
time points/data source

Figure 1. PRISMA flow chart for studies selection process. Adapted from “Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement”
by D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and The PRISMA Group, 2009,
PLoS Medecine, 6(6), e1000097.
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CHAPTER III
TRENDS IN MENTAL HEALTH AND SUBSTANCE USE DISORDERS AND
TREATMENT RECEIPT AMONG PREGNANT AND NONPREGNANT WOMEN IN
THE UNITED STATES, 2008-2014
Introduction
Treatment for mental and substance use disorders will cost the nation $280.5
billion in 2020, an increase from the $171.7 billion cost in 2009 (Substance Abuse and
Mental Health Services Administration [SAMHSA], 2014a). Mental health and substance
use problems are major public health issues affecting women of childbearing age.
Depression is prevalent among women of childbearing age in the United States. Data
from large national surveys indicate the prevalence of depression in childbearing-aged
women is between 7.3% to 12.4% (Cook et al., 2010; Ko, Farr, Dietz, & Robbins, 2012;
Le Strat, Dubertret, & Le Foll, 2011; Mota, Cox, Enns, Calhoun, & Sareen, 2008; VesgaLopez et al., 2008). Women living with depression are at increased risk of having chronic
medical conditions (Farr, Hayes, Bitsko, Bansil, & Dietz, 2011) and substance use
disorders (Connelly, Hazen, Baker-Ericzen, Landsverk, & Horwitz, 2013; Le Strat et al.,
2011). These interrelated disorders need to be recognized and treated using an integrated
approach to ensure effective treatment (United States Department of Health and Human
Services [USDHHS], 2009). The purpose of this study was to compare trends in mental
health and substance use disorders and treatment receipt of pregnant and nonpregnant
women from 2008 to 2014.
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Among mothers, mental illness and substance use disorders have a profound
negative effect on the mother and her child (Connelly et al., 2013; Homish, Cornelius,
Richardson, & Day, 2004; Jaaskelainen, Holmila, Notkola, & Raitasalo, 2016). Pregnant
women with poor mental health are at increased risk for preterm birth (Grigoriadis et al.,
2013), postpartum depression (Goodman, Chenausky, & Freeman, 2014; Norhayati,
Hazlina, & Asrenee, Emilin, 2015), and diminished quality of life (Goodman et al.,
2014). Prenatal alcohol use is associated with deleterious effects such as fetal alcohol
syndrome (Lehikoinen, Orden, Heinonen, & Voutilainen, 2016). Illicit drug use during
pregnancy is also associated with preterm birth and Neonatal Abstinence Syndrome
(NAS) (Narkowicz, Plotka, Polkowska, Biziuk, & Namiesnik, 2013).
The American College of Obstetricians and Gynecologists (ACOG, 2015a,
2015b) endorses a universal screening for mental health and substance use problems
during pregnancy. However, findings based on large national surveys indicated that most
women who needed mental health and substance use treatment did not receive them
(Glasheen, Colpe, Hoffman, & Warren, 2015; Ko et al., 2012; Le Strat et al., 2011;
Vesga-Lopez et al., 2008). This indicates that women face unique barriers (e.g., cost and
stigma) to receipt of mental health (USDHHS, 2009) and substance use treatment (Center
for Substance Abuse Treatment [CSAT], 2009). Yet, recent health reforms have
mandated increased availability for mental health and substance use treatment services,
while emphasizing the importance of integrating both treatments with primary medical
care (Mental Health Parity and Addiction Equity Act [MHPAEA], 2008; Patient
Protection and Affordable Care Act [PPACA], 2010). Little is known about recent trends
in mental and substance use disorders and treatment receipt, particularly mental health
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treatment in pregnant women. Indeed, previous research on trends in mental health and
utilization of mental health treatment in the United States has been conducted among the
general population in the 1990s (Kessler, Demler, et al., 2005). The most recent research
indicated that there was an increase in the use of mental health treatment from 2001 to
2012 along with an increase in the prevalence of poor mental health for 15 days or more
in the past month among the general population (Mojtabai & Jorm, 2015). These puzzling
trends question the efficacy of mental health treatment (Mojtabai & Jorm, 2015) and raise
the question of whether the same pattern of trends occurs among pregnant women.
A growing body of research is beginning to shed light on trends in substance use
treatment among childbearing-aged women (Martin, Longinaker, Mark, Chisolm, &
Terplan, 2015; Martin, Longinaker, & Terplan, 2015; McCabe & Arndt, 2012), yet
without highlighting how the unmet need for substance use treatment has also changed
over time in the general population of women. This is of critical concern because less
than 20% of childbearing-aged women with substance use disorders received treatment
(Terplan, McNamara, & Chisolm, 2012).
Understanding trends in mental health and substance use disorders as well as
treatment receipt while comparing pregnant women and their non-pregnant counterparts
may help in generalizing conclusions specific to pregnant women. In addition, addressing
barriers to treatment can inform health reform and help programs facilitate treatment and
tailor interventions according to the needs of pregnant women. The specific aims of this
study were to:
1. Compare trends from 2008 to 2014 in mental health problems (i.e., past-year major
depressive episode [MDE], anxiety disorder, and past-month psychological
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distress), past-year substance use disorders, receipt of mental health treatment, and
unmet need for substance use treatment of women by pregnancy status.
2. Compare trends from 2008 to 2014 in the receipt of mental health treatment of
women with mental illness by pregnancy status, controlling for severity of mental
illness.
3. Compare and contrast barriers to mental health treatment and substance use
treatment as perceived by pregnant and non-pregnant women from 2008-2010 to
2011-2014.
Background
Women suffer disproportionately from depression and anxiety (Kessler, Berglund,
et al., 2003), and they develop substance use disorders as likely as men after the initiation
of substance use (CSAT, 2009). Given the vulnerability of pregnant women (Lokuge,
Frey, Foster, Soares, & Steiner, 2011), more evidence is needed to understand how
mental health and substance use disorders affect them in comparison with non-pregnant
women over time. In addition, more information is needed about pattern of treatment
receipt among pregnant and nonpregnant women and what barriers impede their receipt
of mental health and substance use treatment over time.
Trends in Mental Health and Substance Use Disorders
Research suggests that hormonal changes in pregnant women may increase their
vulnerability to develop poor mental health (Lokuge et al., 2011). Yet, there is an
inconsistent pattern in the prevalence of psychiatric disorders between pregnant and
nonpregnant women (Ko et al., 2012; Mota et al., 2008; Vesga-Lopez et al., 2008),
reflecting heterogeneity in study populations and methods. For instance, using the 2001
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to 2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC),
Vesga-Lopez et al. (2008) found no significant differences in the 12-month prevalence of
depression and anxiety between past-year pregnant (8.4%, 13.0%, respectively) and
nonpregnant women (8.1%, 14.9%, respectively). Yet, Mota et al. (2008) compared pastyear prevalence of psychiatric disorders between current pregnant and nonpregnant
women using the 2001-2002 NESARC. They found significant differences in the
prevalence of depression (7.3% versus 11.4%) but not for anxiety disorders (13.2%
versus 16.6%) between pregnant and nonpregnant women. Similarly, Ko et al. (2012)
used the National Survey on Drug Use and Health (NSDUH) 2005 to 2009 and found that
pregnant women (7.7%) were less likely to have MDE compared to nonpregnant women
(11.1%).
There is scarce evidence about prenatal depressive and anxiety symptoms from a
national sample of pregnant women. Glasheen et al. (2015) used the NSDUH and found
that the prevalence of past-month serious psychological distress in pregnant women
(4.8%) was lower than nonpregnant women (7.4%); however, pregnant women may feel
more reluctant to report mental health problems than nonpregnant women (Ko et al.,
2012). Hence, in addition to the social desirability effect, inconsistent findings across
studies may be related to other variables that account for the relationship between
pregnancy status and psychiatric disorders but that were not measured in these studies.
Further, addressing and comparing psychiatric disorders between past-year or current
pregnant and nonpregnant women across studies make it difficult to draw conclusions
about the differences between the two groups.
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Pregnant women generally tend to underreport substance use to avoid
stigmatization and losing child custody (Wendell, 2013). National studies revealed that
the prevalence of substance use disorders in pregnant women (3.7% to 14.6%) was lower
than nonpregnant women (9.5% to 19.9%) (Mota et al., 2008; Vesga-Lopez et al., 2008).
However, these studies showed that pregnant women were less likely to have alcohol use
disorders but not illicit drug use disorders compared to nonpregnant women. Yet,
psychiatric disorders are prevalent in women of childbearing age regardless of pregnancy
status; however, little is known about the comparison of trends in these disorders between
the two groups over time.
Trends in Mental Health and Substance Use Treatment Receipt
The proportion of pregnant women exposed to atypical antipsychotics increased
dramatically from 2001 to 2007 (Toh et al. 2013). However, the rate of psychotropic
medicines use was fairly stable from 2006 to 2011 in pregnant women (Hanley &
Mintzes, 2014). Nevertheless, no studies were found indicating if the prevalence of
mental health disorders in pregnant women declined over the same periods. Indeed,
studies based on the 2001-2002 NESARC indicated that pregnant women with
psychiatric disorders were less likely to receive mental health treatment (Le Strat et al.,
2011; Vesga-Lopez et al., 2008). Another study based on the 2005-2009 NSDUH
indicated that major depression was unrecognized more often in pregnant women
(65.9%) than nonpregnant women (58.6%), while only half of depressed mothers
received mental health treatment (Ko et al., 2012). Notably, these studies relied on old
national data and did not examine the trends in psychiatric disorders or mental health
treatment among pregnant women over time.
48

Concerning substance use disorders in pregnancy, McCabe and Arndt (2012)
retrieved the Treatment Episode Data Set (TEDS) which indicated that alcohol abuse
markedly declined from 1998 to 2008 while drug abuse increased in pregnant women;
yet, this trend was more obvious in pregnant than nonpregnant women controlling for
age. In addition, referrals from health care providers of substance abusing pregnant
women were consistently lower compared to referrals from the criminal justice system
over the same time period. A few investigators have focused on examining trends in
treatment admission based on the 1992-2012 TEDS for marijuana (Martin, Longinaker,
Mark, et al., 2015) and opioid use in pregnant women (Martin, Longinaker, & Terplan,
2015), but without a comparison group of nonpregnant women. Findings of these studies
showed that pregnant admissions for substance use treatment were stable over time at
4%; however, admissions of pregnant women increased significantly for prescription
opioids (2% to 28%) and marijuana use (29% to 43%) from 1992 to 2012. Yet, little is
known about recent trends in substance use treatment among pregnant and nonpregnant
women. In addition, given the low rates of treatment for substance use, it is essential to
examine if the unmet need for treatment has changed over time from a general sample of
pregnant and nonpregnant women.
In the consideration of the ongoing public concerns related to mental health and
addiction, the PPACA (2010) builds on the MHPAEA (2008) and mandates early
identification and treatment for mental health and substance use disorders for all adults.
This broad mandates covers perinatal mental health and substance use. Yet, the PPACA
(2010) section 2952 focuses on research and clinical screening of postpartum depression,
giving little attention to mental health during pregnancy. Yet, pregnancy provides the
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appropriate time to screen for these issues (Connelly et al., 2013). Thus, trends in mental
health and treatment for mental health and substance use disorders need to be further
examined in pregnant women to inform medical and legal initiatives.
Barriers to Mental Health and Substance Use Treatment
Although pregnancy can provide an optimum opportunity to offer mental health
and substance use treatment (Connelly et al., 2013; Kuo et al., 2013), pregnant women
have low treatment utilization rates (Glasheen et al., 2015; Vesga-Lopez et al., 2008) and
may face barriers to access treatment (Ko et al., 2012; Kuo et al., 2013). In their
qualitative study, Kuo et al. (2013) found that pregnant women revealed their need for
treatment of both mental illness and substance use. However, judgmental family
relationships, time and transportation challenged these women from seeking treatment for
depression and substance use problems.
There is an ongoing evidence addressing barriers to mental health treatment
among pregnant women (Goodman, 2009; Jesse, Dolbier, & Blanchard, 2008; Kim et al.,
2010; Kingston et al., 2015; Ko et al., 2012; Kopelman et al., 2008; O'Mahen & Flynn,
2008; Rosen, Tolman, & Warner, 2004). Common barriers reported in the literature
include cost (Kim et al., 2010; Ko et al., 2012; Kopelman et al., 2008; O'Mahen & Flynn,
2008), opposition to treatment (Jesse et al., 2008; Kingston et al., 2015; Ko et al., 2012;
Rosen et al., 2004), lack of time (Kim et al., 2010; Ko et al., 2012; Rosen et al., 2004)
and childcare issues (Goodman, 2009; Kopelman et al., 2008), as well as stigma concerns
(Goodman, 2009; Jesse et al., 2008; Ko et al., 2012). Little is known regarding perceived
barriers to mental health treatment and substance use treatment from a national sample of
childbearing-aged women. A study based on the 2005-2009 NSDUH showed that
50

pregnant and non-pregnant women face similar barriers to mental health treatment (Ko et
al., 2012). Among these women, cost was the most common barrier, followed by
opposition to treatment, and stigma.
Women face numerous obstacles in accessing substance use treatment services
such as a lack of gender-specific services, the cost of treatment, stigmatization, and
punitive legal actions for substance use (Otiashvili et al., 2013). According to World
Health Organization (WHO, 2014), stigmatization is a significant issue that should be
prevented when providing treatment to pregnant women with substance use disorders.
Yet, pregnancy itself is a barrier for seeking substance use treatment (Steverson &
Rieckmann, 2009). Fear of losing child custody and prosecution may lead pregnant
women to avoid treatment (Tuchman, 2010). The Guttmacher Institute (2017) reported
that 24 states consider substance use in pregnancy as child abuse and three states consider
it a civil commitment. In addition, 23 states mandate reporting of suspected substance
abuse to the state, while seven require testing of pregnant women.
In response to inconsistent legislations across states, there are growing
professional efforts to advocate for pregnant women and support treatment rather than
criminalization for this vulnerable population (Advocates for Pregnant Women, 2011;
American Nurses Association, 2011; National Perinatal Association, 2013). Beyond these
efforts, there are limited treatment facilities to serve pregnant women with substance use
disorders (Guttmacher Institute, 2017). In a qualitative study of 85 rural pregnant women
in Kentucky, approximately 26% had availability issues with substance use treatment
services (Jackson & Shannon, 2012a). Moreover, 51.4% of women considered stigma
and denial as common acceptability barriers, while 49.4% of them experienced
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accessibility barriers including family responsibilities, and lack of social support and
transportation.
Little is known about the pattern of obstacles that impede women of childbearing
age to receive mental health and substance use treatment over time. One populationbased study showed that the proportion of women-centered services in drug treatment
facilities declined slightly from 43% in 2002 to 40% in 2009 (Terplan, Longinaker, &
Appel, 2015). Findings from the Health Reform Monitoring Survey showed that the
uninsured rate among childbearing-aged women declined from 19.6% in summer 2013 to
13.3% in winter 2014–15 along with the perceived unmet need for care due to cost;
however, access to care remained stable over the same period of time (Shartzer, Garro,
Pellegrini, & Long, 2015). Notably, further studies are needed to address barriers to
mental health and substance use treatment in pregnant and non-pregnant women from the
general population.
Methods
Design
Secondary analysis of a large population-based dataset, the NSDUH, of
childbearing-aged women in the United States from 2008 to 2014 was conducted.
SAMHSA sponsored and designed the NSDUH as a national cross-sectional survey to
provide population estimates of mental health and substance use in U.S household
populations aged 12 or over (Center for Behavioral Health Statistics and Quality
[CBHSQ], 2015). In this study, the NSDUH data were analyzed over time from 2008 as
past-month psychological distress was included in the survey beginning in 2008
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(CBHSQ, 2015). In addition, past-year mental illness estimates were developed using a
clinical follow-up study that started in 2008 and continued until 2012.
Sample
The NSDUH samples participants in each of the 50 states and the District of
Columbia using multistage probability stratified sample (CBHSQ, 2015). Surveys are
administered in person using computer-assisted personal interviewing and audio
computer-assisted self-interviews (ACASI) (CBHSQ, 2015). Pregnant women aged 12 to
17 years were excluded from this study as a specific mental health module was designed
in the NSDUH to provide information on mental health measures (i.e., serious
psychological distress and mental illness) among adults aged 18 or older. The response
rate for the survey ranged from 71.2% to 75.6% between 2008 to 2014 (USDHHS,
SAMHSA, Office of Applied Studies, 2013, 2014a, 2014b, 2014c, 2014d, 2014e, 2015).
The sample for this study included data from 5,520 pregnant women and 11,040 matched
nonpregnant women aged 18 to 44 years. Among these women, 1,003 pregnant and 2,634
nonpregnant women suffered from past-year mental illness.
Measures
Pregnancy status. Women self-reported their pregnancy status (yes/no) based on
the following question: “Are you currently pregnant?” SAMHSA (2010) reported
substantial test-retest reliability of this question (Cohen’s Kappa = .85).
Major depressive episode. The NSDUH uses nine questions addressing MDE
symptoms based on the Diagnostic and Statistical Manual of Mental Disorders: DSM IV
criteria (CBHSQ, 2015). A participant met DSM-IV criteria for MDE (yes/no) if she
reported experiencing at least five or more of nine symptoms nearly every day in the
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same 2-week period in the last 12 months, with at least one of these five symptoms being
depressed mood or loss of interest in daily activities (American Psychiatric Association
[APA], 1994). The MDE measure in the adult depression module of the NSDUH
demonstrated moderate test-retest reliability (Cohen’s Kappa = .52) (SAMHSA, 2010).
Anxiety disorder. Anxiety disorder was measured using one item indicating if a
participant received a diagnosis of anxiety disorder from a doctor or other medical
professionals in the past 12 months. This measure demonstrated acceptable test-retest
reliability (Cohen’s Kappa = .73) (SAMHSA, 2010).
Serious psychological distress. The symptoms of psychological distress in the
past month were measured using the Kessler-6 (K6) Psychological Distress Scale
(Kessler, Barker, et al., 2003). The K6 Scale consists of six items each followed by a 4point scale ranging from “all of the time” to “none of the time.” These items indicate the
frequency of feeling: nervous, hopeless, restless or fidgety, sad or depressed, that
everything was an effort, and no good or worthless; thus, higher scores indicate greater
psychological distress. The total score for the K6 scale ranges from 0 to 24; the cut-off
score of 13 is the indicator of serious psychological distress (CBHSQ, 2015). The validity
of K6 was supported by its prediction of serious mental illness (Kessler, Barker, et al.,
2003). Cronbach’s alpha for the K6 in this study was excellent (α = .91).
Mental illness. The NSDUH defines mental illness in adults aged 18 or older
based on two criteria: (a) the presence of any mental disorder as determined in the
Structured Clinical Interview (SCID) for DSM-IV, excluding substance use disorders; and
(b) the level of functional impairment as determined by the Global Assessment of
Functioning (GAF) scale (Endicott, Spitzer, Fleiss, & Cohen, 1976). Based on these
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mental illness clinical measurements, a regression model was developed to predict the
probability of mental illness among approximately 50,000 cases in a follow-up clinical
study from 2008 to 2012 (CBHSQ, 2015). Specifically, this statistical model predicted
mental illness measurements in the NSDUH: K6 Scale, the abbreviated version of the
World Health Organization Disability Assessment Schedule (WHODAS) (Rehm et al.,
1999), past-year MDE, and suicidal thoughts. Cutpoints were derived from this model to
indicate any mental illness in the past year; based on the level of functional impairment,
mental illness was differentiated into serious, moderate, or mild mental illness. These
cutpoints then were used among the entire adult sample participated in the NSDUH
(CBHSQ, 2015).
Substance use disorders. The NSDUH operationalizes substance use disorders as
an abuse or dependence on alcohol or illicit drugs based on the DSM-IV criteria (CBHSQ,
2015). The participant is considered dependent on a substance if she reported that at least
three out of seven symptoms occurred in a 12-month period: engaging in activities related
to substance use, tolerance, withdrawal, larger or longer use, unsuccessful attempts to cut
down, physical health or emotional problems, and reduced activities (APA, 1994).
Substance abuse and dependence criteria are mutually exclusive. Substance abuse is
defined as reporting at least one of four abuse criteria occurred in a 12-month period:
roles obligations, hazardous use, legal problems, and social problem (APA, 1994). The
validity of the NSDUH in assessing substance use disorders was supported (Jordan, Karg,
Batts, Epstein, & Wiesen, 2008). The test-retest reliability of substance dependence or
abuse measures showed substantial agreement (Cohen’s Kappa = .67) (SAMHSA, 2010).
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Receipt of mental health treatment. Mental health treatment receipt refers to
any treatment received in an inpatient or outpatient setting, or use of prescription drugs
for any problem related to mental health, emotions, or nerves in the past 12 months
(yes/no). These measures demonstrated excellent test-retest reliability (Cohen’s Kappa =
.85) (SAMHSA, 2010).
Unmet need for substance use treatment. The unmet need for substance use
treatment is defined as having the need for treatment for alcohol or illicit drug use that
met the DSM-IV criteria for dependence or abuse, but not receiving that treatment at a
specialty facility (i.e., hospital, rehabilitation facility, or mental health center) (USDHHS,
SAMHSA, Office of Applied Studies, 2015). This measure was used in this study rather
than the receipt of substance use treatment to have larger sample size and better powered
statistical analysis when comparing trends over time by pregnancy status, especially since
few numbers of pregnant women received the treatment for alcohol or illicit drug use
despite their need.
Perceived barriers to mental health and substance use treatment. The
NSDUH includes 28 items addressing reasons for not getting mental health treatment (14
items) and substance use treatment (14 items) among those who perceived treatment need
(USDHHS, SAMHSA, Office of Applied Studies, 2015). Perceived barriers include
factors such as treatment beliefs, readiness for treatment, lack of knowledge about
treatment programs, confidentiality concerns, lack of openings in the substance use
treatment programs, lack of time, and lack of transportation. The majority of items
addressing the barriers to mental health treatment demonstrated good test-retest reliability
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(Cohen’s Kappa ≥ .65); however, the reliability of the items addressing substance use
treatment was not reported (SAMHSA, 2010).
The classification of perceived barriers in this study was adapted from Ko et al.
(2012). Any items measuring perceived barriers that were scored “yes” were classified
into the following categories: (a) cost (three items for mental health treatment; two items
for substance use treatment); (b) stigma (four items for mental health treatment; three
items for substance use treatment); (c) opposition to treatment (four items for each
treatment type); (d) time or transportation limitation (two items for each treatment type);
(e) not knowing where to go (one item for each treatment type); and (f) lack of substance
use treatment programs (two items for substance use treatment).
Procedure
The NSDUH has been conducted by the Federal Government since 1971
(SAMHSA, 2010) and is managed by SAMHSA’s Office of Applied Studies.
Participation in the NSDUH is voluntary and all randomly selected participants are
encouraged to participate regardless of their substances use status. Interviews are
completed in private, as participants answer most of the interview questions using a
laptop computer; hence, the interviewer does not know the answers entered. No prior
computer skills are required to answer the questions. The interviews last approximately
one hour and the participant receives $30 cash at the end of the interview (CBHSQ,
2015). Confidentiality of the answers is protected by law and participants do not give
their full names (NSDUH, 2016).
Given that the current study used de-identified public use data from the 20082014 NSDUH, the study was exempt from the University of Louisville Institutional
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Review Board. In congruence with the terms of use of this dataset as proposed by the
Interuniversity Consortium for Political and Social Research (ICPSR), the principal
investigator (PI) analyzed the NSDUH only for the purpose of research and prevented
any unauthorized access to the data by maintaining it in encrypted files on the PI’s
computer.
Data Analysis
Considering the complex survey design and weighting, statistical analysis was
conducted using complex sample analysis with SPSS software, version 22.0 (IBM Corp.,
2013). As multiple NSDUH survey years were used, the person-level analysis weight was
divided by the numbers of years of survey data used in analyses (i.e., seven years)
(CBHSQ, 2015). Because Bonferroni correction was deemed so conservative (Bland &
Altman, 1995), p-values < .05 were considered statistically significant for analyses even
in the presence of multiple comparisons. Recoded and imputed demographic and
substance use variables were analyzed. Missing data for mental health measures were
excluded from analysis. The NSDUH uses an imputation methodology called “predictive
mean neighborhoods (PMN)” which was developed for the survey in 1999 (CBHSQ,
2015, p.11). PMN combines a regression model imputation and a random nearest
neighbor hot-deck procedure. The hot-deck procedure involves replacing the missing
values with a corresponding value from a donor randomly selected from a set of
candidate donors called the “neighborhood” (CBHSQ, 2015, p.12). The potential donors
in the neighborhood have complete data with a predicted mean close to that of the item of
the nonrespondent.
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Propensity score matching was conducted to match pregnant and nonpregnant
women before analyzing the data. Propensity Score Matching for SPSS (Version 1.0;
Thoemmes, 2012) was used to calculate propensity scores by regressing pregnancy status
onto: age, ethnicity, marital status, education level, employment status, income, health
insurance, and county urbanicity. One-to-two pairs of pregnant and non-pregnant women
were matched. One-to-two pairs matching was selected because it is recommended when
the sample size between the two groups differ substantially, hence reducing bias (Ming &
Rosenbaum, 2000). Compared to adjustment for covariates, propensity score matching
helps in assessing covariate balance between groups without looking at outcomes and
thereby protects against Type I error (Vittinghoff, Glidden, Shiboski, & McCulloch,
2012). Good balance between matched and control groups was indicated in this study as
the standardized mean differences between the groups’ covariate means were of less than
.25 (Ho, Imai, King, & Stuart, 2007).
Descriptive statistics were conducted for the matched sample using weighted
percentages and standard errors (SEs) to describe all categorical variables. Bivariate
analyses using chi-square were conducted to examine differences between pregnant and
nonpregnant women for covariates.
A total of eight logistic regression models were conducted to test the interaction
between time and pregnancy status for the dichotomous outcomes of: MDE, anxiety
disorder, any past-year mental illness, alcohol use disorder, illicit drug use disorder, pastmonth psychological distress, past-year receipt of mental health treatment, and the unmet
need for past-year substance use treatment. The test of model coefficients was conducted
for each model to determine goodness of fit (Vittinghoff et al., 2012).
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Among women with mental illness, a logistic regression model was run to test the
interaction between time and pregnancy status to predict the receipt of mental health
treatment controlling for severity of mental illness. Finally, weighted percentages were
calculated for each type of barrier to mental health and substance use treatment and
compared across two time periods, 2008-2010 and 2011-2014, using chi-square and rank
ordering. The purpose of aggregating data into two time periods was to have an adequate
sample size to describe different types of barriers. Because a small number of pregnant
women reported perceived barriers to substance use treatment, these barriers were
compared across 2008-2010 and 2011-2014 among the total sample of pregnant and
nonpregnant women.
Results
There was a satisfactory balance with the propensity score matching using age,
ethnicity, education, income, employment, health insurance, and county urbanicity (see
Table 4). The majority of the matched sample was white, married, college educated, and
employed. Most of women had an income level of less than $50,000, had health
insurance, and lived in a large urban area.
The rates of past-year MDE decreased slightly from 7.2% in 2008 to 5.9% in
2014 among pregnant women, and remained relatively stable from 2008 (9.4%, 8.7%) to
2014 (9.3%, 8.3%) among nonpregnant women and the total sample of women,
respectively (see Figure 2). The rate of MDE was lowest at 2.7% in 2010 among pregnant
women. However, the rates of anxiety disorder increased from 2008 to 2014 among
pregnant women (4.7% to 6.8%), nonpregnant women (7.3% to 11.2%), and the total
sample (6.5% to 9.9%). Likewise, rates of past-month psychological distress increased
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from 5.4%, 4.9%, and 5.6% in 2008 to 6.7%, 5.1%, and 7.5% in 2014 among the entire
sample as well as pregnant and nonpregnant women, respectively. The rates of past-year
mental illness showed only a slight increase from 2008 to 2014 in the total sample
(21.0% to 22.0%), pregnant (17.5% to 18.3%) and nonpregnant women (22.7% to 23.6%)
(see Figure 2).
Alcohol use disorder remained relatively stable at approximately 6% among the
total sample of childbearing-aged women from 2008 to 2014 regardless of pregnancy
status (see Figure 3). Although the rate of illicit drug use decreased in pregnant women
from 3.6% in 2008 to 2.4% in 2014, it increased in non-pregnant women from 2.0% to
3.3%, reflecting an overall increase among the total sample by 1.2 fold.
The rates of the receipt of mental health treatment remained relatively stable from
2008 to 2014 among pregnant women, nonpregnant women, and the total sample,
respectively, at approximately 12%, 18%, and 16% (see Figure 4). Among those with
mental illness, the rates of the receipt of mental health treatment increased from 2008
(36.6%, 39.0%, 38.4) to 2014 (39.6%, 44.5%, 43.2%) among pregnant, nonpregnant
women, and the total sample, respectively. The rate of unmet need for substance use
treatment remained stable at 7% from 2008 to 2014 among pregnant women. However,
among nonpregnant women as well as the total sample, respectively, the rates increased
from 6.5% and 6.8% in 2008 to 6.8% and 8.3% in 2014.
Comparing trends in mental health problems, substance use disorders, and
treatment receipt over time by pregnancy status, there were no significant interactions
between time and pregnancy status; thus, only main effects are reported (see Table 5). Of
mental health problems, only trends in past-year anxiety disorder (p = .003) and past61

month psychological distress (p = .009) were significant. For a one-year increase from
2008 to 2014, the odds of anxiety disorder increased by 7.0% (Adjusted Odds Ratio
[AOR]: 1.07; 95% Confidence Interval [CI]: 1.02-1.12), and pregnant women had lower
odds of anxiety disorder (AOR: .62; 95% CI: .51-.75) compared to nonpregnant women.
Likewise, for a one-year increase, the odds of past-month psychological distress
increased by 1.06 times (95% CI: 1.01-1.10). Compared to nonpregnant women, pregnant
women had lower odds of past-month serious psychological distress (AOR: .68; 95% CI:
.56-.82). The likelihood of past-year MDE (AOR: 1.01; 95% CI: .96-1.05) and any
mental illness (AOR: 1.02; 95% CI: .98-1.05) did not change over the seven years;
however, pregnant women had significantly lower odds of MDE (AOR: .53; 95% CI: .43.65) and any mental illness (AOR: .65; 95% CI: .58-.74) compared to nonpregnant
women.
There was a significant increase in the odds of illicit drug use disorder from 2008
to 2014 (for one-year increase) (AOR: 1.05; 95% CI: 1.004-1.10); yet, the odds of illicit
drug use disorder was not significantly higher in pregnant women than nonpregnant
women (AOR: 1.06; 95% CI: .83-1.35). There was no significant change in the
probability of alcohol use disorder over time (AOR: 1.02; 95% CI: .97-1.07) or by
pregnancy status (AOR: 1.04; 95% CI: .87-1.24). There were no significant trends in the
mental health treatment receipt (AOR: 1.01; 95% CI: .98-1.04) and the unmet need for
substance use treatment over time (AOR: 1.03; 95% CI: .99-1.08). Pregnant women had
lower odds of receipt of mental health treatment (AOR: .60; 95% CI: .52-.69) compared
to nonpregnant women; yet, there was no significant difference between pregnant and
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nonpregnant women in predicting the probability of the unmet need for substance use
treatment (AOR: 1.01; 95% CI: .86-1.18).
Seventeen percent of pregnant women versus 23.6% of nonpregnant women had
past-year mental illness. There were no significant differences between pregnant and
nonpregnant women with mental illness in any of the covariates (i.e., age, ethnicity,
education, employment status, income level, county urbanicity), except marital status.
Pregnant women (50.2%) were less likely to be married compared to nonpregnant women
(56.7%) [χ2 (1, N = 3,637) = 11.48, p = .031]. However, marital status was not associated
with the receipt of mental health treatment [χ2 (1, N = 3,637) = 3.955, p = .224], and thus
was not including as a covariate in the regression model. Among those with mental
illness, there was no significant interaction between time and pregnancy status and
therefore only main effects are reported in Table 6. The odds of mental health treatment
did not significantly change over time (AOR: 1.04, 95% CI: .98-1.09). Yet, pregnant
women with mental illness had lesser odds of the receipt of mental health treatment
compared to nonpregnant women (AOR: .66; 95% CI: .52-.84). Women with moderate
(AOR: 1.94; 95% CI: 1.51-2.50) and severe mental illness (AOR: 3.87; 95% CI: 3.044.92) had higher odds of the receipt of mental health treatment compared with women
with mild mental illness.
Perceived barriers to mental health treatment among women of childbearing age
ranked similar in 2008-2010 and 2011-2014 in regards: (a) cost (45.2%, 50.6%), (b)
opposition to treatment (41.9%, 41.4%), and (c) stigma (28.2%, 24.7%) (see Figure 5). In
2008-2010, the perceived barrier of not knowing where to go ranked last (19.2%), while
time/transportation limitations had the lowest percentage in 2011-2014 (19.7%).
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However, the order of perceived barriers to substance use treatment among childbearingaged women differed from 2008-2010 to 2011-2014. In 2008-2010, the perceived barriers
ranked in the following order: cost (38.7%), stigma (18.2%), time/transportation
limitations (17%), opposition to treatment and lack of treatment programs (3%), and
finally not knowing where to go (.9%). By 2011-2014, stigma ranked first (35.5%),
followed by cost (25.9%), time/transportation limitations (22.2%), lack of treatment
programs (17.7%), not knowing where to go (8.2%), and opposition to treatment (7.6%).
Perceived barriers to mental health treatment among pregnant women had the
same order as the total sample in 2008-2010 across the two time periods, 2008-2010 and
2011-2014 (see Figure 6). Nonpregnant women had the same order of perceived barriers
to mental health treatment in 2008-2010 and 2011-2014: cost (44.6%, 49.3%), opposition
to treatment (40.8%, 41.3%), stigma (28.6%, 26.4%), not knowing where to go (20.7%,
21.6%), and time/transportation limitations (19.7%, 20.1%).
There were no significant differences in the perceived barriers to mental health
treatment across 2008-2010 to 2011-2014 among the total sample, and pregnant and
nonpregnant women (see Table 7). However, in 2011-2014 women of childbearing age
were significantly more likely to report not knowing where to go (8.2% vs. .9%) and a
lack of treatment programs (17.7% vs. 3.0%) as perceived barriers to substance use
treatment than women in 2008-2010. Other perceived barriers to substance use treatment
did not differ between the two time periods. In 2011-2014, women of childbearing age
who perceived a need for substance use treatment were more likely to live in a nonmetro
(23.2% vs. 9.0%) or small county area (32.7% vs. 13.5%) compared to their counterpart
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groups in 2008-2010 (p < .001). There were no significant differences in other sociodemographic characteristics between the two groups in 2008-2010 and 2011-2014.
Discussion
The purpose of this study was to compare trends in mental health problems,
substance use disorders, mental health treatment receipt, and unmet needs for substance
use treatment by pregnancy status from 2008 to 2014. Among a matched sample of
pregnant and non-pregnant women, there was no significant interaction between time and
pregnancy status in predicting the probability of mental health, substance use disorders,
and treatment receipt. This means that the proportional change in these outcome
measures was the same for pregnant and nonpregnant women over time. However, to our
knowledge, there are no comparable trend studies specifically addressing the difference
between pregnant and nonpregnant women in having mental health problems and
receiving mental health treatment over time.
This study showed that compared to nonpregnant women, pregnant women had
lesser odds of MDE, anxiety disorder, past-year mental illness, and past-month
psychological distress. This is inconsistent with a previous population-based study that
showed no significant difference in the prevalence of psychiatric disorders between
pregnant and nonpregnant women who participated in NESARC (Vesga-Lopez et al.,
2008). Yet, another NESARC-based study (Mota et al., 2008) as well as NSDUH-based
study (Ko et al., 2012) found that pregnant women were less likely to have major
depression compared to nonpregnant women. However, Mota et al. (2008) found that
pregnant women were as likely as nonpregnant women to have anxiety disorder. These
discrepancies may be due to different measures of psychiatric disorders, sample
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characteristics, and controlling for different confounding variables. For instance, the
NSDUH used one question addressing if a healthcare provider told the respondent she
had anxiety disorder or not, while NESARC used structured clinical interviews in
assessing anxiety disorders. Further, the current study analyzed the NSDUH among a
matched sample of pregnant and nonpregnant women, while other population-based
studies adjusted for confounding variables.
In addressing psychological distress symptoms, a population study based on the
NSDUH (Glasheen et al., 2015) was in accord with the current study by suggesting that
pregnant women had lesser odds of past-month psychological distress compared to
nonpregnant women. These findings from general population samples suggest an
interesting comparison with the evidence from clinical samples, as the later captured
advanced clinical symptoms among only pregnant women who received treatments
(Connelly et al., 2013; Fairbrother, Janssen, Antony, Tucker, & Young, 2016;
Fairbrother, Young, Janssen, Antony, & Tucker, 2015; Gavin et al., 2011; Melville,
Gavin, Guo, Fan, & Katon, 2010; Qiu, Gelaye, Fida, & Williams, 2012). Given that these
clinical studies lack comparison groups of nonpregnant women, drawing a clear
conclusion about the association between pregnancy and mental disorders is limited.
In the present study, there was a significant increase in the probability of past-year
anxiety disorder and past-month psychological distress over the seven years among the
total sample of pregnant and nonpregnant. Anxiety is among the most prevalent disorders
in the United States and women are 1.5 times more likely to have an anxiety disorder
compared to men (Kessler, Berglund, et al., 2005). Yet, a previous trend study showed no
significant increase in any psychiatric disorder from 1990 to 2003 among the general
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population (Kessler, Demler, et al., 2005), whereas a recent trend study did not focus on
examining trends in anxiety disorders (Mojtabai & Jorm, 2015). This emphasizes the
need for further studies to examine the magnitude of anxiety disorder among women of
childbearing age, particularly pregnant women.
In the current study, there was a significant increase in the probability of pastmonth psychological distress but not past-year MDE or mental illness. Yet, Mojtabai and
Jorm (2015) found no significant change in the proportion of past-month psychological
distress or past-year MDE among the general population from 2001 to 2012. This
suggests that childbearing-aged women in this study tended to report non-specific recent
distress symptoms rather than past-year mental health conditions. Moreover, the increase
in the probability of anxiety disorder and past-month psychological distress, as well as
the absence of significant change in the proportion of MDE and mental illness may be
related to unsubstantial increase in the receipt of mental health treatment. The link
between trends in the receipt of mental health treatment and in mental health problems
should be interpreted with caution. Previous trend studies revealed puzzling findings in
which the receipt of mental health treatment increased while the proportion of mental
health problems either did not change (Kessler, Demler, et al., 2005; Mojtabai & Jorm,
2015) or increased (Mojtabai & Jorm, 2015) over the same period of time. Therefore, the
quality of mental health treatment provided to women may be more important in
assessing the change in mental health problems.
Research suggests that although women have more frequent contact with health
care providers, obstetric providers lack training in care of women with depression
(ACOG, 2010) and anxiety (Leddy, Lawrence, & Schulkin, 2011). Mental health care
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providers are also reluctant to treat depression during pregnancy (Byatt, Biebel,
Debordes-Jackson, et al., 2013; Palladino et al., 2011). Literature also indicated an
absence of standardized procedures for depression care (Palladino et al., 2011) as well as
inadequate referral systems and coordinated follow-up care (Palladino et al., 2011; Price,
Corder-Mabe, & Austin, 2012), all of which may influence the status of mental health
among women of childbearing age.
The nonsignificant increase in the receipt of mental health treatment in this study
is incongruent with previous trend studies among the general population that showed an
increase in the receipt of mental health treatment from 1990-2003 (Kessler, Demler, et
al., 2005) and from 2000 to 2014 (Mojtabai & Jorm, 2015). This suggests that women of
childbearing age have specific mental health needs (USDHHS, 2009) and may experience
unique multilevel barriers to access treatment (Byatt, Simas, Lundquist, Johnson, &
Ziedonis, 2012). A systematic review revealed that screening alone for depression among
perinatal women was associated with only 22% mental health treatment receipt; yet, this
rate was doubled in the presence of patient engagement interventions, on-site
assessments, and training for perinatal care providers (Byatt, Levin, Ziedonis, Simas, &
Allison, 2015). This emphasizes the need for interventions that address strategies
identified by both patient and health care providers to increase mental health treatment
use (Byatt, Biebel, Friedman et al., 2013).
In contrast with previous trend studies that examined trends in the use of
antipsychotic drugs during pregnancy (Hanley & Mintzes, 2014; Toh et al., 2013), the
current study has focused on the receipt of any mental health treatment including
outpatient counseling, inpatient treatment, and prescription drugs for mental health
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problems. Hence, these studies are not comparable with the current study due to different
measures of mental health treatment as well as the time of examining trends.
In the current study, pregnant women were as likely as nonpregnant women to
have alcohol and illicit drug use disorders. This finding is in accord with previous
population studies based on the 2001-2002 NESARC that found no significant difference
between pregnant and nonpregnant women in developing illicit drug use disorders (Mota
et al. 2008; Vesga-lopez et al., 2008). However, these studies revealed that pregnant
women were less likely to have alcohol use disorders compared to nonpregnant women.
It is noteworthy that these studies relied on an old national dataset that used structured
clinical interviews in assessing substance use disorders rather than self-report
questionnaires that may result in this discrepancy. Yet, there is a dearth of updated
literature that compared substance use disorders among pregnant and nonpregnant
women from the general population. Most of what is known about substance use
problems is based on admission data that focused on illicit drug use among only pregnant
women (Martin, Longinaker, Mark, et al., 2015; Martin, Longinaker, & Terplan, 2015).
One study included a comparison group of nonpregnant women and suggested that
treatment admission rate for illicit drug abuse increased more profoundly among pregnant
women compared to nonpregnant women from 1998 to 2008 (McCabe & Arndt, 2012).
However, these findings should not be generalized to the population as the majority of
childbearing-aged women with substance use disorders do not receive treatment (Terplan
et al., 2012).
The present study showed a significant increase in the probability of illicit drug
use disorder from 2008 to 2014 among women of childbearing age. SAMHSA (2013)
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also reported based on TED an increase in the percentage of illicit drug abuse but not
alcohol abuse among pregnant and nonpregnant women from 2000 to 2010. These
findings indicate a critical need for interventions to help women of childbearing age with
substance use disorders, hence preventing devastating health consequences associated
with substance use during pregnancy.
The present study showed that the gap between the need and receipt of substance
use treatment did not change from 2008 to 2014 among both pregnant and nonpregnant
women. The rate of treatment admission among pregnant women was relatively stable
from 2000 (4.4%) to 2010 (4.8%) (SAMHSA, 2013). Women in this study experienced
an unmet need for substance use treatment over the seven years, despite treatment
initiatives (ACOG, 2015a, 2015b) and legislation (MHPAEA, 2008; PPACA, 2010). This
emphasizes the need for prevention and interventional strategies tailored according to the
specific needs of childbearing-aged women.
Mental Illness and Trends in the Receipt of Mental Health Treatment
Among women with mental illness, there was no significant interaction between
time and pregnancy status in predicting the probability of mental health treatment receipt.
This indicates that the change in the odds of the receipt of mental health treatment over
time was similar for pregnant and nonpregnant women. Yet, pregnant women had a lower
odds of the receipt of mental health treatment despite their mental illness. This is
congruent with previous studies indicating that pregnant women with psychiatric
disorders (Mota et al., 2008; Vesga-Lopez et al., 2008) or psychological distress
(Glasheen et al., 2015) were less likely to receive mental health treatment compared to
nonpregnant women.
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However, the present study found that pregnant women, regardless of having
mental illness, had a lower odds of receipt of mental health treatment compared to
nonpregnant women. This raises a question in regards the relationship between treatment
need and the severity of mental illness. Given the fact that psychiatric disorders in
women are rarely recognized (Ko et al., 2012) or treated (Glasheen et al., 2015; Ko et al.,
2012; Vesga-Lopez et al., 2008), women of childbearing age may not access treatment
due to structural, system, and personal barriers until their mental condition is advanced
(Byatt et al., 2012). This is also of critical concern as the present study also showed no
significant increase in the likelihood of mental health treatment receipt among women of
childbearing age with mental illness from 2008 to 2014, while pregnant women had a
lower odds of mental health treatment receipt compared to nonpregnant women.
Although this study covered a period of time that coincided with policy initiatives
including MHPAEA (2008) and PPACA (2010), it did not show a substantial increase in
the receipt of mental health treatment. This study did not specifically address the effect of
these policies; however, it yielded a critical concern reflecting that there are complex
integrated obstacles that may affect the receipt of both mental health and substance use
treatment among women of childbearing age.
Barriers to Mental health and Substance Use Treatment
This study showed that the most common barriers to mental health treatment in
2008-2010 and 2011-2014 included cost, followed by opposition to treatment, and
stigma. These barriers did not differ in their rank or percentages between 2008-2010 and
2011-2014 among pregnant and nonpregnant women. Other barriers included time and
transportation limitations that had lower proportions than not where to go among
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pregnant women in the two time periods. One clinical study showed that perinatal women
reported more concerns regarding structural barriers to depression care (i.e., insurance,
inability to pay, transportation, and childcare) than knowledge (not sure whom to contact
and not knowing the best treatment) and attitudinal barriers (lack of motivation and
hopelessness that treatment would work) (O’Mahen & Flynn, 2008). However, the same
rank of barriers found in this study was reported in a previous population study based on
2005-2009 NSDUH of women of reproductive age (Ko et al., 2012), suggesting that
strategies provided to enhance access to treatment for mental health problems among
women of childbearing age might be inadequate over the nine years.
Despite the enactment of PPACA in 2010, cost had the highest percentage as a
perceived barrier to mental health treatment across 2008-2010 and 2011-2014. Findings
from 2013 Kaiser Women’s Health Survey, conducted just before the start of the
PPACA’s major coverage expansion, showed that cost was a major obstacle to getting
mental health care among 23% of uninsured women, 6% of women with private
insurance, and 9% of Medicaid covered women (Salganicoff, Ranji, Beamesderfer, &
Kurani, 2014). Beyond coverage and affordability, this national representative survey
suggested that logistical barriers such as time, transportation, sick leave, and childcare
also impeded access to care. Interestingly, between summer 2013 and winter 2014–2015,
the Health Reform Monitoring Survey revealed that the uninsurance rate decreased from
19.6% to 13.3% among women of childbearing age and the unmet need for care due to
cost decreased by 10.4% (Shartzer et al., 2015). This coverage improvement was not
translated into significant enhancement in the access to care, and nearly one in four lowincome women was uninsured in winter 2014–2015. This suggests the need for efforts to
72

enroll uninsured women on the one hand, and on the other hand to design interventions
and strategies to overcome other structural, attitudinal, and knowledge barriers to mental
health care.
The present study showed that the rank of barriers to substance use treatment
among women of childbearing age changed from: cost, stigma, time/transportation
limitation, opposition to treatment/lack of treatment programs, and not knowing to go in
2008-2010 to: stigma, cost, time/transportation limitation, lack of treatment programs, not
knowing where to go, and opposition to treatment in 2011-2014. Beyond the limited
health insurance coverage of substance use problems (CSAT, 2009) women perceived
stigma as the most important barrier to substance use treatment in 2011-2014. Given that
these women also reported opposition to treatment as the least important barrier, this
suggests that even when women are willing to accept treatment; the stigma linked with
their substance use impeded them. According to the CSAT (2009), stigma toward
substance use women is greater than that toward men, and women have feelings of
shame, guilt, and low self-esteem because of their substance use, all of which create more
treatment needs to be addressed. Congruently, WHO (2014) and SAMHSA (2014c)
emphasized the importance of minimizing a judgmental attitude and stigmatization when
providing care for women of childbearing age. According to SAMHSA (2014c), public
institutions and health service systems need to adapt the framework of trauma-informed
care to help resolve and not aggravate trauma related issues among women with
substance use disorder.
Cost was rated as the second barrier to substance use treatment. Corresponding
with the PPACA that requires the coverage of preventive measures such as substance use
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screening without cost sharing, the awareness about these rules is still inadequate and
only 31% of women were screened for alcohol or drug use from 2011 to 2013
(Salganicoff et al., 2014).
Importantly, lack of treatment programs had a significantly higher percentage in
2010-2014 (17.7%) than 2008-2010 (3.0%). This is congruent with recent findings from
qualitative studies revealing that the availability of substance use treatment services is a
challenge to women seeking treatment (Jackson & Shannon, 2012a; Otiashvili et al.,
2013). Although the proportion of facilities that provided substance abuse treatment
services for adult women and pregnant or postpartum women increased from 35% and
15%, respectively, in 2010 (SAMHSA, 2011b) to 46% and 21% in 2014(SAMHSA,
2015), these rates are still low and a number of states have sought to increase the
availability of drug treatment services especially for pregnant women (Guttmacher,
2017). In 2011-2014, childbearing-aged women in the current study were more likely to
live in nonmetro and small county areas than women in 2008-2014. This suggests that
these women were likely to face a massively different group of barriers than residents in
large urban areas such as access to and perceived effectiveness of treatment (Fortney &
Booth, 2001).
Another significant finding from the current study is that more women in 20112014 than 2008-2010 did not know where to go to get substance use treatment. This is of
critical concern as compared to men, women with substance use disorders have a higher
incidence of poverty and childcare responsibilities (SAMHSA, 2011a). Unfortunately,
only 3.4% of substance use treatment facilities in 2014 provided residential beds for
clients’ children (SAMHSA, 2015). Hence, even if women are highly motivated to get
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treatment, they face additional barriers in finding treatment programs that can address
their specific needs (CSAT, 2009).
Limitations
A number of limitations should be considered when interpreting the results of this
study. First, data were analyzed only over seven years because mental illness measures
were only included in the NSDUH in 2008. Second, although this study used one-to-two
matching between pregnant and nonpregnant women to increase the sample size and
power of the analyses, perceived barriers to substance use treatment among pregnant
women were not examined over time due to the small sample size of pregnant women
reported perceived need for substance use treatment. Third, other variables not included
in this study may have affected the propensity scores. Yet, the two groups were wellmatched as indicated by balanced statistics, suggesting that the variance in the control
group was reduced. Fourth, pregnancy status was measured based on self-report; thus, it
was susceptible to recall bias. Fifth, postpartum women could not be identified from
other nonpregnant women using publicly available data. However, a study based on the
2008-2012 NSDUH reported that only approximately 8,000 postpartum women of 18-44
years old participated in the survey, indicating an approximate rate of less than 10% of
nonpregnant women (Glasheen et al., 2015).
Sixth, measurement of MDE and substance use disorder in the NSDUH relied on
questionnaires to operationalize the DSM-IV criteria rather than conducting clinical
interviews. In addition, measurement of anxiety relied on one item which might also
increase recall bias. Seventh, women answered questions about their mental health and
substance use disorder and treatment receipt in the past year, while they specified their
75

current pregnancy status. These events may be occurred during or before pregnancy.
However, this study included past-month psychological distress to increase the possibility
of assessing prenatal mental health, although this also cannot be captured if the woman
was pregnant in the first few weeks. Yet, the majority of pregnant women in this study
(68.7%) were in their second and third trimester. Eighth, pregnant women might tend to
under report their mental health and substance use problems and treatment receipt due to
a social desirability effect; yet, the NSDUH uses ACASI to reduce this response bias.
Finally, mental health problems may increase access to treatment which in turn may
affect these problems. However, due to the cross-sectional nature of the NSDUH, a
cause-effect relationship between treatment receipt and mental health cannot be
concluded.
Recommendations
The findings from this study showed increased trends in anxiety disorder and
past-month psychological distress, underscoring the need for preventive and
interventional strategies addressing these mental health problems among women of
childbearing age. Pregnant women tended to report fewer mental health problems than
nonpregnant women; however, differences in the receipt of mental health treatment of
pregnant and nonpregnant women suggested that screening and treatment should not be
generalized across women of childbearing broadly. More programs and initiatives are
needed to increase the receipt of mental health treatment among a vulnerable population
of pregnant women especially since cost, stigma, and opposition to treatment continued
to be the most important obstacles to mental health treatment over time.

76

Trend data presented in this study emphasized the importance of addressing the
needs of women with illicit drug use disorder. Women had higher concerns regarding
availability of substance use treatment services in 2011-2014 than 2008-2010,
emphasizing that parity legislation and treatment initiatives should seek to increase
services tailored according to the need of childbearing-aged women. Findings from this
study also highlight the importance of additional strategies addressing stigma, cost, and
time/transportation limitations to improve access to substance use treatment. This study
coincided with important health reforms, MHPAEA (2008) and PPACA (2010);
however, future research is needed to specifically explore how these policies affect the
receipt of mental health and substance use treatment among pregnant women.
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Table 4
Sociodemographic Characteristics of Matched Samples of Pregnant and Non-pregnant
Women Aged 18-44, NSDUH 2008- 2014 (N = 16,560)

Characteristics
Age
18-25
26-44
Ethnicity
White
African American
Other nonHispanicsa
Hispanics
Marital status
Married
Unmarried
Education
Less than high
school
High school
College graduate
Employment
Employed full time
Employed part time
Other
Unemployed
Income
<$20,000
$20,000-49,999
≥$50,000
Health insurance
Insured
Uninsured
County type
Large
Small
Nonmetro

Total sample
Wtd. % (SE)

Pregnant
womena
Wtd.% (SE)

Non-pregnant
womenb
Wtd.% (SE)

36.5 (0.6)
63.5 (0.6)

37.5(1.0)
62.5 (1.0)

59.0 (0.7)
13.7 (0.4)
8.9 (0.4)
18.4 (0.5)

χ2

p-value

36.0 (0.6)
64.0 (0.6)

3.44

.178

58.8 (1.2)
14.3 (0.8)
8.7 (0.6)
18.3 (0.8)

59.1 (0.9)
13.5 (0.5)
9.0 (0.5)
18.4 (0.7)

1.96

.885

61.2 (0.7)
38.8 (0.7)

60.7 (1.1)
39.3 (1.1)

61.5 (0.7)
38.5 (0.7)

.88

.497

15.8 (0.4)

15.5 (0.7)

16.0 (0.5)

1.19

.714

26.2 (0.6)
58.0 (0.7)

26.0 (0.9)
58.6 (1.0)

26.3 (0.6)
57.7 (0.7)

43.0 (0.7)
17.9 (0.5)
32.5 (0.5)
6.7 (0.3)

42.8 (1.1)
17.6 (1.0)
32.7 (1.0)
6.9 (0.5)

43.1 (0.8)
18.0(0.6)
32.4 (0.7)
6.6(0.3)

.85

.935

22.6 (0.5)
29.8 (0.7)
47.6 (0.8)

22.4 (0.9)
30.4 (1.2)
47.2 (1.2)

22.7 (0.7)
29.5 (0.8)
47.9 (0.9)

1.96

.885

89.9 (0.4)
10.1 (0.4)

90.2 (0.5)
9.8 (0.5)

89.8 (0.5)
10.2 (0.5)

.62

.546

52.8 (0.9)
53.2 (1.2)
52.6 (0.9)
2.24
.526
31.6 (0.7)
31.8 (1.0)
31.5 (0.7)
15.6 (0.5)
15.0 (0.7)
15.9 (0.6)
Note. No covariates exhibited a large imbalance (|Standardized Mean Differences| > .25).
Imputed and recoded variables were used. NSDUH = National Survey on Drug Use and
Health; Wt. % = Weighted Percentage; SE = Standard Error.
a
Other nonHispanics included Native American/Alaska Native, Native Hawaiian/Pacific
Islander, Asian, and more than one race.
a
n = 5,520; bn = 11,040.
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Figure 2. Trends in mental health problems rates from 2008 to 2014 among a matched sample of pregnant and nonpregnant
women aged 18-44, National Survey on Drug Use and Health. Frequencies and weighted percentages do not include missing data
addressing mental health.
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Figure 3. Trends in substance use disorders rates from 2008 to 2014 among a matched sample of pregnant and nonpregnant women,
National Survey on Drug Use and Health. Imputed and recoded variables addressing substance use were used. Substance use
disorder includes alcohol or illicit drug use dependence or abuse measured based on questions operationalized the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) criteria. Illicit drugs include heroin, marijuana, cocaine, inhalants, sedatives,
tranquilizers, hallucinogens, stimulants, and analgesics

81
Figure 4. Trends in rates of treatment receipt for mental health and substance use disorders from 2008-2014 among a matched
sample of pregnant and nonpregnant women, National Survey on Drug Use and Health. Imputed and recoded variables were used.
Frequencies and weighted percentages do not include missing data addressing mental health.

Table 5
Logistic Regression Modeling the Probability of Mental Health and Substance Use Disorders and Treatment Receipt from 20082014 among a Matched Sample of Pregnant and Nonpregnant Women, NSDUH (N = 16,560)
Pregnant vs. Nonpregnant Womena

Model/Outcomes
1. Major depressive episode
2. Anxiety disorder
3. Serious psychological
distress (past month)
4. Past-year mental illness
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5. Alcohol use disorderb
6. Illicit drug use disorder

b,c

7. Mental health treatment

Time (one-year increase)

AOR

95% CI

p-value

AOR

95% CI

p-value

.53

.43-.65

<.001

1.01

.96-1.05

.791

.62

.51-.75

<.001

1.07

1.02-1.12

.003

.68

.56-.82

< .001

1.06

1.01-1.10

.009

.65

.58-.74

<.001

1.02

.98-1.05

.331

1.04

.87-1.24

.660

1.02

.97-1.07

.375

1.06

.83-1.35

.645

1.05

1.004-1.10

.034

.60

.52-.69

< .001

1.01

.98-1.04

.445

8. Unmet need for substance use
1.01
.86-1.18
.939
1.03
.99-1.08
.125
treatment
Note. Imputed and recoded variables were used. Frequencies and weighted percentages do not include missing data addressing
mental health. NSDUH = National Survey on Drug Use and Health.
a
Nonpregnant women were the reference group. bSubstance use disorder includes substance use dependence or abuse measured
based on questions operationalized the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria. cIllicit drugs
include heroin, marijuana, cocaine, inhalants, sedatives, tranquilizers, hallucinogens, stimulants, and analgesics.

Table 6
Logistic Regression Modeling the Probability of the Receipt of Mental Health Treatment
by Pregnant and Nonpregnant Women with Mental Illness from 2008 to 2014,
Controlling for Severity of Illness, NSDUH (N = 3,637)
Characteristics
Pregnancy status
Nonpregnant women

AOR

95% CI

p-value

Reference

Reference

.001

Pregnant women

.66

.52-.84

Time (one year increase)

1.04

.98-1.09

.176

Severity of mental illness
Mild mental illness
Moderate mental illness
Severe mental illness

Reference
1.94
3.87

Reference
1.51-2.50
3.04-4.92

<.001

Note. Imputed and recoded variables were used. Frequencies and weighted percentages
do not include missing data addressing mental health. NSDUH = National Survey on
Drug Use and Health.
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A. Perceived barriers to mental health treatment among women of childbearing age (N = 1,436)
2008-2010 (n = 625)

2011-2014 (n = 811)

Not knowing where to go

19.2%

Time/transportation limitations

19.7%

Time/transportation limitations

20.2%

Not knowing where to go

20.3%

Stigma

Stigma

28.2%

Opposition to treatment

41.9%

Opposition to treatment

Cost

45.2%

Cost

24.7%
41.4%
50.6%
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B. Perceived barriers to substance use treatment among women of childbearing age (N = 103)
2008-2010 (n = 44)
Not knowing where to go

2011-2014 (n = 59)

0.9%

Opposition to treatment

7.6%
8.2%

Lack of treatment programs

3.0%

Not knowing where to go

Opposition to treatment

3.0%

Lack of treatment programs

Time/transportation limitations
Stigma
Cost

17.0%

Time/transportation limitations

18.2%

Cost
38.7%

Stigma

17.7%
22.2%

25.9%
35.5%

Figure 5. Weighted percentages and rank ordering of perceived barriers to mental health and substance use treamtent from
2008-2010 to 2011-2014 among women of childbearing age perceived need for treatment, National Survey on Drug Use and
Health. Imputed and recoded variables were used. Frequencies and weighted percentages do not include missing data
addressing mental health.

A. Perceived barriers to mental health treatment among pregnant women (N = 390)
2008-2010 (n = 177)
Not knowing where to go

2011-2014 (n = 213)
Not knowing where to go

14.8%

Time/transportation limitations
Stigma

21.5%
27.3%

16.4%

Time/transportation limitations

18.6%

Stigma

19.3%

Opposition to treatment

44.8%

Opposition to treatment

Cost

47%

Cost

41.6%
54.8%

B. Perceived barriers to mental health treatment among nonpregnant women (N = 1046)
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2011-2014 (n = 598)

2008-2010 (n = 448)
Time/transportation limitations

19.7%

Time/transportation limitations

Not knowing where to go

20.7%

Not knwoing where to go

Stigma

Stigma

28.6%

Opposition to treatment

40.8%

Opposition to treatment

Cost

44.6%

Cost

20.1%
21.6%
26.4%
41.3%
49.3%

Figure 6. Weighted percentages and rank ordering of perceived barriers to mental health treatment from 2008-2010 to 20112014 among pregnant and nonpregnant women perceived need for treatment, National Survey on Drug Use and Health.
Frequencies and weighted percentages do not include missing data addressing mental health.

Table 7
Perceived Barriers to Mental Health Treatment and Substance Use Treatment in Pregnant and Nonpregnant Women
Perceived Need for Treatment from 2008-2010 to 2011-2014 (NSDUH)

Perceived Barriers
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Mental health treatment
(N = 1,436)
Cost
Stigma
Opposition to treatment
Time/transportation
Not knowing where to go
Substance Use Treatment
(N = 103)
Cost
Stigma
Opposition to treatment
Time/transportation
Not knowing where to go
Lack of treatment
programs

Total Sample
Time
Time
1
2
Wt. % Wt. %

χ2

p

45.2
28.2
41.9
20.2
19.2

50.6
24.7
41.4
19.7
20.3

3.95
2.24
.03
.05
.28

.261
.368
.914
.899
.768

38.7
18.2
3.0
17.0
.90
3.0

25.9
35.5
7.6
22.2
8.2
17.7

1.80
3.30
.88
.37
4.45
2.28

.356
.211
.286
.758
.003
.014

Pregnanta,b
Time
Time
1
2
Wt. % Wt. %

47.0
27.3
44.8
21.5
14.8

42.8
18.6
5.5
5.5
6.9
0.0

54.8
19.3
41.6
18.6
16.4

41.9
63.3
.30
16.7
6.4
7.3

χ2

p

2.30
3.40
.40
.50
.18

.317
.185
.711
.643
.768

NA
NA
NA
NA
NA
NA

NA
NA
NA
NA
NA
NA

Nonpregnantc,d
Time
Time
1
2
Wt. % Wt. %

44.6
28.6
40.8
19.7
20.7

37.0
18.0
1.9
21.9
1.4
1.2

49.3
26.4
41.3
20.1
21.6

20.3
25.7
10.2
24.1
21.6
8.5

χ2

p

2.13
.59
.03
.09
.11

.400
.636
.926
.941
.851

2.30
.53
1.56
.04
5.06
1.44

.325
.616
.098
.921
<.001
.055

Note. Imputed and recoded variables were used. NSDUH = National Survey on Drug Use and Health; Time 1 = 2008-2010; Time 2 =
2011-2014; Wt. % = Weighted Percentage; SE = Standard Error; NA = Statistical differences were not examined due to small sample
size of pregnant women.
a
n = 390 pregnant women perceived need to mental health treatment; bn = 31 pregnant women perceived need to substance use treatment;
c
n = 1046 nonpregnant women perceived need to mental health treatment; dn = 72 nonpregnant women perceived need to substance use
treatment.

CHAPTER IV
PREDICTORS OF MENTAL HEALTH AND SUBSTANCE USE TREATMENT
RECEIPT AND ETHNIC DISPARITIES IN MENTAL HEALTH TREATMENT IN A
NATIONAL SAMPLE OF PREGNANT WOMEN WITH MENTAL HEALTH
AND/OR SUBSTANCE USE DISORDERS
Introduction
The purpose of this study was to examine factors associated with the receipt of
mental health and substance use treatment and determine ethnic disparities in mental
health treatment among pregnant women with mental health and/or substance use
disorders. Pregnant women with mental health and/or substance use disorders are a
vulnerable population. Depression affects 8.2% to 12.4% of pregnant women in the
United States (Cook et al., 2010; Le Strat, Dubertret, & Le Foll, 2011; Vesga-Lopez et
al., 2008) and is associated with co-occurring anxiety and substance use disorders (Le
Strat et al., 2011).
Poor mental health during pregnancy is linked with reduced quality of life
(Goodman, Chenausky, & Freeman, 2014), preterm delivery (Grigoriadis et al., 2013),
high risk for postpartum depression (Goodman et al., 2014), impaired maternal-child
bonding (Grigoriadis et al., 2013; Rossen et al., 2016), and behavioral and cognitive
disorders in children of depressed mothers (Csaszar, Melichercikova, & Dubovicky,
2014). These adverse health consequences may become more complex and prevalent for

87

the mother and her child when are associated with prenatal substance use (Connelly,
Hazen, Baker-Ericzen, Landsverk, & Horwitz, 2013; Homish, Cornelius, Richardson, &
Day, 2004; Jaaskelainen, Holmila, Notkola, & Raitasalo, 2016). In 2012 and 2013, 5.4%
of pregnant women used illicit drugs and 9.4% of them used alcohol in the past month
(Substance Abuse and Mental Health Services Administration [SAMHSA], 2014b).
Despite effective treatments for mental health and substance use disorders (Baker
et al., 2010; Marais et al., 2011; May et al., 2013; Meyer, Johnston, Crocker, & Heil,
2015), only 10.3% to 39% of pregnant women with these complex health issues receive
treatment (Cook et al., 2010; Glasheen, Colpe, Hoffman, & Warren, 2015; Le Strat et al.,
2011, Rosen, Tolman, & Warner, 2004; Song, Sands, & Wong, 2004; Vesga-Lopez et al.,
2008). Low rates of treatment for mental health problems occur despite ongoing medical
recommendations (American College of Obstetricians and Gynecologists [ACOG],
2015b) and state screening initiatives (Agency for Healthcare Research and Quality,
2016). Moreover, pregnant women who use substances are often involved with the law
before they are screened or referred to treatment by health care providers (McCabe &
Arndt, 2012; Terplan, Smith, Kozloski, & Pollack, 2010). Inadequate treatment for
prenatal substance use is associated with prolonged hospitalizations of prenatally affected
infants (Patrick, Davis, Lehmann, & Cooper, 2015) and expensive child protective
services (Ondersma, Simpson, Brestan, &Ward, 2000), making prenatal substance use a
significant public health problem.
Pregnant women face barriers (e.g., stigmatization) to access treatment for mental
health problems (Ko, Farr, Dietz, & Robbins, 2012), and those who are ethnic and racial
minorities continue to experience health care disparities (Chang, Tabet, Elder, Kiel, &
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Flick, 2016). However, little is known regarding factors associated with mental
health/substance use treatment receipt, perceived barriers to mental health treatment, and
ethnic care disparities in a general population of pregnant women.
Numerous studies have focused on the correlates of mental health problems
during pregnancy (Fairbrother, Janssen, Antony, Tucker, & Young, 2016; Fairbrother,
Young, Janssen, Antony, & Tucker, 2015; Le Strat et al., 2011; Melville, Gavin, Guo,
Fan, & Katon, 2010; Witt et al., 2010), but few have given attention to factors associated
with mental health treatment receipt. Mental health treatment may motivate pregnant
women with substance use disorders to access treatment for substance use issues (Rade et
al., 2015). Hence, addressing factors associated with the receipt of mental health
treatment can be used to establish preventive and interventional strategies to overcome
under-utilization of mental health treatment and thereby improve access to substance use
treatment. This is of critical concern because the growing literature, despite its
importance, has focused on factors related to retention in treatment programs for
substance use disorders (Brigham, Winhusen, Lewis, & Kropp, 2010; Kissin, Svikis,
Moylan, Haug, & Stitzer, 2004; Knight, Logan, & Simpson, 2001; Ondersma, Winhusen,
& Lewis, 2010) rather than examining the rate and predictors of the receipt of treatment
in a general population of pregnant women. A clear understanding of these factors, while
addressing ethnic care disparities and reasons for the unmet need for mental health
treatment, may help identify solutions to the under-treatment for mental health and
substance use disorders in a vulnerable population of pregnant women.
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Background
Pregnant women with mental health and substance use disorders remain
undertreated despite the adverse health consequences associated with their condition and
the availability of different treatment modalities (Glasheen et al., 2015; Le Strat et al.,
2011; Terplan, McNamara, & Chisolm, 2012; Vesga-Lopez et al., 2008). Therefore, it is
vital that pregnant women with these disorders are not only recognized but also treated.
Much information remains to be understood regarding how pregnant women’s sociodemographic and clinical characteristics influence the receipt of mental health and
substance use treatment.
Previous population-based studies either only reported the prevalence of mental
health treatment in pregnant women with psychiatric disorders (Cook et al., 2010; Le
Strat et al., 2011; Vesga-Lopez et al., 2008) or examined predictors of the receipt of
mental health (Glasheen et al., 2015) and substance use treatment (Terplan et al., 2012) in
women of childbearing age while adjusting for pregnancy status. Several factors may
specifically bear on whether pregnant women are able to receive treatment for mental
health and substance use disorders including predisposing (e.g., age, ethnicity, marital
status, and education level), enabling (e.g., income and health insurance), and need
factors. The specific aims of this study were to:
1. Identify predictors of the receipt of mental health treatment and substance use
treatment among pregnant women with mental health or substance use disorders
given predisposing characteristics (i.e., age, ethnicity, marital status, education
level, and employment status), enabling resources (i.e., income, health insurance,
and county type), and perceived and actual need for treatment, controlling for time.
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2. Examine differences in the receipt of mental health treatment among White and
nonWhite pregnant women with mental health (i.e., depression, anxiety, and
serious psychological distress) and/or substance use disorders, controlling for time
and confounding variables (i.e., age, marital status, education level, employment
status, income, health insurance, county type, self-rated health status, and severity
of distress symptoms).
3. Compare and contrast perceived barriers to mental health treatment among
pregnant women who perceived need for treatment across mental health and/or
substance use disorders and ethnicity.
Predisposing Characteristics
Pregnant women become more vulnerable because of reported disparities in
antenatal depression (Cook et al., 2010; Mukherjee, Trepka, Pierre-Victor, Bahelah, &
Avent, 2016) and substance use problems (Cook et al., 2010; Connelly et al., 2013).
However, there is sparse evidence on racial/ethnic differences in the receipt of mental
health/substance use treatment among this population. Studies based on the National
Epidemiologic Survey on Alcohol and Related Conditions (NESARC) did not report the
differences across racial/ethnicity groups in the receipt of mental health treatment (Le
Strat et al., 2011; Vesga-Lopez et al., 2008). Other studies examined race/ethnicity as a
correlate of mental health treatment utilization among perinatal women, suggesting that
Hispanic (Geier, Hills, Gonzales, Tum, & Finley, 2015; Glasheen et al., 2015) and Black
women reported receipt of mental health treatment proportionately less than their
counterparts (Glasheen et al., 2015).
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A few studies focused explicitly on examining racial/ethnic differences in the
receipt of mental health treatment (Chang et al., 2016; Song et al., 2004). Using data from
the Florida Healthy Start prenatal screening program 2008-2012, Chang et al. (2016)
reported that White pregnant women with depressive symptoms had the highest rates of
mental health services utilization compared to Mexicans and other Hispanics. Ethnic
minority pregnant women who entered substance use treatment also reported unmet need
for mental health treatment (Coleman-Cowger, 2012). Because mental health treatment
receipt is a key factor in enhancing the participation in substance use treatment (Rade et
al., 2015), further research is needed to address racial disparities in mental health care
among pregnant women with a broad range of psychiatric problems.
Compared to Whites, African American pregnant women with substance use
problems were less likely both to be motivated to enroll in (Mitchell, Severtson, &
Latimer, 2008) and receive substance use treatment (McCabe & Arndt, 2012). These
ethnic differences in the receipt of substance use treatment showed a significant trend
among pregnant women between 1998 (34.4% Blacks vs. 54.1% Whites) to 2008 (20.5%
Blacks vs. 60.3% Whites) (McCabe & Arndt, 2012).
Prior research revealed inconsistent findings regarding the associations among the
receipt of mental health treatment and maternal age (Flynn, Blow, & Marcus, 2006;
Glasheen et al., 2015; Rosen et al., 2004), educational level (Flynn et al., 2006; Glasheen
et al., 2015; Goodman, 2009; Smith et al., 2009), employment status (Flynn et al., 2006;
Glasheen et al., 2015; Smith et al. 2009), and marital status (Chang et al., 2016; Flynn et
al., 2006; Glasheen et al., 2015; Smith et al., 2009), reflecting the heterogeneity in the
design and sample across studies.
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The relationship between predispositional characteristics and substance use
treatment is also unclear. One study found that unmarried women were more likely to
receive treatment than married women (Messer, Clark, & Martin, 1996), whereas
Kotelchuck et al. (2017) found them less likely to receive treatment; other studies showed
no significant association between marital status and treatment receipt in pregnant
(Haller, Miles, & Dawson, 2001) and childbearing-aged women (Terplan et al., 2012).
Although a few population-based studies revealed that women of reproductive age who
had at least a high school education (Kotelchuck et al., 2017; Terplan et al., 2012) and
who were employed had higher odds of receipt of substance use treatment (Terplan et al.,
2012), other studies did not find a significant relationship among pregnant women who
received current (Haller et al., 2001; Messer et al., 1996) or lifetime substance use
treatment (Walton-Moss & McCaul, 2006). Maternal age in a few population-based and
clinical studies did not influence the receipt of substance use treatment (Messer et al.,
1996; Rosen et al., 2004). Yet, McCabe and Arndt (2012) reported that pregnant women
aged 21–24 years had an 8.5% point increase in the receipt of substance use treatment
from 1998 to 2008.
Enabling Factors
Economically disadvantaged pregnant women are unlikely to access mental health
(Song et al., 2004) and substance use treatment (Center for Substance Abuse Treatment
[CSAT], 2009). However, a few studies showed that income was not associated with the
receipt of mental health (Glasheen et al., 2015; Goodman, 2009; Smith et al., 2009) or
substance use treatment (Haller et al., 2001). These findings may be related to the
homogeneity of the clinical samples (Haller et al., 2001; Smith et al., 2009) or the
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influence of other mediators or moderators on the relationship between income and
treatment receipt that were not examined. Uninsured women of childbearing age also
demonstrated unmet need for mental health (Farr, Bitsko, Hayes, & Dietz, 2010) and
substance use treatment (CSAT, 2009). A population-based study showed that health
insurance coverage was associated with and predicted mental health treatment receipt in
perinatal women and childbearing-aged women, respectively (Glasheen et al., 2015).
However, another study showed that health insurance coverage did not increase the
probability of the receipt of substance use treatment in women of childbearing age after
adjusting for other socio-demographic characteristics (Terplan et al., 2012).
Unfortunately, substance use treatment services impose additional financial requirements
that may not be covered by health insurance, thus creating other financial barriers to
treatment (CSAT, 2009).
Rural women received mental health treatment later in the development of their
health condition and therefore need more intensive treatments (United States Department
of Health and Human Services [USDHHS], 2003). However, Heil, Sigmon, Jones, and
Wagner (2008) found that rural opioid-using pregnant women when compared with urban
women might have characteristics associated with better treatment outcomes; however,
they face more barriers to access treatment due to larger distance from treatment service.
In qualitative studies of rural pregnant women, barriers to mental health (e.g.,
dissatisfaction with the health care system and lack of trust) (Jesse, Dolbier, & Blanchard,
2008) and substance use treatment (e.g., availability, stigma, and lack of transportation)
(Jackson & Shannon, 2012a) were identified. To date, very few population-based studies
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examined the relationship between urban residency and mental health or substance use
treatment receipt in women of childbearing age (Rosen et al., 2004).
Perceived and Clinical Needs for Mental Health/Substance Use Treatment
Approximately, 39% of women of childbearing age with past major depressive
episode (MDE) reported unmet treatment needs (Ko et al., 2012) and less than 20% of
women who needed substance use treatment received it (Terplan et al., 2012). Yet, little
is known about the relationship among the perceived need for and receipt of treatment for
mental health and substance use disorders in pregnant women.
Research on pregnant women’s mental health gives little attention to how mental
health or substance use issues differentiate the receipt of treatment in the general
population. A study based on the NESARC showed that pregnant women with major
depression and any other psychiatric disorders had higher odds of the receipt of mental
health treatment compared to those without these disorders (Le Strat et al., 2011).
Moreover, a study based on the National Survey on Drug Use and Health (NSDUH)
revealed that history of depression or anxiety disorders was associated with the receipt of
mental health treatment in perinatal women with serious psychological distress (Glasheen
et al., 2015). Yet, these population-based studies did not indicate that substance use
problems were associated with the receipt of mental health treatment. However, Rosen et
al. (2004) reported that comorbid mental health and substance use disorders increased the
probability of receipt of substance use and mental health treatment in women aged 18-54
years. Nevertheless, the authors did not specify pregnancy status or the correlates of each
type of mental health and substance use treatment.
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A few clinical studies suggest that substance-related factors play a vital role in
pregnant women’s utilization of substance use treatment. The type of substance used
appears to influence this relationship; illicit drug use was related to substance use
treatment acceptance, but alcohol use showed an inconsistent pattern in this relationship
(Haller et al., 2001; Messer et al., 1996; Walton-Moss & McCaul, 2006). For instance,
Haller et al. (2001) found that the drug severity composite score was related to treatment
among pregnant women who used drugs while alcohol use did not affect receipt of
treatment. Pregnant women with comorbid mental health and substance use problems
were more likely to receive substance use treatment (Haller et al., 2001; Rade et al.,
2015). However, these findings of these clinical studies cannot be generalized to the
general population. To date, little is known regarding how need factors are related to the
receipt of substance use treatment in pregnant women from the general population.
Perceived Barriers to Mental Health Treatment
The receipt of mental health treatment among perinatal women is a complex
phenomenon involving individual, healthcare provider, and health system barriers (Battle,
Salisbury, Schofield, & Ortiz-Hernandezet, 2013; Kim et al., 2010). Clinical studies that
specifically examined perceived barriers to mental health treatment among pregnant
women indicated the most common barriers include: cost/lack of insurance (Kim et al.,
2010; Kopelman et al., 2008), stigma (Battle et al., 2013; Goodman, 2009; Jesse et al.,
2008), lack of time (Goodman, 2009; Kim et al., 2010; Kopelman et al., 2008) and
transportation (Kopelman et al., 2008), opposition to treatment (Jesse et al., 2008),
dissatisfaction with the health care (Jesse et al., 2008; Kopelman et al., 2008), and not
knowing where to go (Kopelman et al., 2008). The only population-based study of
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perceived barriers to mental health treatment among childbearing-aged women revealed
consistent findings in which cost (54.8%), opposition to treatment (41.7%), stigma
(26.3%), lack of time or transportation (18.1%), and not knowing where to go for
treatment (16.7%) were the common barriers to mental health treatment (Ko et al., 2012).
These perceived barriers did not differ by pregnancy status.
To date, research has focused on women with depression; hence, whether
perceived barriers to treatment differ between mental health and/or substance use
disorders is not known nor have ethnic differences in mental health treatment barriers
been fully explored in pregnant women (O’Mahen, Henshaw, Jones, & Flynn, 2011).
Recent research identified important barriers to mental health care for comorbid women
(e.g., cost and fear from treatment) (Rosen et al., 2004) and ethnic minority pregnant
women (e.g., stigma and lack of trust) (Jesse et al., 2008). However, O’Mahen and Flynn
(2008) did not find differences between White and African American perinatal women
regarding perceived structural (e.g., insurance, cost, transportation, and childcare),
knowledge, and attitudinal barriers with respect to treatment of depression.
Theoretical Framework
This study used the Behavioral Model of Health Service Use (Andersen, 1995) to
explain ethnic/racial care disparities and predictors of the receipt of mental health and
substance use treatment among pregnant women (see Figure 7). Andersen’s (1995)
behavioral model incorporates individual and contextual determinant of health services
use.
This model postulates that there are three components of individuals’ health
services utilization. First, predisposing factors include: (a) demographic characteristics of
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age and sex representing “biological imperatives” (p. 2); (b) social factors such as
education, ethnicity, and employment; and (c) attitudes, values, and knowledge related to
health and health services that might affect individuals’ subsequent perceptions of need
and use of health services. According to Andersen’s (1995) model, social factors
determine the persons’ ability to cope with problems and influence their enabling
resources which in turn facilitate or impede health services’ use. Second, enabling factors
include: (a) availability and accessibility of services; (b) income; (c) health insurance
status; (d) transportation; and (e) travel time to and waiting times for health care. The
third component is the individual’s treatment needs which involve perceived and
evaluated need.
Andersen’s (1995) behavioral model has been extensively used in studies
addressing health services utilization (Babitsch, Gohl, & von Lengerke, 2012). In this
study predisposing characteristics (i.e., age, ethnicity, marital status, education level, and
employment status), enabling resources (i.e., income, health insurance, and county type),
and perceived and actual need for treatment were examined as predictors of the receipt of
mental health and substance use treatment (see Figure 8).
Methods
Design
Secondary analysis of existing data from the NSDUH 2008-2014 was conducted.
The NSDUH is a national cross-sectional survey funded by SAMHSA (Center for
Behavioral Health Statistics and Quality [CBHSQ], 2015). This large population-based
survey provides information about mental health and substance use problems along with
treatment for mental health and substance disorders among the civilian,
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noninstitutionalized population aged 12 years old or older (CBHSQ, 2015). Data were
aggregated for seven years to obtain a large sample size, thus enabling the detection of
rare events such as substance use treatment among pregnant women as well as ethnic care
disparities.
Sample
An independent, multistage probability stratified sample was used to collect data
from participants in each of the 50 states and the District of Columbia (CBHSQ, 2015).
The data were collected using both face-to-face interviews and audio computer-assisted
self-interviews (ACASI) (CBHSQ, 2015). The sample for this study was restricted to
pregnant women aged 18 to 44 years old who had mental health or substance use
disorders. Pregnant women aged 12 to 17 years were excluded because the NSDUH
included a different mental health module administered only to adults aged 18 and over.
A total of 5,520 pregnant women participated in the survey from 2008 to 2014, including
1,106 pregnant women with mental health problems and 521 women with substance use
disorders.
Measures
Pregnancy status. Women who participated in the NSDUH were classified based
on their self-report of pregnancy status (yes/no). The self-report of pregnancy status
showed substantial test-retest reliability (Cohen’s Kappa = .85) (SAMHSA, 2010).
Predisposing characteristics. Predisposing characteristics included: (a) age
category (18-25; 26-44); (b) ethnicity (Hispanic, White, African American, and other
nonHispanics, i.e., Native American/Alaska Native, Native Hawaiian/Pacific Islander,
Asian, and more than one race; (c) education level (less than high school, high school
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graduate, and college graduate); (d) marital status (married and unmarried, i.e., never
been married, divorced or separated, and widowed), and (e) employment status
(unemployed and employed, i.e., full-time, part-time, and not in labor force).
Enabling factors. Enabling factors included: (a) total family income (< $20,000;
$20,000–49,999; $50,000-$74,999; and ≥$75,000); (b) health insurance (uninsured and
insured); and (c) county urbanicity (large, small, and nonmetro). The socio-demographic
characteristics were grouped accordingly based on the sample size in each category. The
demographic variables demonstrated almost perfect test-retest reliability (Cohen’s Kappa
ranging from .95 to 1.0) (SAMHSA, 2010).
Need factors. Need factors included self-rated health status (poor/fair and
excellent/good/very good), mental health and substance use disorders, as well as
perceived need for treatment.
Substance use disorders. The NSDUH includes structured questions designed to
operationalize the Diagnostic and Statistical Manual of Mental Disorders: DSM-IV
(American Psychiatric Association [APA], 1994) criteria for abuse and dependence of
alcohol and illicit drugs (CBHSQ, 2015). Dependence on a substance is defined as
reporting at least three out of seven dependence symptoms occurred in a 12-month period
(i.e., engaging in activities related to substance use, tolerance, withdrawal, larger or
longer use, unsuccessful attempts to cut down, physical health or emotional problems,
and reduced activities) (APA, 1994). Substance abuse involves not meeting the criteria
for dependence on that substance but reporting at least one of four abuse criteria occur in
a 12-month period (i.e., roles obligations, hazardous use, legal problems, and social
problem) (APA, 1994). The validity of the NSDUH in assessing substance use disorders
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was supported (Jordan, Karg, Batts, Epstein, & Wiesen, 2008). In addition, the test-retest
reliability of substance dependence or abuse measures showed substantial agreement
(Cohen’s Kappa = .67) (SAMHSA, 2010).
Mental health problems (i.e., major depressive episode, anxiety disorder, or
serious psychological distress). The NSDUH adapted questions from the National
Comorbidity Survey Replication (NCS-R) to measure symptoms of MDE (yes/no)
consistently with the DSM-IV criteria (CBHSQ, 2015). The adult MDE measure
demonstrated moderate test-retest reliability (Cohen’s Kappa = .52) (SAMHSA, 2010).
Anxiety disorder (yes/no) was measured using a single item addressing whether a doctor
or other medical professional told participants that they had anxiety disorder in the past
12 months. This measure demonstrated substantial test-retest reliability (Cohen’s Kappa
= .73) (SAMHSA, 2010).
The NSDUH uses Kessler-6 (K6) Psychological Distress Scale (Kessler, Barker,
et al., 2003) to measure symptoms of psychological distress during the past year. The K6
Scale is a 6-item self-report instrument that ranks items on a 4-point scale ranging from
“all of the time” to “none of the time.” These items ask about the frequency of feeling:
nervous, hopeless, restless or fidgety, sad or depressed, that everything was an effort, and
no good or worthless. The range of the total scores is 0 to 24; higher scores indicate
greater psychological distress. The cut-off score of 13 is the indicator of serious
psychological distress (CBHSQ, 2015). The K6 predicted serious mental illness (Kessler,
Barker, et al., 2003) thereby supporting its validity. Cronbach’s alpha for the K6 in the
present sample had excellent reliability (α = .91). In this study, serious psychological
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distress was examined as an outcome variable and included as a confounding variable to
control severity of distress symptoms when addressing ethnic care disparities.
Perceived need for treatment. The NSDUH includes two items addressing
whether participants perceived a need for the treatment for alcohol (one item) and illicit
drugs (one item) (yes/no). The recorded variable addressing the perceived need for
treatment for alcohol or illicit drug use was used in this study. The perceived need for
mental health treatment was measured using a single item addressing whether
participants perceived a need for mental health treatment or counseling during the past 12
months but did not get it (yes/no). Measures of perceived need for treatment
demonstrated substantial test-retest reliability (Cohen’s Kappa = .86 for substance use
treatment; Cohen’s Kappa = .65 for mental health treatment) (SAMHSA, 2010).
Receipt of mental health treatment. The NSDUH includes three items
addressing whether participants received treatment for any problem with emotions,
nerves, or mental health in the past 12 months in an inpatient or outpatient setting, or
used prescription medication for mental health problems (yes/no). These measures
demonstrated excellent test-retest reliability (Cohen’s Kappas = .85) (SAMHSA, 2010).
Receipt of substance use treatment. The NSDUH includes 18 items (yes/no)
addressing the receipt of treatment for alcohol (nine items) and illicit drugs use problems
(nine items) during the past 12 months in any of the following venues: hospitals, inpatient
or outpatient residential drug or alcohol rehabilitation facilities, outpatient mental health
facilities, emergency departments, private doctor's offices, prisons/jails, self-help groups
such as Alcoholics Anonymous (AA), Narcotics Anonymous (NA), or some other places.
The substance use treatment measures showed strong test-retest reliability (Cohen’s
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Kappa = .87) (SAMHSA, 2010). In this study, the recoded variable that indicates the
receipt of treatment for alcohol or illicit drug use at any venue during the past 12 months
was used.
Perceived barriers to mental health treatment. The NSDUH includes 14 items
addressing reasons for not getting mental health treatment (USDHHS, SAMHSA, Office
of Applied Studies, 2015). Perceived barriers include factors such as treatment beliefs,
readiness for treatment, lack of knowledge about treatment programs, confidentiality
concerns, lack of time, and lack of transportation. The majority of items addressing the
barriers to mental health treatment demonstrated good test-retest reliability (Cohen’s
Kappa ≥ .65) (SAMHSA, 2010).
The classification of perceived barriers used by Ko et al. (2012) was adapted for
use in this study. Any items measuring perceived barriers that were scored “yes” were
classified into the following categories: (a) cost (three items: could not afford cost,
insurance did not cover at all, and insurance did not pay enough); (b) stigma (four items:
fear of neighbors’ negative opinion, fear of negative effects on job, confidentiality
concerns, and did not want others to find out); (c) opposition to treatment (four items:
didn’t think treatment was needed at the time, could handle problems without treatment,
didn’t think treatment would help, and fear of being committed/medicated); (d) time or
transportation limitation (two items: didn’t have time, and no transportation or
inconvenient); (e) and did not know where to go.
Procedure
This study used existing de-identified, publicly available data from the NSDUH
2008-2014. Hence, an exemption certification was received for the current study from the
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University of Louisville Institutional Review Board. Approval to use these data for the
proposed research was obtained from SAMHSA through the Interuniversity Consortium
for Political and Social Research (ICPSR). The principal investigator (PI) agreed to: (a)
use the data only for research purposes; (b) report to the ICPSR if the identity of any
subject is discovered accidentally; and (c) keep the data safe from unauthorized access.
Thus, the data were saved as encrypted file on the investigator’s computer.
Data Analysis
Statistical analysis was conducted using complex sample analysis with SPSS
software, version 22.0 (IBM Corp., 2013). Considering the complex survey design and
probability of sampling, a weighting variable was included by diving the final personlevel analysis weights by seven (i.e., the number of years of pooled data), according to
the guidelines of the NSDUH (CBHSQ, 2015). P-values < .05 were considered
statistically significant for all analyses. Bonferroni correction was deemed conservative
(Bland & Altman, 1995); hence, multiple comparisons were considered when interpreting
ethnic care disparities across mental health and/or substance use disorders. The recoded
and imputed variables for demographic and substance use variables were analyzed, while
missing data for mental health variables were excluded from analyses.
Descriptive statistics were conducted for the entire sample using weighted
percentages and standard errors (SEs) to describe all categorical variables; means and SEs
were used to describe psychological distress. Bivariate analyses using chi-square and ttest were performed to examine the associations/differences among predisposing,
enabling, and need factors and receipt of treatment groups.
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Two logistic regression models were conducted to model the probability of the
receipt of mental health treatment and substance use treatment. Unadjusted and adjusted
odds ratios were calculated for best predictors. The full model contained characteristics
with p-value less than .15 in bivariate analyses, confounding variables, and time.
Multicollinearity was assessed by tolerance and variance inflation factor (VIF). A
backward selection method was used to determine which variables to include in the final
model. All models were compared using the likelihood ratio test and the Akaike
Information Criterion (AIC) and Bayesian Information Criterion (BIC) fit statistics
(Vittinghoff, Glidden, Shiboski, & McCulloch, 2012).
Five separate logistic regression models were run to model the probability of the
receipt of mental health treatment among each group of pregnant women with: major
depression, anxiety disorder, serious psychological distress, and/or substance use
disorders, controlling for time and confounding variables (i.e., age, income, education,
marital status, employment status, health insurance, county type, self-rated health status,
severity of distress symptoms, and time). Ethnicity was included as the main variable in
each model. Finally, weighted percentages were calculated for each type of perceived
barrier and compared across types of disorders and ethnicity using chi-square.
Results
Sample Characteristics
A total of 5,520 pregnant women of childbearing age (18-44 years) participated in
the NSDUH 2008-2014. Most participants were white (58.8%), college graduates
(58.6%), employed (93.1%), and had a family income of less than $50,000 (see Table 8).
Approximately 17% of pregnant women had mental health problems in the past year (i.e.,
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MDE, anxiety, or serious psychological distress), 7.6% of them met the DSM-IV criteria
for the substance use disorders, and 4.1% of them had comorbid mental health and
substance disorders. Only 44.5% and 13.1% of pregnant women with mental health or
substance use disorders received treatment for mental health and substance use problems,
respectively.
Among pregnant women with mental health problems (i.e., MDE, anxiety, or
serious psychological distress) (N = 1,106), the majority aged 26-44 years, were white,
unmarried, college educated, employed, insured, had income of less than $50,000, and
lived in urban residency. Most of pregnant women with mental health problems
perceived their health status as good or excellent. Approximately, 34% of them had MDE
or anxiety disorder in the previous year. Only, 20% of pregnant women had comorbid
mental health and substance use disorders. Approximately 75% of pregnant women had
serious psychological distress (K-6 score ≥ 13); the mean score for the K-6 scale of 15.54
(see Table 9).
Most of pregnant women with substance use disorders (N = 521) aged 18 to 25
years, were white, unmarried, college educated, employed, had health insurance
coverage, lived in urban residency, and had an income of less than $50,000. The majority
perceived their health as excellent or good and did not perceive a need for substance use
treatment (95.5%). Forty-one percent of pregnant women had alcohol abuse and 34.9% of
them had alcohol dependence, while 10% and 31.1% met the DSM-IV criteria for illicit
drug abuse and dependence, respectively. Around 28% of women had comorbid
depression/anxiety and substance use disorders (see Table 10).
Factors Associated with Mental Health/Substance Use Treatment
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Compared to pregnant women with mental health problems who did not receive
mental health treatment, those who received the treatment were significantly more likely
to be age 26 to 44 years (p = .001), white (p < .001), and married (p = .13); have college
education (p = .002); have a higher income (p = .008); and have health insurance
coverage (p = .036). Pregnant women who received mental health treatment were more
likely to: perceive need for treatment (p < .001); have a past-year MDE (p = .014); and
have anxiety disorder (p < .001) compared to those who did not receive treatment. They
also had lower scores on serious psychological distress (M = 15.44, SE = .43) than nontreatment recipients (M = 15.62, SE = .29) (p < .001) (see Table 9). Pregnant women with
substance use disorders who received substance use treatment were significantly more
likely to have illicit drug abuse or dependence (p = .002) and have comorbid
depression/anxiety and substance use disorders (p = .007) compared to those who did not
receive the treatment (see Table 10).
Predictors of Mental Health/Substance Use Treatment
A binary logistic regression analysis was conducted to examine the ability of
variables to predict the likelihood of the receipt of mental health treatment. The full
model contained 14 variables: five predisposing characteristics, three enabling, and six
need factors. Using backward elimination, variables were removed one at a time
according to the least significant p-value in the following order: income, age, self-rated
health status, substance use disorders, urban residency, employment status, perceived
need for treatment, and marital status. In the final model, ethnicity, educational level,
health insurance status, past-year serious psychological distress, MDE, and anxiety
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disorder provided the best predictive model of the receipt of mental health treatment.
Both the AIC and BIC were assessed to choose the more parsimonious final model.
The adjusted odds ratios in the final model (see Table 11) indicated that anxiety
disorder was the strongest predictor of the receipt of mental health treatment. After
controlling for other variables in the model, pregnant women with past-year anxiety
disorder had over 17 times the odds of the receipt of mental health treatment compared
with those who did not have anxiety (Adjusted Odds Ratio [AOR]: 17.34; 95%
Confidence Interval [CI]: 8.64-34.81). Compared to White pregnant women, African
Americans (AOR: .38; 95% CI = .20-.74) and other NonHispanics (AOR: .17; 95% CI:
.05-.59) had much lesser odds of mental health treatment receipt. Pregnant women who
had a college education had almost three times the odds of mental health treatment
receipt compared to those who had less than a high school education (AOR: 2.84; 95% CI
= 1.36-5.91). MDE (AOR: 2.48; CI: 1.44-4.27) and health insurance coverage (AOR:
2.34; 95% CI: 1.16-4.71) increased the likelihood of mental health treatment receipt.
After adjusting other variables in the model, for a one-unit increase in the psychological
distress score, the odds of mental health treatment receipt increased significantly by 1.06
times (95% CI: 1.003-1.12).
To predict the likelihood of the receipt of substance use treatment, the full
regression model contained 13 variables: five predisposing characteristics, three enabling
factors, and five need factors. Backward elimination was used to remove one variable at a
time based on the least significant p-value in the following order: educational level,
employment, health insurance, marital status, perceived need, age, income, and self-rated
health status. In the final model, ethnicity, urban residency, alcohol use disorders, illicit
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drug use disorders, and comorbid mental health and substance use disorders were the best
predictors of the receipt of substance use treatment. The AIC and BIC were assessed to
choose the best predictive model.
After controlling for other variables in the final model (see Table 12), illicit drug
dependence was the strongest predictor of the likelihood of substance use treatment
(AOR: 8.83, 95% CI: 3.10-25.16), followed by illicit drug abuse (AOR: 7.89, 95% CI:
1.81-34.4), large urban residency (versus small urban) (AOR: 4.40, 95% CI: 1.82-10.62),
comorbid depression/anxiety and substance use disorders (AOR: 3.13, 95% CI: 1.407.02), alcohol use dependence (AOR: 2.99, 95% CI: 1.37-6.49), and finally nonWhite
ethnicity (vs. Whites) (AOR: .39, 95% CI: .19-.80).
Ethnic Disparities in Mental Health Treatment Receipt
Regardless of mental health or substance use disorders and ethnicity background,
a higher percentage of pregnant women received prescription drugs or outpatient
counseling rather than inpatient treatment (see Table 13). Overall, nonWhite pregnant
women with mental health and/or substance use disorders were less likely to receive any
mental health treatment, outpatient mental health treatment, or prescription drugs than
Whites. NonWhite pregnant women with serious psychological distress were
significantly less likely to receive any mental health treatment (23.8% vs. 47.3%) (p <
.001) or prescription drugs (18.2% vs. 37.7%) (p < .001). Compared to nonWhites, White
pregnant women with substance use disorders (31.3% vs. 18.5%; p = .019) and comorbid
mental health and substance use disorders (54.8% vs. 30.7%; p = .003) were more likely
to receive any mental health treatment.
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Bivariate associations with ethnicity and predisposing, enabling, and need
factors. White pregnant women with any mental health problem were more likely to be
age of 26-44 years (57.3% vs. 42.3%) (p = .008), married (53.3% vs. 31.7%) (p <.001),
and college graduates (56.1% vs. 40%) (p = .005); have a family income of ≥ $50,000
(48.2% vs. 19.1%) (p <.001); and live in nonmetropolitan and small urban areas (62.5%
vs. 40.5) (p <.001). The same pattern of the relationship was found between ethnicity
(Whites vs. nonWhites) and age of 26-44 (58.1% vs. 41.4% (p = .018), married-marital
status (56.6% vs. 31.2%) (p < .001), college education (60.1% vs. 41.3%) (p = .033),
income of ≥ $50,000 (45.7% vs. 16.3%) (p < .001), and small urban and nonmetropolitan
residency (68.4% vs. 38.5%) (p = .001) in pregnant with MDE. Similarly, 26-44 years
age (54.1% vs. 39.2%) (p = .018), married-marital status (51.3% vs. 30.5%) (p < .001),
high income (45.7% vs. 16.3%) (p <.001), and large urban residency (39.1% vs. 58.9%)
(p = .001) differentiated White and nonWhite ethnicity in pregnant women with serious
psychological distress.
Likewise, compared to nonWhites, White pregnant women with substance use
disorders were more likely to be 26-44 years old (54.0% vs. 35.5%) (p = .012), have a
college education (59.7% vs. 42.2%) (p = .030), and income of ≥ $50,000 (50.3% vs.
27.0%) (p = .002), and live in small urban and nonmetropolitan residency (55.8% vs.
37.8%) (p = .015). Yet, only large urban residency (61.1% vs. 31.3%) (p = .002) and high
income level (23.1% vs. 48.8%) (p = .002) differentiated nonWhite and White ethnicity
among women with comorbid mental health and substance use disorders, respectively.
Finally, there was no significant association between ethnicity and self-rated health status
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and severity of distress symptoms in pregnant women, regardless of the type of mental
health and/or substance use disorders.
Odds of mental health treatment receipt. Unadjusted and adjusted logistic
regression models were constructed for MDE, anxiety disorder, serious psychological
distress, substance use disorders, and comorbid mental health and substance use disorders
to examine the effect of ethnicity on mental health treatment receipt. As indicated in
Table 14, after controlling predisposing, enabling, and need factors in the model,
nonWhite pregnant women with MDE (AOR: .49, 95% CI: .27-.92), serious
psychological distress (AOR: .34, 95% CI: .20-.59), substance use disorders (AOR: .46,
95% CI: .23-.93), and comorbid mental health and substance use disorders (AOR: .27,
95% CI: .13-.57) had a much lower odds of receipt of mental health treatment compared
to Whites.
Perceived Barriers to Mental Health Treatment
Among pregnant women who perceived need for treatment because of mental
health, substance use disorders, and comorbid mental health and substance use disorders,
respectively, cost (52.8%, 57.5%, 54.8%), opposition to treatment (40.6%, 45.2%,
43.2%), and stigma (22.6%, 38.1%, 36.7%) were the most frequent self-reported barriers
to mental health treatment (see Table 15). Pregnant women with MDE were significantly
more likely to self-report cost (p = .025) and not knowing where to go (p = .002) as
barriers to mental health treatment compared to those without depressive episode.
However, depressed pregnant women were less likely to have opposition to treatment
compared to non-depressed women (p = .012). Pregnant women with anxiety disorder
were more likely to perceive time/transportation limitations to the receipt of mental
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health treatment compared with those without anxiety (p = .014). Pregnant women who
perceived a need for treatment and had substance use disorders (p < .001) or comorbid
mental health and substance use disorders (p = .035) were significantly more likely to
experience stigma to mental health treatment receipt in comparison with those without
these disorders.
White and nonWhite pregnant women with mental health problems did not differ
in the perceived barriers of: opposition to treatment, time/transportation limitations, and
not knowing where to go (see Figure 9). However, White pregnant women were
significantly more likely to perceive cost as a barrier to mental health treatment.
Although Whites were less likely to self-report stigma as a barrier to mental health
treatment compared to nonWhites, the difference was not significant. There were no
significant differences in perceived barriers to mental health treatment among White and
nonWhite pregnant women with substance use disorders (see Figure 10) or comorbid
mental health and substance disorders (see Figure 11).
Discussion
Despite their needs, pregnant women with mental health and substance use
disorders had low rates of mental health and substance use treatment receipt. In this
study, 45% of pregnant women with mental health problems received mental health
treatment and only 13% of those with substance use disorders received substance use
treatment. These rates are comparable with rates reported in studies based on the NSDUH
addressing mental health treatment (Glasheen et al., 2015; Ko et al., 2012) and substance
use treatment (Terplan et al., 2010) and vary in comparison with other population-based
studies focusing on mental health treatment (Cook et al., 2010; Le Strat et al., 2011;
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Rosen et al., 2004; Song et al., 2004; Vesga-Lopez et al., 2008). For instance, studies
based on the NESARC reported lower rates of mental health treatment (6.1% to 26.5%)
(Le Strat et al., 2011; Vesga-Lopez, 2008).This discrepancy may be due to differences
between the NSDUH and NESARC (as well as other surveys) in the survey design and
measures used to assess mental health and substance use disorders (e.g., DSM-IV based
self-report instrument in the NSDUH vs. diagnostic interview in the NESARC).
Nevertheless, the gap between the need for and receipt of treatment has been found
consistently across studies of pregnant women with these complex health issues (Cook et
al., 2010; Glasheen et al., 2015; Le Strat et al., 2011, Rosen et al., 2004, Song et al.,
2004, Vesga-Lopez et al., 2008), suggesting an urgent call to address their needs.
Predisposing and Enabling Predictors of Treatment Receipt
Of the predisposing characteristics, only ethnicity predicted the receipt of both
mental health treatment and substance use treatment. African Americans and other nonHispanics had a lower odds of the receipt of mental health treatment; nonWhite pregnant
women with substance use disorders had .39 times the odds of substance use treatment
receipt, yet only after controlling for other variables in the model. This ethnic disparity in
treatment receipt is consistent with prior population-based studies (Chang et al., 2016;
Geier et al., 2015; Glasheen et al., 2015; McCabe & Arndt, 2012; Song et al., 2004).
Educational level and health insurance coverage predicted the receipt of mental
health treatment but not substance use treatment. This supports findings of prior research,
namely that perinatal women with mental health issues who received mental health
treatment, compared to those who did not receive any treatment, were more likely to have
a higher educational level (Glasheen et al., 2015) and health insurance coverage
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(Glasheen et al., 2015; Smith et al., 2009). In this study health insurance was not related
to the receipt of substance use treatment which may be due to the homogenous sample of
pregnant women who had health insurance. Other possible explanations for the
differences in how health insurance differentiated the receipt of mental health treatment
versus substance use treatment may include that: (a) health insurance benefits tend to
cover mental health care rather substance use treatment (Clark, Power, Le Fauve, &
Lopez, 2008); and (b) some Medicaid programs do not cover treatment for substance use
disorders which also hinders the access to treatment (CSAT, 2009).
The findings are congruent with prior clinical studies in indicating no significant
relationship between educational level and substance use treatment receipt (Haller et al.,
2001; Messer et al., 1996; Wolton-Moss et al., 2006), although in contrast, Terplan et al.
(2012) found that higher educational level predicted receipt of substance use treatment.
Although income was significantly associated with the receipt of mental health treatment,
it was not one of the predictors of treatment receipt in the final model. This indicates that
there were stronger predictors (e.g., health insurance) that increased the likelihood of the
receipt of mental health treatment in this study sample.
After controlling for other predisposing and need factors, large urban residency
increased the probability of substance use treatment receipt. This finding extends the
growing evidence on the effect of residency on pregnant women’s ability to access
treatment (Heil et al., 2008; Jackson & Shannon, 2012b). Interestingly, the urban
residency was not associated with the receipt of mental health treatment, suggesting that
substance use treatment programs are less available than mental health services and
therefore this creates a greater challenge to access treatment (CSAT, 2009). A review of
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literature indicates that individuals residing in rural areas have distinctive beliefs,
attitudes, and financial constrains that might influence their access to substance use
treatment (Fortney & Booth, 2001). There is a need for more research that sheds the
lights on factors influencing the likelihood rural pregnant women seek treatment.
Maternal age was not associated with substance use treatment, yet it differentiated
the receipt of mental health treatment but not after controlling other variables in the
regression model. Similarly, previous studies of the relationships of receipt of mental
health and substance use treatment with maternal age (Flynn et al., 2006; Glasheen et al.,
2015; McCabe & Arndt, 2012; Messer et al., 1996; Rosen et al., 2004), employment
status (Flynn et al., 2006; Glasheen et al., 2015; Goodman, 2009; Haller et al., 2001;
Messer et al., 1996; Smith et al. 2009; Terplan et al., 2012), and marital status (Flynn et
al., 2006; Glasheen et al., 2015; Messer et al., 1996; Smith et al. 2009; Terplan et al.,
2012) are inconclusive. The current study adds to the literature by shedding light on these
relationships.
Need Factors Predicting Treatment Receipt
To date, little is known regarding how perceived need for treatment contributes to
the receipt of treatment in pregnant women. In a clinical sample of perinatal women, only
40% of those who perceived a need for treatment of depression or anxiety received that
treatment (Goodman & Tyer-Viola, 2010). Yet, perceived need for mental health
treatment in the present study failed to be in the final best predictive model, suggesting
that other predisposing, enabling, and need factors are more significant predictors of the
receipt of mental health treatment. Unfortunately, in the present study, the majority of
pregnant women with substance use disorders (96%) did not perceive a need for
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treatment and did not receive it. Importantly, pregnant women with substance use
disorders continue to deny their needs for treatment which serves as an obstacle to
treatment (CSAT, 2009).
Need factors markedly differentiated the receipt of mental health and substance
use treatment. Anxiety disorder was the strongest predictor of the receipt of mental health
treatment, accounting for other predisposing and enabling factors in the model. It had
almost 17 times the odds of receipt of mental health treatment, while MDE and serious
psychological distress (for one-unit increase) had 2.48 and 1.06 times the odds of
treatment receipt, respectively. There are no previous population-based studies
comparable to this study with respect to the design and sample to contrast these findings.
The only NSDUH-based study that has focused on examining predictors of mental health
treatment receipt among childbearing-aged women with past-month serious
psychological distress showed that anxiety disorder had 3.5 times the odds of mental
health treatment while depression disorder had 5.5 times the odds, controlling for
pregnancy status (Glasheen et al., 2015). However, depression disorder was measured in
this study based on the self-report of receiving a diagnosis of depression rather than
meeting the DSM-IV criteria for MDE, and therefore the differences in the measures and
sample may contribute to the discrepancy in the results between our study and Glasheen’s
et al. (2015) study. Of studies conducted solely among pregnant women, Byatt, Xiao,
Dinh, and Waring (2016) found that pregnant women with depressive symptoms who
participated in the National Health and Nutrition Examination Survey 2005-2012 had
higher odds of mental health care compared to those without depressive symptoms.
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Consistent with another population-based study (Le Strat et al., 2011), comorbid
mental health and substance use disorders were not associated with the receipt of mental
health treatment in childbearing-aged women. However, in this study, pregnant women
with comorbid mental health and substance use disorders had 3.13 the odds of substance
use treatment receipt. This is reflected in a clinical study that showed that despite
pregnant women’s need for mental health treatment they only received a substance usefocused treatment (Coleman-Cowger, 2012).
The results of this study also echo those of other studies that examined the
associations among the type and severity of substance use and substance use treatment,
namely that drug use disorders increased the likelihood of substance use treatment in
pregnant women (Haller et al., 2001; Messer et al. 1996; Wolton-Moss et al., 2006). In
this study, illicit drug dependence rather than abuse was the strongest predictor of the
receipt of substance use treatment. It had 8.83 the odds of the receipt of treatment while
abuse had 7.89 the odds. Furthermore, only alcohol dependence but not abuse predicted
the receipt of treatment. A study based on the Treatment Episode Data Set (TEDS) 19982008 showed that there was an increase in the treatment rate for illicit drug disorder while
a decline for alcohol use disorder in women of childbearing age and particularly among
pregnant women (McCabe & Arndt, 2012). The link between substance dependence
diagnoses and treatment receipt was anticipated because dependence is associated with
more problems related to substance use (Dawson, Saha, & Grant, 2010). On the other
hand, this may indicate that pregnant women did not access treatment until the severity of
their substance use became paramount, suggesting a delayed access to treatment due to
numerous barriers (CSAT, 2009). Given that alcohol abuse was the most common
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substance use disorder among pregnant women in the current study, screening and brief
intervention are recommended to help pregnant women decrease antenatal alcohol
consumption (Marais et al., 2011).
Ethnic Disparities in Mental Health Treatment
Consistent with previous research (Chang et al., 2016; Coleman-Cowger, 2012;
Geier et al., 2015; Glasheen et al., 2015; Song et al., 2004), nonWhite pregnant women
were less likely to receive any mental health treatment compared to Whites. Interestingly,
the data in the present study showed that nonWhite pregnant women compared with
Whites were less likely to receive prescription drugs for mental health and substance use
problems and this relationship was significant among those with serious psychological
distress. Research findings also indicate that ethnic minorities in the general population
(Cooper et al., 2003) and in pregnant women (Goodman, Dimidjian, & Williams, 2013;
Yamamoto, McCormick, & Burris, 2015) are less likely to find prescription drugs
acceptable to treat mental health problems, suggesting negative cultural beliefs toward
treatment.
Aggregating data for seven years of the NSDUH enabled examination of ethnic
differences in the receipt of any mental health treatment, controlling for predisposing,
enabling, and need factors. Among White and nonWhite pregnant women with mental
health and/or substance use disorders, the findings indicated differential pattern in the
receipt of mental health treatment. NonWhite pregnant women were less likely to receive
any mental health treatment for MDE and serious psychological distress. These
differences were reflected in other studies in which ethnicity was examined as a
correlates of treatment receipt (Geier et al., 2015; Glasheen et al., 2015) and in another
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study that focused explicitly on ethnic care disparities among pregnant women with
depressive symptoms (Chang et al., 2016). However, in the current study there were no
differences between White and nonWhite pregnant women with anxiety disorder in the
receipt of mental health treatment. This can be due to recall bias in reporting anxiety
disorder, as this study relied only on one item addressing whether participants received a
diagnosis of anxiety disorder in the past year. In addition, this can be also explained by
the fact that ethnic minorities, particularly African Americans, tend to voluntary seek
treatment specifically for anxiety-like symptoms, whether from a physician or mental
health specialists, or in an emergency room (Snowden, 2001). Therefore, this might
account for the discrepancy between the two groups.
This study also extends prior research that has studied ethnic care disparities
(Chang et al .2016; Song et al., 2004) in emphasizing that nonWhite pregnant women are
less likely to use mental health treatment for substance use disorders and comorbid
mental health and substance use disorders. This finding is consistent with those of a study
in which Black women with substance use disorders did not receive mental health
treatment despite their needs compared to Whites (Coleman-Cowger, 2012).
The current study showed that the greatest ethnic care discrepancy was for
comorbid mental health and substance use disorders. NonWhite pregnant women had .27
times the odds of receipt of treatment compared to Whites. Taking the inverse of these
odds, White pregnant women were almost four times more likely to receive mental health
treatment compared to nonWhites. It is noteworthy, that even after applying the formal
correction for multiple comparison, the differences in mental health treatment for
comorbid mental health and substance use disorders would still have been significant (p =
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.001). Furthermore, it is of particular interest that ethnic disparities in the receipt of
mental health treatment persisted after controlling other characteristics and particularly
indicators of socioeconomic status. This perennial problem of mental health disparities
for ethnic and racial minorities has remained for decades in the United States (Leong &
Kalibatseva, 2011; Snowden, 2012), suggesting that significant changes should be made
in the mental health care system, especially for pregnant women.
Perceived Barriers to Mental health treatment
The common barriers reported by pregnant women in this study included
perceived cost, opposition to treatment, and stigma, regardless of their disorder, i.e.,
mental health and/or substance use disorders, and ethnicity. This perception is also
common among pregnant women from clinical samples (Battle et al., 2013; Goodman,
2009; Jesse et al., 2008; Kim et al., 2010; Kopelman et al., 2008) and the general
population (Ko et al., 2012).
Pregnant women who perceived a need for mental health treatment because of
MDE were significantly more likely to report cost and not knowing where to go as
barriers to mental health treatment. This is congruent with research reports that focused
specifically on women with depressive symptoms (Kim et al., 2010; Kopelman et al.,
2008). However, in contrast with these studies, the current study showed that pregnant
women with MDE compared to those without depression but with a perceived need for
treatment were significantly less likely to have an opposition to treatment. This suggests
that depressive symptoms may motivate pregnant women to accept treatment. However,
research suggests that depression or anxiety disorders of pregnant women, despite their
perceived need for mental health treatment, are unidentified by clinicians (Goodman &
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Tyer-Viola, 2010). Moreover, findings from clinical samples proposed that care providers
themselves are reluctant to provide mental health treatment to pregnant women,
particularly pharmacotherapy, which creates additional barriers to treatment receipt
(Byatt, Biebel, Debordes-Jackson, et al., 2013; Weinreb, Byatt, Moore Simas, Tenner, &
Savageau, 2014).
Although little is known regarding barriers to mental health treatment specifically
in pregnant women with anxiety disorders, this study extends prior research in
demonstrating that time/transportation limitations are significant barriers perceived by
these women. Similarly, time was the most common barrier to receive treatment for
anxiety or depression among a clinical sample of perinatal women (Goodman, 2009). In
addition, results from the NCS-R showed that transportation significantly impeded the
receipt of mental health treatment in respondents from the general population with
moderate to severe mental illness (Mojtabai et al., 2011).
Pregnant women with substance use disorders and comorbid substance use
disorders were more likely to perceive stigma as a barrier to mental health treatment. The
CSAT (2009) also reported that stigma linked with substance use among pregnant women
impeded the access to treatment. The current study signifies the role of stigma when these
women have specific mental health needs because of substance use issues.
Despite ethnic disparities in the receipt of mental health treatment, perceived
barriers to treatment were similar among White and nonWhite pregnant women with
substance use disorders and comorbid mental health and substance use disorders.
However, compared to nonWhites, White pregnant women with mental health problems
were more likely to perceive cost as a barrier to mental health treatment. Although
121

nonWhite pregnant women had lower income compared to Whites, those who are poor
are eligible to Medicaid (American Pregnancy Association, 2017) and therefore this may
lessen their perception of financial constrains with respect to mental health treatment. In
addition, regardless of health insurance status, ethnic minorities often believe that they
can treat their mental illness through willpower and evading morbid thoughts rather than
seeking mental health treatment (Snowden, 2001). Moreover, most of the White pregnant
women in this sample were married which means that they may face more financial
constrains when they are in need to access mental health treatment. Consistently,
Mojtabai et al. (2011) found that married respondents in the NCS-R had higher odds of
reporting structural barriers (e.g., financial barrier) to mental health treatment than
unmarried respondents from the general population.
A higher percentage of nonWhite pregnant women with mental health problems
perceived stigma as a barrier to mental health treatment than Whites, although the
difference between these two groups was not significant. This is similar to the perception
in the general population in the United States (Leong & Kalibatseva, 2011). Yet, the data
in this study showed an opposite pattern in which White pregnant women with substance
use disorders perceived stigma as a greater barrier than nonWhites. Although the
difference was not significant, it is consistent with one population-based study that
reported nonBlacks with alcohol use disorders were more likely to report stigma as a
reason for not seeking substance use treatment than Blacks (Grant, 1997). The findings of
the current study provide an interesting perspective in regards how ethnicity and type of
disorder relate to the perception of stigma as a barrier to mental health treatment. Further
clinical and population-based studies are needed to examine how cultural and
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predisposing beliefs shape the access to treatment across ethnic groups of pregnant
women.
Limitations
The NSDUH measured pregnant at the time of interview but assessed mental
health and substance use disorders in the past year so that these problems may not have
occurred during pregnancy. Second, the diagnosis of pregnancy was based on self-report;
thus, recall bias may affect the estimation of the number of pregnant women in this
survey. Social desirability effect might cause pregnant women to be reluctant to disclose
issues related to mental health and substance use issues. However, the NSDUH uses
computer-assisted interviews to lessen this bias. Fourth, the NSDUH measures MDE and
substance use disorders using a DSM-IV based self-report instrument rather than clinical
interview which may introduce bias. This bias may be increased in measuring anxiety
disorder as this depended on one self-report item--receiving a diagnosis from a health
care provider.
Although aggregating data allowed examination predictors of mental health
receipt, caution should be taken when interpreting the predictors of substance use
treatment due to the small sample size of pregnant women who received the treatment. In
addition, even though this study sheds light on ethnic care disparities, the small sample
sizes in ethnic groups led us to group them in only two categories (nonWhites vs.
Whites). This study also focused on any mental health treatment rather than specific
treatment modalities when examining predictors of treatment and ethnic care disparities.
Finally, the NSDUH is a cross-sectional survey; thus, cause-effect relationships cannot be
drawn.
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Recommendations
These findings reinforce that low rates of treatment receipt for mental health and
substance use disorders remain a significant public health problem among pregnant
women in the United States. Given that anxiety disorder and illicit drug dependence are
the best predictors of mental health and substance use treatment, respectively, pregnancy
provides a unique opportunity not only to screen but also to intervene with pregnant
women who have these and other mental health and substance use problems. The findings
from the present study document ethnic care disparities, suggesting the need for public
education and preventive and interventional strategies to address the needs of ethnic
minority pregnant women.
Expansion of health insurance coverage for mental health treatment is essential as
cost was the most common barrier to treatment. Screening, outreach, and treatment
efforts should focus on pregnant women with substance use disorders to increase
recognition and early treatment. As stigma is attached to substance use disorders, it is
important to educate health care providers regarding prenatal substance use and traumainformed care (SAMHSA, 2014c), thus facilitating the receipt of treatment.
Further research is needed to understand cultural and belief barriers to mental
health treatment as perceived by ethnic minorities. In addition, future research is
recommended to examine the association between the receipt of mental health and
substance use treatment.
Finally, the Behavioral Model of Health Services Use of Andersen (1995) was
useful in predicting the receipt of mental health/substance use treatment given
predisposing, enabling, and need factors among pregnant women with mental health/
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substance use disorder. It also identified ethnic disparities in the receipt of mental health
treatment among these women and thereby can be used to guide future research
addressing a vulnerable population of pregnant women.

125

Table 8
Socio-demographic Characteristics of Pregnant Women Aged 18-44, NSDUH 20082014 (N = 5,520)
Characteristics
Categories
Weighted %
SE
Age in years
18-25
37.4
1.0
26-44
62.6
1.0
Ethnicity

White
African American
Other nonHispanica
Hispanic

58.8
14.2
8.6
18.3

1.2
0.8
0.6
0.9

Marital status

Married
Unmarried

60.7
39.3

1.1
1.1

Education

Less than high
school
High school
College graduate

15.4

0.7

26.0
58.6

0.9
1.0

Employment status

Employed
Unemployed

93.1
6.9

0.5
0.5

Family income

<$20,000
$20,000-49,999
$50,000-$74,999
≥$75,000

22.4
30.4
17.1
30.1

0.9
1.1
0.7
1.1

Health insurance

Insured
Uninsured

90.2
9.8

0.5
0.5

County urbanicity

Large urban
Small urban
Nonmetro

53.2
31.8
15.0

1.2
1.0
0.7

Self-rated health
status

Excellent/very
95.1
0.4
good/good
Fair/poor
4.9
0.4
Note. Imputed and recoded variables were used. Frequencies and weighted percentages
do not include missing data addressing mental health. NSDUH = National Survey on
Drug Use and Health; SE = Standard Error.
a
Other nonHispanics included Native American/Alaska Native, Native Hawaiian/Pacific
Islander, Asian, and more than one race.
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Table 9
Characteristics Associated with Receipt of Mental Health Treatment among Pregnant
Women with Mental Health Problems Aged 18-44 Years, NSDUH 2008-2014 (N = 1,106)

Characteristics
Age in years
18-25
26-44

Total Sample
Wt. % (SE)

Receipt of Mental Health
Treatment
Yes (n = 453) No (n = 650)
Wt. % (SE)
Wt. % (SE)

χ

pvalue

2

47.7 (2.4)
52.3 (2.4)

39.3 (3.4)
60.7 (3.4)

54.5 (3.0)
45.5 (3.0)

25.15

.001

Ethnicity
White
African American
Other NonHispanica
Hispanic

66.9 (2.2)
12.7 (1.6)
5.2 (0.9)
15.2 (1.5)

79.7 (2.9)
6.8 (1.6)
2.8 (0.9)
10.7 (2.1)

56.7 (3.1)
17.3 (2.5)
7.1 (1.5)
18.8 (2.3)

66.82

<.001

Marital status
Married
Unmarried

46.3 (2.8)
53.7 (2.8)

54.4 (3.6)
45.6 (3.6)

39.8 (4.3)
60.2 (4.3)

23.31

.013

Education
<High school
High school
College graduate

18.3 (1.4)
31.0 (2.1)
50.7 (2.1)

14.0 (2.2)
25.9 (3.2)
60.1 (3.7)

21.7 (2.1)
35.1 (3.0)
43.2 (2.9)

31.39

.002

Employment status
Employed
Unemployed

90.4 (1.1)
9.6 (1.1)

91.1 (1.6)
8.9 (1.6)

89.9 (1.6)
10.1 (1.6)

.47

.593

Family income
<$20,000
$20,000-$49,999
$50,000-$74,999
≥$75,000

28.8 (2.2)
32.5 (2.2)
15.6 (1.8)
23.0 (2.3)

24.7 (2.8)
27.6 (2.8)
18.0 (3.2)
29.7 (3.5)

32.1 (3.1)
36.5 (3.2)
13.7 (2.1)
17.7 (2.9)

31.83

.008

Health insurance
Insured
Uninsured

88.0 (1.6)
12.0 (1.6)

91.3 (1.9)
8.7 (1.9)

85.4 (2.3)
14.6 (2.3)

8.93

.036

County urbanicity
Nonmetropolitan
Small
Large

18.8 (1.6)
36.4 (2.5)
44.7 (2.5)

21.2 (2.4)
36.2 (3.5)
42.6 (3.8)

16.9 (2.0)
36.6 (3.3)
46.5 (3.5)

3.52

.445

(Continued)
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Characteristics

Total Sample
Wt. % (SE)

Receipt of Mental Health
Treatment
Yes (n = 453) No (n = 650)
Wt. % (SE)
Wt. % (SE)

χ

pvalue

2

Self-rated health
status
Poor/fair
Excellent/very/good

10.4 (1.4)
89.6 (1.4)

9.0 (2.0)
91.0 (2.0)

11.5 (2.1)
88.5 (2.1)

1.84

.400

Perceived need for
treatment
Yes
No

28.1 (2.5)
71.9 (2.5)

36.2 (3.6)
63.8 (3.6)

21.6 (2.7)
78.4 (2.7)

28.69

<.001

Serious psychological
distress (Mean, SE)

15.54 (.24)

15.44 (.43)

15.62 (.29)

65.68

<.001

Major depressive
episode
Yes
No

33.9 (2.3)
66.1 (2.3)

39.6 (3.5)
60.4 (3.5)

29.4 (2.6)
70.6 (2.6)

12.50

.014

Anxiety disorder
Yes
No

33.6 (2.0)
66.4 (2.0)

59.1 (3.3)
40.9 (3.3)

13.2 (1.8)
86.8 (1.8)

256.05

<.001

Substance use
disorderb
Yes
20.0 (1.7)
20.3 (2.4)
19.8 (2.2)
.03
.893
No
80.0 (1.7)
79.7 (2.4)
80.2 (2.2)
Note. Imputed and recoded variables were used. Frequencies and weighted percentages
do not include missing data addressing mental health. NSDUH = National Survey on
Drug Use and Health; SE = Standard Error; Wt. % = Weighted percentages.
a
Other nonHispanics include Native American/Alaska Native, Native Hawaiian/Pacific
Islander, Asian, and more than one race. bSubstance use disorder includes alcohol or
illicit drug use dependence or abuse measured based on the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV) criteria.
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Table 10
Characteristics Associated with Receipt of Substance Use Treatment among Pregnant
Women with Substance Use Disorders Aged 18-44 Years, NSDUH 2008-2014 (N = 521)

Total Sample
Wt. % (SE)

Receipt of Substance Use
Treatment
Yes (n = 68) No (n = 453)
Wt. % (SE)
Wt. % (SE)

χ

2

pvalue

Characteristics
Age in years
18-25
26-44

53.2 (3.5)
46.8 (3.5)

51.1 (9.2)
48.9 (9.2)

53.5 (3.5)
46.5 (3.5)

.15

.789

Ethnicity
White
NonWhitea

60.9 (3.1)
39.1 (3.1)

66.1 (7.3)
33.9 (7.3)

60.1 (3.4)
39.9 (3.4)

.89

.480

Marital status
Married
Unmarried

30.7 (3.2)
69.3 (3.2)

18.9 (8.8)
81.1 (8.8)

32.5 (3.4)
67.5 (3.4)

5.14

.218

Education
<High school
High school
College graduate

20.4 (2.1)
26.6 (2.6)
52.9 (3.3)

29.4 (8.2)
27.9 (6.6)
42.8 (8.5)

19.1 (2.1)
26.4 (2.6)
54.5 (3.6)

4.63

.281

Employment
Employed
Unemployed

89.5 (1.8)
10.5 (1.8)

88.7 (3.8)
11.3 (3.8)

89.6 (2.0)
10.4 (2.0)

.05

.817

Family Income
<$20,000
$20,000-49,999
≥$50,000

29.3 (2.9)
29.5 (2.5)
41.2 (3.1)

39.4 (8.6)
30.2 (7.7)
30.4 (7.9)

27.8 (3.2)
29.4 (2.7)
42.8 (3.2)

4.92

.297

Health insurance
Insured
Uninsured

91.8 (1.1)
8.2 (1.1)

92.6 (3.6)
7.4 (3.6)

91.7 (1.3)
8.3 (1.3)

.07

.831

County urbanicity
Nonmetropolitan
Small urban
Large urban

19.3 (2.2)
29.5 (2.9)
51.2 (3.3)

19.1 (5.6)
15.3 (4.4)
65.5 (7.4)

19.3 (2.5)
31.7 (3.2)
49.1 (3.7)

8.48

.059

Self-rated health
status
9.4 (2.0)
Poor/Fair
Excellent/very/good 90.6 (2.0)

10.8 (6.5)
89.2 (6.5)

9.2 (2.0)
90.8 (2.0)

.19
.796
(Continued)
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Receipt of Substance Use
Treatment
Yes (n = 68) No (n = 453)
Wt. % (SE)
Wt. % (SE)

Characteristics

Total Sample
Wt. % (SE)

Perceived need for
treatment
Yes
No

4.5 (1.0)
95.5 (1.0)

7.6 (4.6)
92.4 (4.6)

Alcohol use disorder
None
Abuseb
Dependencec

23.8 (2.7)
41.3 (3.6)
34.9 (3.3)

Illicit drug use
disorderd
None
Abuseb
Dependencec

58.9 (2.9)
10.0 (1.6)
31.1 (2.4)

χ2

pvalue

4.0 (0.9)
96.0 (0.9)

1.79

.316

26.8 (6.6)
26.1 (8.1)
47.2 (8.8)

23.3 (2.8)
43.6 (3.9)
33.1 (3.5)

8.09

.128

27.7 (8.8)
19.3 (6.6)
53.0 (8.3)

63.6 (3.2)
8.6 (1.9)
27.8 (2.4)

31.81

.002

Depression/anxiety
disorders
Yes
27.8 (2.7)
49.5 (8.6)
24.7 (3.1)
16.86
.007
No
72.2 (2.7)
50.5 (8.6)
75.3 (3.1)
Note. Imputed and recoded variables were used. Frequencies and weighted percentages
do not include missing data addressing mental health. NSDUH = National Survey on
Drug Use and Health; SE = Standard Error; Wt. Percentages = Weighted Percentages.
a
Other nonHispanics include Native American/Alaska Native, Native Hawaiian/Pacific
Islander, Asian, and more than one race. bSubstance abuse involves not meeting the
criteria for dependence on that substance but reporting at least one of four abuse criteria
occur in a 12-month period (i.e., roles obligations, hazardous use, legal problems, and
social problem). cDependence on a substance involves reporting at least three out of
seven dependence symptoms occur in a 12-month period (i.e., engaging in activities
related to substance use, tolerance, withdrawal, larger or longer use, unsuccessful
attempts to cut down, physical health or emotional problems, and reduced activities).
d
Illicit drugs include heroin, marijuana, cocaine, inhalants, sedatives, tranquilizers,
hallucinogens, stimulants, and analgesics.
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Table 11
Logistic Regression Using Backward Elimination to Identify the Best Predictive Model of
the Probability of Mental Health Treatment Receipt among Pregnant Women Aged 18-44
years with Mental Health Problems, Controlling for Time, NSDUH 2008-2014 (N =
1,106)
Characteristics
Ethnicity
White
African American
Other nonHispanicsa
Hispanic

Unadjusted
OR
Reference
.28
.28
.40

95% CI

Adjusted
OR

95% CI

.16-.51**
.13-.63
.23-.71

Reference
.38
.17
.72

.20-.74**
.05-.59
.39-1.31

.67-2.50
1.36-5.91**

Education
<High school
High school
College graduate

Reference
1.15
2.16

.67-1.96
1.31-3.54**

Reference
1.29
2.84

Health insurance status
Uninsured
Insured

Reference
1.79

1.03-3.10*

Reference
2.34

1.16-4.71*

.99

.95-1.04

1.06

1.003-1.12*

1.07-2.26*

Reference
2.48

1.44-4.27**

Serious psychological
distress (One unit
increase)
Major depressive episode
No
Yes

Reference
1.57

Anxiety disorder
No
Reference
Reference
Yes
9.51
6.19-14.61***
17.34
8.64-34.81***
Note. Imputed and recoded variables were used. NSDUH = National Survey on Drug Use
and Health; OR = Odds Ratio; CI = Confidence Intervals.
a
Other nonHispanics include Native American/Alaska Native, Native Hawaiian/Pacific
Islander, Asian, and more than one race.
*p < .05. **p < .01. ***p < .001.
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Table 12
Logistic Regression Using Backward Elimination to Identify the Best Predictive Model of
the Probability of Substance Use Treatment Receipt among Pregnant Women Aged 18-44
years with Substance Use Disorders, NSDUH 2008-2014, Controlling Time (N = 521)
Characteristics
County urbanicity
Small urban
Nonmetro
Large urban

Unadjusted
OR
Reference
2.05
2.76

95% CI

Adjusted
OR

95% CI

.85-4.95
1.24-6.15*

Reference
2.570
4.40

.89-7.43
1.82-10.62**

.19-.80*

Ethnicity
Whites
NonWhitesa

Reference
.77

.38-1.59

Reference
.39

Alcohol use disorder
None
Abuseb
Dependencec

Reference
.52
1.24

.21-1.32
.57-2.71

Reference
2.84
2.99

.95-8.48
1.37-6.49*

Illicit drug use disorderd
None
Abuseb
Dependencec

Reference
5.16
4.38

1.35-19.78**
1.77-10.82

Reference
7.89
8.83

1.81-34.40***
3.10-25.16

Depression/Anxiety disorders
No
Reference
Reference
Yes
2.98
1.32-6.71**
3.13
1.40-7.02**
Note. Imputed and recoded variables were used. Frequencies and weighted percentages
do not include missing data addressing mental health. NSDUH = National Survey on
Drug Use and Health; OR = Odds Ratio; CI = Confidence Intervals.
a
NonWhites include African Americans, Hispanics, and Other nonHispanics, i.e., Native
American/Alaska Native, Native Hawaiian/Pacific Islander, Asian, and more than one
race. bSubstance abuse involves not meeting the criteria for dependence on that substance
but reporting at least one of four abuse criteria occur in a 12-month period (i.e., roles
obligations, hazardous use, legal problems, and social problem). cDependence on a
substance involves reporting at least three out of seven dependence symptoms occur in a
12-month period (i.e., engaging in activities related to substance use, tolerance,
withdrawal, larger or longer use, unsuccessful attempts to cut down, physical health or
emotional problems, and reduced activities). dIllicit drugs include heroin, marijuana,
cocaine, inhalants, sedatives, tranquilizers, hallucinogens, stimulants, and analgesics.
*p < .05. **p < .01. ***p < .001.
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Table 13
Percentages of Mental Health Treatment Modalities in Non-Hispanic White and Nonwhite Pregnant Women with
Mental Health and Substance Use Disorders and Aged 18-44 Years, NSDUH 2008-2014
Women with Depression (N = 381)
Total sample
Whites (n = 227) NonWhitesa (n = 154)
Mental health treatment
Wt. % (SE)
Wt. % (SE)
Wt.% (SE)
χ2
p-value
Any treatment (n = 179)
Outpatient treatment (n = 105)
Inpatient treatment (n = 21)
Prescription drugs (n = 142)

51.8 (3.2)
33.3 (3.7)
3.9 (1.0)
40.5 (3.0)

55.8 (4.1)
35.2 (4.8)
3.3 (1.1)
44.8 (3.9)

42.9 (5.0)
29.2 (4.6)
5.2 (1.9)
30.9 (5.2)

5.38
1.32
.80
6.53

.062
.373
.347
.054

1.22
.39
1.20
1.90

.461
.673
.241
.388
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Women with Anxiety (N = 379)
Total sample
Whites (n = 296)
NonWhites (n = 83)
Wt. % (SE)
Wt. % (SE)
Wt. % (SE)
Any treatment (n = 271)
Outpatient treatment (n = 141)
Inpatient treatment (n = 17)
Prescription drugs (n = 241)

78.2 (2.7)
45.7 (3.6)
3.0 (0.9)
67.9 (3.4)

79.4 (3.1)
46.6 (3.8)
2.5 (0.9)
69.6 (3.7)

73.7 (7.0)
42.7 (8.5)
4.9 (2.3)
61.6 (8.6)

Women with Serious Psychological Distress (N = 842)
Total sample
Whites (n = 482) NonWhites (n = 360)
Wt. % (SE)
Wt. % (SE)
Wt. % (SE)
Any treatment (n = 308)
Outpatient treatment (n = 178)
Inpatient treatment (n = 35)
Prescription drugs (n = 247)

38.6 (2.5)
24.5 (2.3)
3.5 (0.9)
30.4 (2.4)

47.3 (3.4)
29.7 (3.6)
3.2 (1.0)
37.7 (3.3)

23.8 (3.4)
15.7 (2.3)
4.0 (1.5)
18.2 (3.1)

45.70
20.61
.45
35.08

<.0001
.003
.593
<.0001
(Continued)

Women with Substance Use Disordersb (N = 521)
Total sample
Whites (n = 284)
NonWhites (n = 237)
Wt. % (SE)
Wt. % (SE)
Wt. % (SE)
Any treatment (n = 140)
Outpatient treatment (n = 76)
Inpatient treatment (n = 21)
Prescription drugs (n = 104)

26.4 (2.9)
14.8 (2.1)
2.8 (1.0)
19.1 (2.5)

31.3 (4.1)
16.7 (3.0)
2.4 (1.1)
21.7 (3.5)

18.5 (3.4)
11.8 (2.8)
3.5 (2.1)
14.9 (3.0)

χ2
10.40
2.32
.54
3.63

p-value
.019
.249
.619
.145

Women with Comorbid Mental Health and Substance Use
Disorders (N = 244)
Total sample
Whites (n = 89)
NonWhites (n = 112)
Wt. % (SE)
Wt. % (SE)
Wt. % (SE)
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Any treatment (n = 110)
44.9 (3.8)
54.8 (4.3)
30.7 (5.7)
13.83
. 003
Outpatient treatment (n = 65)
26.6 (3.6)
30.6 (4.9)
20.9 (4.6)
2.89
.161
Inpatient treatment (n = 18)
6.2 (2.4)
5.5 (2.6)
7.3 (4.3)
.34
.696
Prescription drugs (n = 83)
33.4 (3.6)
39.1 (4.8)
25.2 (5.4)
5.12
.074
Note. Imputed and recoded variables were used. Frequencies and weighted percentages do not include missing data
addressing mental health. NSDUH = National Survey on Drug Use and Health; Wt. %= Weighted Percentages; SE =
Standard Error.
a
NonWhites include African Americans, Hispanics, and Other nonHispanics, i.e., Native American/Alaska Native, Native
Hawaiian/Pacific Islander, Asian, and more than one race. bSubstance use disorders include alcohol or illicit drug use
dependence or abuse measured based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria.

Table 14
Logistic Regression Model of the Probability of the Receipt of Mental Health Treatment
in Pregnant Women Aged 18-44Years by type of Mental Health and/or Substance Use
Disorders and Ethnicity, NSDUH 2008-2014
Unadjusted
OR

95% CI

Adjusted
OR

1. Major depression (N = 381)
NonWhitesa vs. Whites

.60

.34-1.03

.49

.27-.92*

2. Anxiety disorder (N = 379)
NonWhites vs. Whites

.73

.31-1.73

.91

.37-2.27

3. Serious psychological
distressb (N = 842)
NonWhites vs. Whites

.35

.22-.56***

.34

.20-59***

4. Substance use
disordersc (N = 521)
NonWhites vs. Whites

.50

.27-.89*

.46

.23-.93*

Model/Disorder

95% CI

5. Comorbid
disordersd (N = 244)
NonWhites vs. Whites
.37
.19-.70**
.27
.13-.57**
Note. Control variables include predisposing factors (i.e., age, education, marital status,
employment status); enabling factors (i.e., income, health insurance, and county type);
need factors (i.e., self-rated health status and severity of distress symptoms); and time.
Imputed and recoded variables were used. Frequencies and weighted percentages do not
include missing data addressing mental health. NSDUH = National Survey on Drug Use
and Health; OR = Odds Ratio; CI = Confidence Intervals.
a
NonWhites include African Americans, Hispanics, and Other nonHispanics, i.e., Native
American/Alaska Native, Native Hawaiian/Pacific Islander, Asian, and more than one
race. bIncluded those who had a score of 13 or above on the Kessler-6 Psychological
Distress Scale. cSubstance use disorders include alcohol or illicit drug use dependence or
abuse measured based on the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) criteria. dComorbid disorders involve mental health (i.e, major depressive
episode, anxiety disorder, or serious psychological distress) and substance use disorders.
*p < .05. **p < .01. ***p < .001.

135

Table 15
Differences in Perceived Barriers to Mental Health Treatment among Pregnant Women with Mental Health and/or Substance
Use Disorders and Perceived Need for Treatment, NSDUH (2008-2014) (N = 391)
Cost
Wt.% (SE)

Opposition to
Treatment
Wt.% (SE)

Stigma
Wt.% (SE)

Time/transportation
limitations
Wt.% (SE)

Not knowing
where to go
Wt.% (SE)

Yes
No

52.8 (3.8)
49.2 (7.0)

40.6 (3.4)
48.6 (7.3)

22.6 (3.4)
22.4 (5.4)

21.1 (2.7)
16.0 (4.9)

16.6 (2.6)
13.2 (3.4)

Major depression:

Yes
No

61.1 (5.2)*
46.2 (3.9)

33.4 (3.3)*
48.1 (4.6)

23.7 (5.2)
22.1 (4.0)

17.8 (3.3)
20.5 (3.2)

24.2 (4.7)**
11.2 (2.0)

Anxiety disorder:

Yes
No

51.7 (6.7)
52.0 (4.3)

35.9 (6.1)
45.2 (4.0)

17.7 (4.1)
24.4 (3.9)

31.1 (5.5)*
15.4 (2.4)

13.0 (3.5)
16.8 (2.8)

Yes
No

52.3(4.4)
51.0 (5.6)

39.5 (4.0)
48.5 (6.5)

22.9 (4.1)
21.6 (4.7)

17.9 (3.3)
22.8 (4.4)

18.0 (2.9)
11.5 (2.6)

Yes
No

57.5 (6.0)
49.5 (4.1)

45.2 (6.3)
41.8 (4.3)

38.1 (6.3)***
16.2 (3.3)

15.0 (4.3)
21.6 (3.1)

18.0 (6.0)
14.7 (3.0)

Disorders

Any mental health problem:
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Serious psychological
distress:a
Substance use disorders:b
Comorbid disorders:c

Yes
54.8 (6.0)
43.2 (4.0)
36.7(4.1)*
16.3 (3.3)
14.8 (2.9)
No
44.1 (7.9)
47.5 (8.2)
18.1 (6.0)
17.3 (5.6)
8.7 (3.5)
Note. Imputed and recoded variables were used. Frequencies and weighted percentages do not include missing data addressing
mental health. NSDUH = National Survey on Drug Use and Health; CI= Confidence Intervals.
a
Included those who had a score of 13 or above on the Kessler-6 Psychological Distress Scale. bSubstance use disorders include
alcohol or illicit drug use dependence or abuse measured based on the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) criteria. cComorbid disorders involve mental health (i.e., major depressive episode, anxiety disorder, or serious
psychological distress) and substance use disorders.
*p < .05. **p < .01. ***p < .001.
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Figure 7. The Behavioral Model of Health Services Use. Adapted from “Revisiting the Behavioral Model and Access to
Medical Care: Does it Matter?” by R.M. Andersen, 1995, Journal of Health and Social Behavior, 36(1), p. 8.
Permission for use in the dissertation is not required according to the American Sociological Association.
http://www.asanet.org/research-publications/journal-resources/reprint-permissions
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Figure 8. Theoretical framework adapted the Behavioral Model of Health Services Use. Adapted from “Revisiting the Behavioral
Model and Access to Medical Care: Does it Matter?” by R.M. Andersen, 1995, Journal of Health and Social Behavior, 36(1), p. 8.

a
b

**

Figure 9. Perceived barriers to mental health treatment in White and NonWhite pregnant
women with mental health problems who perceived need for treatment, National Survey
on Drug Use and Health, 2008-2014 (N = 296). Imputed and recoded variables were
used. Frequencies and weighted percentages do not include missing data addressing
mental health. NonWhites include African Americans, Hispanics, and other
nonHispanics, i.e., Native American/Alaska Native, Native Hawaiian/Pacific Islander,
Asian, and more than one race.
a
n = 195. bn = 101.
** p < .01.
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a
b

Figure 10. Perceived barriers to mental health treatment in White and NonWhite
pregnant women with substance use disorders who perceived a need for treatment,
National Survey on Drug Use and Health (N = 127). Imputed and recoded variables were
used. Frequencies and weighted percentages do not include missing data addressing
mental health. NonWhites include African Americans, Hispanics, and other
nonHispanics, i.e., Native American/Alaska Native, Native Hawaiian/Pacific Islander,
Asian, and more than one race.
a
n = 72. bn = 55.
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a
b

Figure 11. Perceived barriers to mental health treatment in pregnant women with
comorbid mental health and substance use disorders who perceived a need for treatment,
National Survey on Drug Use and Health, 2008-2014 (N = 114). NonWhites include
African Americans, Hispanics, and other nonHispanics, i.e., Native American/Alaska
Native, Native Hawaiian/Pacific Islander, Asian, and more than one race.
a
n = 66. bn = 48.
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CHAPTER V
DISCUSSION AND CONCLUSION

The purposes of this dissertation were to: (1) systematically review literature of
trend and population-based studies on mental health and substance use disorders and
treatment receipt among pregnant women in the United States; (2) compare trends in
mental health and substance use disorders and treatment receipt by pregnancy status from
2008 to 2014; and (3) identify predictors of treatment receipt for mental health and
substance use disorders and examine ethnic care disparities in mental health treatment
among pregnant women with mental health and/or substance use disorders in the United
States.
Synthesis of Findings and Implications
Trends in Mental Health and Substance Use Disorders
Chapter Two was a systematic review of trend studies on mental health disorders,
particularly depression, anxiety disorder, and psychological distress, among pregnant
women in the United States. However, the review revealed a lack of recent evidence
addressing trends in mental health disorders among pregnant women in the United States.
Yet in Chapter Three, a significant increase was identified in the rates of past-year
anxiety disorder and past-month serious psychological distress among women of
childbearing age from 2008 to 2014. This is congruent with the increase in poor mental
health for 15 days or more in the past month from 2001 to 2012 among the general
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population in the United States (Mojtabi & Jorm, 2015). Interestingly, Chapter Four
findings revealed that past-year anxiety disorder was the best predictor of receipt of
mental health treatment among pregnant women. This emphasizes the need to screen and
treat these mental health problems during prenatal period. In addition, evidence-based
prevention strategies are required to reduce the negative health consequences of mental
health disorders for the mother and her child.
The systematic review of trend studies on maternal substance use disorders
revealed that maternal abuse of opioid, cannabis and hallucinogens, and
methamphetamine increased from 1999 to 2008; however, cocaine abuse decreased
significantly while alcohol abuse declined slightly (Pan & Yi, 2013). Maeda et al. (2014)
found that opioid use disorder increased from 1998 to 2011. Similarly, Chapter Three
showed a significant linear trend in illicit drug use disorder from 2008 to 2014 among
women of childbearing age. It is noteworthy that the studies reviewed did not compare
trends in substance use disorders by pregnancy status; however, the findings in Chapter
Three did not indicate a significant difference between pregnant and nonpregnant women
in illicit drug or alcohol use disorders over time. Unfortunately, there is a paucity of
studies specifically addressing trends in the national estimates of substance use disorders
among pregnant and nonpregnant women in the United States. It is crucial to conduct
such studies especially given that treatment admissions for illicit drug use disorders
increased profoundly among pregnant women from 1998 to 2008 compared to
nonpregnant women (McCabe & Arndt, 2012).
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Trends in Treatment Receipt
The systematic review revealed an increase in antidepressant use among pregnant
women from 1995 to 2010 (Andrade et al., 2008; Bobo et al., 2014; Meunier et al., 2013),
whereas the rate of psychotropic medications use remained stable from 2006 to 2010
(Hanley & Mintzes, 2014). These studies did not compare trends by pregnancy status.
However, Hanley and Mintzes (2014) found that the rates of psychotropic medication use
were higher before pregnancy than in the first and second trimesters of pregnancy.
Although antidepressant use during pregnancy is controversial (Yamamoto et al.,
2015), there was only one study of a nationally representative sample on antidepressant
use among pregnant women in the United States identified for review (Meunier et al.,
2013). Hence, further research is needed to reflect recent trends in antidepressant use
among nationally representative sample of pregnant women. The systematic review also
showed there is a lack of evidence regarding trends in the receipt of any mental health
treatment modalities including prescription drugs, outpatient counseling, or inpatient
treatment among pregnant women. In contrast, trends in the receipt of any of these
modalities were examined in Chapter Three; thus, the findings from Chapters Two and
Three are not comparable in regards to the receipt of mental health treatment. Chapter
Three revealed no significant increase in the receipt of mental health treatment among
women of childbearing age from 2008 to 2014. However, pregnant women had a lower
likelihood of treatment receipt compared to nonpregnant women. The findings presented
in Chapter Three revealed were similar. Trends in the receipt of mental health treatment
among childbearing-aged women with mental illness were evaluated, controlling for
severity of mental illness. The trends in receipt of mental health treatment among
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pregnant women were inconsistent with the increase over time in mental health treatment
among the general population (Mojtabi & Jorm, 2015). This suggests that women of
childbearing age may have special mental health needs.
Interestingly, there was no significant interaction between pregnancy status and
time in predicting mental health treatment receipt as discussed in Chapter Three; pregnant
women had a lower odds of mental health treatment receipt compared to nonpregnant
women. On the other hand, the systematic review revealed mixed findings regarding the
difference between pregnant and nonpregnant women in the receipt of mental health
treatment which may be due to the heterogeneity of samples and measures of mental
health problems. The Chapter Three findings were in accord with a study based on the
2008-2012 NSDUH (Glasheen et al., 2015), although the two studies included different
samples (e.g., women with past-year mental illness in Chapter Three versus women with
past-month psychological distress in the study of Glasheen et al.). Thus, it is crucial to
conduct more research about the difference between pregnant and nonpregnant women in
the receipt of mental health treatment to tailor interventions according to the needs of
pregnant women.
The systematic review indicated an increase in treatment admissions for illicit
drug use disorder from 1998 to 2008 (McCabe & Arndt, 2012), and for marijuana
(Martin, Longinaker, Mark, et al., 2015) and opioid use disorders from 1992 to 2012
(Martin, Longinaker, & Terplan, 2015). Yet, treatment admissions decreased over time
for cocaine and alcohol use (Martin, Longinaker, Mark, et al., 2015; McCabe & Arndt,
2012). Overall, treatment admissions for substance use disorders remained stable from
1992 to 2012 at 4% among pregnant women (Martin, Longinaker, Mark, et al., 2015).
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This suggests that there was no improvement in the utilization of substance use treatment
services among pregnant women. The findings in Chapter Three supported this as the rate
of unmet need for substance use treatment remained stable at 7% from 2008 to 2014
among pregnant women. This is of critical concern because several states enacted laws
that stigmatized prenatal illicit substance use in pregnant women (Guttmacher Institute,
2017). Subsequently, many pregnant women do not seek treatment to avoid losing
custody of their child (Tuchman, 2010). Legal and treatment initiatives should focus on
the specific needs of pregnant women with substance use disorders. According to the
CSAT (2009), an atmosphere of hope, acceptance, and support is essential for women to
overcome the challenges of substance use disorder and receive substance use treatment.
Factors Associated with Treatment Receipt
The systematic review of population-based studies, although they were few,
revealed that factors related to the receipt of mental health treatment included White
ethnicity (Bennett et al., 2010; Byatt et al., 2016; Chang et al., 2016), older reproductive
age, college education (Chang et al., 2016), having assistance/insurance coverage
(Bennett et al., 2010; Chang et al., 2016), and having mental health problems (Byatt et
al., 2016; Roberson et al., 2016). Multivariate analyses from Chapter Four supported
these findings. The final predictive model for mental health treatment receipt contained
six variables: White ethnicity, college education, health insurance coverage, past-year
anxiety disorder, MDE, and serious psychological distress.
While the only national study focused on depressive symptoms among pregnant
women (Byatt et al., 2016), Chapter Four findings added to the literature by identifying
the best predictors of mental health treatment receipt given the need factors for treatment.
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Anxiety disorder was the strongest predictor, followed by MDE and serious
psychological distress. These findings indicate the critical nature of screening and
treatment initiatives for these mental health problems during pregnancy; emphasis on
anxiety disorder is particularly warranted, especially since it is more often ignored than
depression in pregnant women (Fairbrother et al., 2016; Fairbrother et al., 2015).
Only two population-based studies identified for the systematic review examined
factors associated with substance use treatment receipt among childbearing-aged women
(Terplan et al., 2012) and pregnant women (Kotelchuck et al., 2017). Factors related to
treatment receipt in these studies included college education, older reproductive age, and
governmental assistance/private health insurance. Compared to those who did not receive
treatment, Kotelchuck et al. (2017) also found that Black or Hispanic women were less
likely to receive substance use treatment whereas those with fewer health or psychiatric
conditions were more likely to receive treatment. The best predictive model of substance
use treatment receipt in Chapter Four indicated that White ethnicity and comorbid
depression/anxiety increased the likelihood of substance use treatment receipt. Similarly,
the review of trend studies in Chapter Two indicated that substance use treatment
admissions of Whites and pregnant women with comorbid psychiatric illness increased
over time (Martin, Longinaker, Mark, et al., 2015). This supports the importance of
addressing mental health needs of pregnant women with substance use disorders. Increase
access to substance use treatment among ethnic minority pregnant women is essential.
Chapter Four contributes to the literature by addressing how need factors for
treatment differentiate the receipt of substance use treatment among pregnant women.
Illicit drug dependence was the best predictor of treatment receipt followed by illicit drug
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abuse and alcohol use dependence. This is congruent with the trend studies reviewed in
Chapter Two which revealed an increase in treatment admissions for illicit drug use
disorder over time (Martin, Longinaker, Mark, et al., 2015; Martin, Longinaker, &
Terplan, 2015; McCabe & Arndt, 2012). There is a need for evidence-based preventive
strategies to minimize the burden of illicit drug use disorders for the mother, her child,
and society. Given that substance use is a modifiable health behavior (Kuo et al., 2013;
Massey et al., 2011), health care providers should screen and intervene early to prevent
women from developing severe substance use disorders.
Ethnic Care Disparities in Mental Health Treatment Receipt
Only three population-based studies reviewed in Chapter Two explicitly
addressed ethnic care disparities in the receipt of mental health treatment (Chang et al.,
2016; Coleman-Cowger, 2012; Yamamoto et al., 2015). These studies indicated that
White pregnant women were more likely to receive mental health treatment than
nonWhites. A series of logistic regression models in Chapter Four also revealed that
nonWhite ethnicity (versus White) decreased the likelihood of mental health treatment
receipt in pregnant women with MDE, serious psychological distress, substance use
disorders, and comorbid mental health and substance use disorders even after controlling
for predisposing factors, enabling factors, and severity of distress symptoms. These
findings indicate that ethnic minority pregnant women may have specific cultural beliefs
and attitudes about seeking mental health treatment (O’Mahen & Flynn, 2008). Further
research is needed to address potential cultural differences. Screening initiatives and
mental health program interventions targeting ethnic minority pregnant women are also
necessary.
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Barriers to Treatment Receipt
Findings from the population-based studies reviewed indicated that barriers to
mental health treatment included cost, opposition to treatment, stigma,
time/transportation limitations, and not knowing where to go (Ko et al., 2012) as well as
provider-patient conversation regarding depression (Farr et al., 2016) and providers’
competency in treatment/referrals (Price et al., 2012). Chapter Three also indicated that
cost, opposition to treatment, and stigma were the most common barriers among pregnant
women. In addition, their rank order and percentages did not differ across two time
periods, 2008-2010 and 2011-2014.
Chapter Four also expanded these findings and added to the literature by
comparing perceived barriers to mental health treatment across types of mental health
and/or substance use disorders and ethnicity. Compared to pregnant women without
MDE, those with MDE were more likely to perceive cost and not knowing where to go as
barriers to mental health treatment and less likely to have opposition to treatment.
Pregnant women with anxiety disorder were more likely to report the lack of
time/transportations as barriers to mental health treatment compared to those without
anxiety. Those who had substance use disorders or comorbid mental health and substance
use disorders were more likely to perceive stigma attached to the receipt of mental health
treatment as a barrier compared to pregnant women without these disorders.
Furthermore, the findings in Chapter Four indicated there were no differences
between White and nonWhite pregnant women with mental health problems, substance
use disorders, and comorbid mental health and substance use disorders in the proportions
of perceived opposition to treatment, stigma, time/transportation limitations, and not
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knowing where to go. These findings are congruent with those of one study in which
there were no differences between White and African American perinatal women in the
perceived structural (e.g., insurance, cost, and transportation), knowledge, and attitudinal
barriers to depression treatment (O’Mahen & Flynn, 2008). However, in Chapter Four,
Whites were more likely to perceive cost as an obstacle to mental health treatment.
Findings from the systematic review and the two data based manuscripts in this
dissertation reflect the complexity of barriers to mental health treatment and provide
information relevant to health reform on the importance of addressing such barriers and
increasing the sensitivity of healthcare providers in regards unique mental health needs of
pregnant women to enhance their access to treatment. Further research is needed to
compare barriers to mental health treatment across different ethnic groups.
The systematic review demonstrated the paucity of studies addressing barriers to
substance use treatment among pregnant women. In the first data based study, perceived
barriers to substance use treatment among childbearing-aged women differed from 20082010 to 2011-2014. For instance, in 2008-2010, cost ranked first and followed by stigma,
whereas stigma ranked first and followed by cost in 2011-2014. Interestingly, women of
childbearing age in 2011-2014 were more likely to report not knowing where to go and a
lack of treatment programs as obstacles to the receipt of substance use treatment than
women in 2008-2010. Upstream efforts are needed to meet the needs of pregnant women
with substance use disorders. These women are stigmatized and their specific needs are
still unmet (CSAT, 2009). Legal and treatment initiatives are critical to increase the
availability of treatment facilities that acknowledge the “biopsychosocial uniqueness” of
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women with substance use disorders (CSAT, 2009, p.1) and provide specific strategies to
improve access to care such as trauma-informed care (SAMHSA, 2014c).
Summary
This dissertation is innovative because it: (a) includes a systematic review of trend
and population-based studies on mental health and substance use disorders among
pregnant women in the United States, (b) contains one of the first studies that compared
trends in both mental health and substance use disorders and treatment receipt by
pregnancy status, and (c) fills a gap in the literature by studying factors associated with
the receipt of treatment for mental health and substance use disorders and addressing
ethnic health care disparities and barriers to mental health treatment experienced by a
national sample of pregnant women.
The findings clearly support the gap between the need for and the receipt of
treatment among pregnant women with mental health and substance use disorders. Trends
in the receipt of mental health treatment and the unmet need for substance use treatment
did not change from 2008-2014 among childbearing-aged women, whereas anxiety
disorders, past-month psychological distress, and illicit drug use disorder increased over
the same time period. Further research is needed to address the seriousness of these
disorders, particularly mental health problems, among pregnant women in the United
States over time.
This research underscores that factors associated with both mental health and
substance use treatment receipt are complex and involve predisposing (e.g., ethnicity),
enabling (e.g., health insurance and urban residency), and need factors (e.g., anxiety
disorder and illicit drug use disorder). This research also showed that numerous obstacles
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impede women of childbearing age in accessing mental health and substance use
treatment. In addition, disparities in mental health treatment also exist among pregnant
women with mental health and/or substance use disorders.
This dissertation provides new insights for improving maternal mental health. It
has significant clinical implications because pregnancy provides an opportunity to screen
and intervene with mental health and substance use problems. The information generated
from this dissertation may help in designing programs according to the needs of pregnant
women. There is a need for evidence-based preventive and treatment strategies to
minimize the effects of mental health problems and substance use disorders for the
mother, her child, and society. Health care providers play a significant role in screening
and identifying pregnant women at risk for and those who have mental health and
substance use disorders.
This research indicates needed changes in health policy to improve the health of a
vulnerable population of pregnant women. There is a need to develop strategies
addressing the unique barriers (e.g., cost, stigma, opposition to treatment, available
treatment programs, and not knowing to go) that impede pregnant and nonpregnant
women to access mental health and substance use treatment. Specific and evidence-based
interventions tailored to the needs of ethnic minority pregnant women are essential. More
research and clinical practice changes are required to focus on mental health needs of
pregnant women with substance use disorders. Further research is needed to examine the
association between the receipt of mental health and substance use treatment. Developing
strategies integrating the two systems is also crucial.
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To improve maternal mental health and to disseminate a message of hope for
pregnant women, collaboration among researchers, policy makers, and healthcare
providers is required. Hopefully, this dissertation provides a contribution for a better
understanding of the needs of pregnant women with mental health and substance use
disorders.

153

REFERENCES

Accortt, E. E., Cheadle, A. C., & Dunkel Schetter, C. (2015). Prenatal depression and
adverse birth outcomes: An updated systematic review. Maternal and Child
Health Journal, 19(6), 1306-1337. doi: 10.1007/s10995-014-1637-2
Advocates for Pregnant Women. (2011). Medical and public health statements
addressing prosecution and punishment of pregnant women. Retrieved from
http://advocatesforpregnantwomen.org/Health%20Statements%20re.%20Punitive
%20Policies%20NAPW%202015.pdf
Agency for Healthcare Research and Quality. (2016). Screening for Depression.
Retrieved from http://www.ahrq.gov/professionals/prevention-chroniccare/healthier-pregnancy/preventive/depression.html
American College of Obstetricians and Gynecologists. (2010). Committee opinion no.
453: Screening for depression during and after pregnancy. Obstetrics and
Gynecology, 115(2 Pt 1), 394.
American College of Obstetricians and Gynecologists. (2015a). Committee opinion no.
633: Alcohol abuse and other substance use disorders: ethical issues in obstetric
and gynecologic practice. (2015). Obstetrics and Gynecology, 125(6), 1529-1537.
doi: 10.1097/01.AOG.0000466371.86393.9b
American College of Obstetricians and Gynecologists. (2015b). Screening for perinatal
depression. Retrieved from https://www.acog.org/-/media/Committee154

Opinions/Committee-on-Obstetricractice/co630.pdf?dmc=1&ts=20160630T1521017957
American Nurses Association. (2011). Non-punitive alcohol and drug treatment for
pregnant and breast-feeding women and their exposed children. Retrieved from
http://www.nursingworld.org/MainMenuCategories/EthicsStandards/EthicsPosition-Statements/Non-punitive-Alcohol-and-Drug-Treatment-for-Pregnantand-Breast-feeding-Women-and-the-Exposed-Childr.pdf
American Pregnancy Association. (2017). Medicaid for pregnant women. Retrieved from
http://americanpregnancy.org/planning/medicaid-for-pregnant-women/
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental
disorders: DSM IV (4th ed.). Washington, DC: Author.
Andersen, R. M. (1995). Revisiting the behavioral model and access to medical care:
Does it matter? Journal of Health and Social Behavior, 36(1), 1-10.
Andrade, S. E., Raebel, M. A., Brown, J., Lane, K., Livingston, J., Boudreau, D., . . .
Willy, M. E. (2008). Use of antidepressant medications during pregnancy: A
multisite study. American Journal of Obstetrics and Gynecology, 198(2), 194.
e191-194. e195.
Babitsch, B., Gohl, D., & von Lengerke, T. (2012). Re-revisiting Andersen’s Behavioral
Model of Health Services Use: A systematic review of studies from 1998–2011.
GMS Psycho-Social-Medicine, 9.
Baker, A. L., Kavanagh, D. J., Kay-Lambkin, F. J., Hunt, S. A., Lewin, T. J., Carr, V. J.,
& Connolly, J. (2010). Randomized controlled trial of cognitive-behavioural

155

therapy for coexisting depression and alcohol problems: Short-term outcome.
Addiction, 105(1), 87-99. doi: 10.1111/j.1360-0443.2009.02757.x
Battle, C. L., Salisbury, A. L., Schofield, C. A., & Ortiz-Hernandez, S. (2013). Perinatal
antidepressant use: Understanding women's preferences and concerns. Journal of
Psychiatric Practice, 19(6), 443-453. doi: 10.1097/01.pra.0000438183.74359.46
Bennett, I. M., Marcus, S. C., Palmer, S. C., & Coyne, J. C. (2010). Pregnancy-related
discontinuation of antidepressants and depression care visits among Medicaid
recipients. Psychiatric Services, 61(4), 386-391.
Bland, J. M., & Altman, D. G. (1995). Multiple significance tests: The Bonferroni
method. British Medical Journal, 310(6973), 170.
Bobo, W. V., Epstein, R. A., Hayes, R. M., Shelton, R. C., Hartert, T. V., Mitchel, E., . . .
Wu, P. (2014). The effect of regulatory advisories on maternal antidepressant
prescribing, 1995–2007: An interrupted time series study of 228,876 pregnancies.
Archives of Women's Mental Health, 17(1), 17-26.
Bowen, A., Duncan, V., Peacock, S., Bowen, R., Schwartz, L., Campbell, D., &
Muhajarine, N. (2014). Mood and anxiety problems in perinatal Indigenous
women in Australia, New Zealand, Canada, and the United States: A critical
review of the literature. Transcultural Psychiatry, 51(1), 93-111. doi:
10.1177/1363461513501712
Brigham, G., Winhusen, T., Lewis, D., & Kropp, F. (2010). Incentives for retention of
pregnant substance users: A secondary analysis. Journal of Substance Abuse
Treatment, 38(1), 90-95. doi: 10.1016/j.jsat.2009.05.005

156

Byatt, N., Biebel, K., Debordes-Jackson, G., Lundquist, R. S., Simas, T. A. M., Weinreb,
L., & Ziedonis, D. (2013). Community mental health provider reluctance to
provide pharmacotherapy may be a barrier to addressing perinatal depression: A
preliminary study. Psychiatric Quarterly, 84(2), 169-174.
Byatt, N., Biebel, K., Friedman, L., Debordes-Jackson, G., Ziedonis, D., & Pbert, L.
(2013). Patient’s views on depression care in obstetric settings: How do they
compare to the views of perinatal health care professionals? General Hospital
Psychiatry, 35(6), 598-604.
Byatt, N., Levin, L. L., Ziedonis, D., TA, M. S., & Allison, J. (2015). Enhancing
participation in depression care in outpatient perinatal care settings: A systematic
review. Obstetrics and Gynecology, 126(5), 1048-1058.
Byatt, N., Simas, T. A. M., Lundquist, R. S., Johnson, J. V., & Ziedonis, D. M. (2012).
Strategies for improving perinatal depression treatment in North American
outpatient obstetric settings. Journal of Psychosomatic Obstetrics and
Gynecology, 33(4), 143-161.
Byatt, N., Xiao, R. S., Dinh, K. H., & Waring, M. E. (2016). Mental health care use in
relation to depressive symptoms among pregnant women in the USA. Archives of
Women's Mental Health, 19(1), 187-191.
Center for Behavioral Health Statistics and Quality. (2015). 2014 National Survey on
Drug Use and Health: Methodological summary and definitions. Rockville, MD:
Substance Abuse and Mental Health Services Administration.

157

Centers for Disease Control and Prevention. (2013).Vital signs: Overdoses of prescription
opioid pain relievers and other drugs among women--United States, 1999-2010.
MMWR. Morbidity and Mortality Weekly Report, 62(26), 537.
Center for Substance Abuse Treatment. (2009). Substance abuse treatment: Addressing
the specific needs of women. Retrieved from
http://store.samhsa.gov/shin/content//SMA15-4426/SMA15-4426.pdf
Chang, J. J., Tabet, M., Elder, K., Kiel, D. W., & Flick, L. H. (2016). Racial/ethnic
differences in the correlates of mental health services use among pregnant women
with depressive symptoms. Maternal and Child Health Journal, 20(9), 19111922. doi: 10.1007/s10995-016-2005-1
Clark, H. W., Power, A. K., Le Fauve, C. E., & Lopez, E. I. (2008). Policy and practice
implications of epidemiological surveys on co-occurring mental and substance
use disorders. Journal of Substance Abuse Treatment, 34(1), 3-13. doi:
10.1016/j.jsat.2006.12.032
Coleman-Cowger, V. H. (2012). Mental health treatment need among pregnant and
postpartum women/girls entering substance abuse treatment. Psychology of
Addictive Behaviors, 26(2), 345-350. doi: 10.1037/a0025355
Connelly, C. D., Hazen, A. L., Baker-Ericzen, M. J., Landsverk, J., & Horwitz, S. M.
(2013). Is screening for depression in the perinatal period enough? The cooccurrence of depression, substance abuse, and intimate partner violence in
culturally diverse pregnant women. Journal of Women's Health, 22(10), 844-852.
doi: 10.1089/jwh.2012.4121

158

Cook, C. A., Flick, L. H., Homan, S. M., Campbell, C., McSweeney, M., & Gallagher,
M. E. (2010). Psychiatric disorders and treatment in low-income pregnant women.
Journal of Women's Health (Larchmt), 19(7), 1251-1262. doi:
10.1089/jwh.2009.1854
Cooper, L. A., Gonzales, J. J., Gallo, J. J., Rost, K. M., Meredith, L. S., Rubenstein, L.
V., . . . Ford, D. E. (2003). The acceptability of treatment for depression among
African-American, Hispanic, and White primary care patients. Medical Care,
41(4), 479-489. doi: 10.1097/01.mlr.0000053228.58042.e4
Csaszar, E., Melichercikova, K., & Dubovicky, M. (2014). Neuroendocrine and
behavioral consequences of untreated and treated depression in pregnancy and
lactation. Neuro Endocrinology Letters, 35(2), 169-174.
Dawson, D. A., Saha, T. D., & Grant, B. F. (2010). A multidimensional assessment of the
validity and utility of alcohol use disorder severity as determined by Item
Response Theory models. Drug and Alcohol Dependence, 107(1), 31-38. doi:
10.1016/j.drugalcdep.2009.08.019
Endicott, J., Spitzer, R. L., Fleiss, J. L., & Cohen, J. (1976). The Global Assessment
Scale: A procedure for measuring overall severity of psychiatric disturbance.
Archives of General Psychiatry, 33(6), 766-771.
Fairbrother, N., Janssen, P., Antony, M. M., Tucker, E., & Young, A. H. (2016). Perinatal
anxiety disorder prevalence and incidence. Journal of Affective Disorders, 200,
148-155.

159

Fairbrother, N., Young, A. H., Janssen, P., Antony, M. M., & Tucker, E. (2015).
Depression and anxiety during the perinatal period. BioMed Central Psychiatry,
15(1), 206.
Farr, S. L., Bitsko, R. H., Hayes, D. K., & Dietz, P. M. (2010). Mental health and access
to services among US women of reproductive age. American Journal of
Obstetrics and Gynecology, 203(6), 542.e541-549. doi:
10.1016/j.ajog.2010.07.007
Farr, S. L., Hayes, D. K., Bitsko, R. H., Bansil, P., & Dietz, P. M. (2011). Depression,
diabetes, and chronic disease risk factors among US women of reproductive age.
Preventing Chronic Disease, 8(6), A119.
Farr, S. L., Ko, J. Y., Burley, K., & Gupta, S. (2016). Provider communication on
perinatal depression: A population-based study. Archives of Women's Mental
Health, 19(1), 35-40.
Flynn, H. A., Blow, F. C., & Marcus, S. M. (2006). Rates and predictors of depression
treatment among pregnant women in hospital-affiliated obstetrics practices.
General Hospital Psychiatry, 28(4), 289-295. doi:
10.1016/j.genhosppsych.2006.04.002
Fortney, J., & Booth, B. M. (2001). Access to substance abuse services in rural areas.
Recent Developments in Alcoholism, 15, 177-197.
Gavin, A. R., Melville, J. L., Rue, T., Guo, Y., Dina, K. T., & Katon, W. J. (2011). Racial
differences in the prevalence of antenatal depression. General Hospital
Psychiatry, 33(2), 87-93.

160

Geier, M. L., Hills, N., Gonzales, M., Tum, K., & Finley, P. R. (2015). Detection and
treatment rates for perinatal depression in a state Medicaid population. CNS
Spectrums, 20(1), 11-19. doi: 10.1017/s1092852914000510
Glasheen, C., Colpe, L., Hoffman, V., & Warren, L. K. (2015). Prevalence of serious
psychological distress and mental health treatment in a national sample of
pregnant and postpartum women. Maternal and Child Health Journal, 19(1), 204216. doi: 10.1007/s10995-014-1511-2
Goodman, J. H. (2009). Women's attitudes, preferences, and perceived barriers to
treatment for perinatal depression. Birth, 36(1), 60-69. doi: 10.1111/j.1523536X.2008.00296.x
Goodman, J. H., Chenausky, K. L., & Freeman, M. P. (2014). Anxiety disorders during
pregnancy: A systematic review. Journal of Clinical Psychiatry, 75(10), e11531184. doi: 10.4088/JCP.14r09035
Goodman, J. H., & Tyer-Viola, L. (2010). Detection, treatment, and referral of perinatal
depression and anxiety by obstetrical providers. Journal of Women's Health
(Larchmt), 19(3), 477-490. doi: 10.1089/jwh.2008.1352
Goodman, S. H., Dimidjian, S., & Williams, K. G. (2013). Pregnant African American
women's attitudes toward perinatal depression prevention. Cultural Diversity and
Ethnic Minority Psychology, 19(1), 50-57. doi: 10.1037/a0030565
Grant, B. F. (1997). Barriers to alcoholism treatment: Reasons for not seeking treatment
in a general population sample. Journal of Studies on Alcohol, 58(4), 365-371.
Grigoriadis, S., VonderPorten, E. H., Mamisashvili, L., Tomlinson, G., Dennis, C. L.,
Koren, G., . . . Ross, L. E. (2013). The impact of maternal depression during

161

pregnancy on perinatal outcomes: A systematic review and meta-analysis. Journal
of Clinical Psychiatry, 74(4), e321-341. doi: 10.4088/JCP.12r07968
Guttmacher Institute. (2017). Substance use during pregnancy. Retrieved from
https://www.guttmacher.org/state-policy/explore/substance-use-during-pregnancy
Haller, D. L., Miles, D. R., & Dawson, K. S. (2003). Factors influencing treatment
enrollment by pregnant substance abusers. American Journal of Drug and Alcohol
Abuse, 29(1), 117-131.
Hand, D. J., Short, V. L., & Abatemarco, D. J. (2017). Substance use, treatment, and
demographic characteristics of pregnant women entering treatment for opioid use
disorder differ by United States census region. Journal of Substance Abuse
Treatment, 76, 58-63.
Hanley, G. E., & Mintzes, B. (2014). Patterns of psychotropic medicine use in pregnancy
in the United States from 2006 to 2011 among women with private insurance.
BioMed Central Pregnancy and Childbirth, 14, 242. doi: 10.1186/1471-2393-14242
Hasin, D. S., Goodwin, R. D., Stinson, F. S., & Grant, B. F. (2005). Epidemiology of
major depressive disorder: Results from the National Epidemiologic Survey on
Alcoholism and Related Conditions. Archives of General Psychiatry, 62(10),
1097-1106. doi: 10.1001/archpsyc.62.10.1097
Heil, S. H., Sigmon, S. C., Jones, H. E., & Wagner, M. (2008). Comparison of
characteristics of opioid-using pregnant women in rural and urban settings.
American Journal of Drug and Alcohol Abuse, 34(4), 463-471. doi:
10.1080/00952990802122358

162

Ho, D. E., Imai, K., King, G., & Stuart, E. A. (2007). Matching as nonparametric
preprocessing for reducing model dependence in parametric causal inference.
Political Analysis, 15(3), 199-236.
Homish, G. G., Cornelius, J. R., Richardson, G. A., & Day, N. L. (2004). Antenatal risk
factors associated with postpartum comorbid alcohol use and depressive
symptomatology. Alcoholism Clinical and Experimental Research, 28(8), 12421248.
Hudak, M. L., & Tan, R. C. (2012). Neonatal drug withdrawal. Pediatrics, 129(2), e540560. doi: 10.1542/peds.2011-3212
Irner, T. B., Teasdale, T. W., Nielsen, T., Vedal, S., & Olofsson, M. (2012). Substance
use during pregnancy and postnatal outcomes. Journal of Addictive Diseases,
31(1), 19-28.
Jaaskelainen, M., Holmila, M., Notkola, I. L., & Raitasalo, K. (2016). Mental disorders
and harmful substance use in children of substance abusing parents: A
longitudinal register-based study on a complete birth cohort born in 1991. Drug
and Alcohol Review, 35(6), 728-740. doi: 10.1111/dar.12417
Jackson, A., & Shannon, L. (2012a). Barriers to receiving substance abuse treatment
among rural pregnant women in Kentucky. Maternal and Child Health Journal,
16(9), 1762-1770. doi: 10.1007/s10995-011-0923-5
Jackson, A., & Shannon, L. (2012b). Examining barriers to and motivations for substance
abuse treatment among pregnant women: Does urban-rural residence matter?
Women Health, 52(6), 570-586. doi: 10.1080/03630242.2012.699508

163

Jaques, S., Kingsbury, A., Henshcke, P., Chomchai, C., Clews, S., Falconer, J., . . . Oei, J.
(2014). Cannabis, the pregnant woman and her child: Weeding out the myths.
Journal of Perinatology, 34(6), 417-424.
Jesse, D. E., Dolbier, C. L., & Blanchard, A. (2008). Barriers to seeking help and
treatment suggestions for prenatal depressive symptoms: Focus groups with rural
low-income women. Issues in Mental Health Nursing, 29(1), 3-19. doi:
10.1080/01612840701748664
Jordan, B. K., Karg, R. S., Batts, K. R., Epstein, J. F., & Wiesen, C. (2008). A clinical
validation of the National Survey on Drug Use and Health assessment of
substance use disorders. Addictive Behaviors, 33(6), 782-798.
Kessler, R. C., Barker, P. R., Colpe, L. J., Epstein, J. F., Gfroerer, J. C., Hiripi, E., . . .
Zaslavsky, A. M. (2003). Screening for serious mental illness in the general
population. Archives of General Psychiatry, 60(2), 184-189.
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., . . .
Wang, P. S. (2003). The epidemiology of major depressive disorder: Results from
the National Comorbidity Survey Replication (NCS-R). Journal of the American
Medical Association, 289(23), 3095-3105. doi: 10.1001/jama.289.23.3095
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E.
(2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders
in the National Comorbidity Survey Replication. Archives of General Psychiatry,
62(6), 593-602.

164

Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., . . .
Zaslavsky, A. M. (2005). Prevalence and treatment of mental disorders, 1990 to
2003. New England Journal of Medicine, 352(24), 2515-2523.
Kim, J. J., La Porte, L. M., Corcoran, M., Magasi, S., Batza, J., & Silver, R. K. (2010).
Barriers to mental health treatment among obstetric patients at risk for depression.
American Journal of Obstetrics and Gynecology, 202(3), 312.e311-315. doi:
10.1016/j.ajog.2010.01.004
Kingston, D., Austin, M. P., Heaman, M., McDonald, S., Lasiuk, G., Sword, W., . . .
Biringer, A. (2015). Barriers and facilitators of mental health screening in
pregnancy. Journal of Affective Disorders, 186, 350-357. doi:
10.1016/j.jad.2015.06.029
Kingston, D., Tough, S., & Whitfield, H. (2012). Prenatal and postpartum maternal
psychological distress and infant development: A systematic review. Child
Psychiatry and Human Development, 43(5), 683-714. doi: 10.1007/s10578-0120291-4
Kissin, W. B., Svikis, D. S., Moylan, P., Haug, N. A., & Stitzer, M. L. (2004). Identifying
pregnant women at risk for early attrition from substance abuse treatment. Journal
of Substance Abuse Treatment, 27(1), 31-38. doi: 10.1016/j.jsat.2004.03.007
Knight, D. K., Logan, S. M., & Simpson, D. D. (2001). Predictors of program completion
for women in residential substance abuse treatment. American Journal of Drug
and Alcohol Abuse, 27(1), 1-18.

165

Ko, J. Y., Farr, S. L., Dietz, P. M., & Robbins, C. L. (2012). Depression and treatment
among US pregnant and nonpregnant women of reproductive age, 2005–2009.
Journal of Women's Health, 21(8), 830-836.
Kopelman, R. C., Moel, J., Mertens, C., Stuart, S., Arndt, S., & O'Hara, M. W. (2008).
Barriers to care for antenatal depression. Psychiatric Services, 59(4), 429-432.
doi: 10.1176/ps.2008.59.4.429
Kotelchuck, M., Cheng, E. R., Belanoff, C., Cabral, H. J., Babakhanlou-Chase, H.,
Derrington, T. M., . . . Bernstein, J. (2017). The prevalence and impact of
substance use disorder and treatment on maternal obstetric experiences and birth
outcomes among singleton deliveries in Massachusetts. Maternal and Child
Health Journal, 21(4), 893-902.
Kuo, C., Schonbrun, Y. C., Zlotnick, C., Bates, N., Todorova, R., Kao, J. C., & Johnson,
J. (2013). A qualitative study of treatment needs among pregnant and postpartum
women with substance use and depression. Substance Use and Misuse, 48(14),
1498-1508. doi: 10.3109/10826084.2013.800116
Lambert, B., & Bauer, C. R. (2012). Developmental and behavioral consequences of
prenatal cocaine exposure: A review. Journal of Perinatology, 32(11), 819-828.
Lancaster, C. A., Gold, K. J., Flynn, H. A., Yoo, H., Marcus, S. M., & Davis, M. M.
(2010). Risk factors for depressive symptoms during pregnancy: A systematic
review. American Journal of Obstetrics and Gynecology, 202(1), 5-14.
Le Strat, Y., Dubertret, C., & Le Foll, B. (2011). Prevalence and correlates of major
depressive episode in pregnant and postpartum women in the United States.
Journal of Affective Disorders, 135(1-3), 128-138. doi: 10.1016/j.jad.2011.07.004

166

Leddy, M. A., Lawrence, H., & Schulkin, J. (2011). Obstetrician-gynecologists and
women's mental health: findings of the Collaborative Ambulatory Research
Network 2005–2009. Obstetrical and Gynecological Survey, 66(5), 316-323.
Lehikoinen, A., Orden, M. R., Heinonen, S., & Voutilainen, R. (2016). Maternal drug or
alcohol abuse is associated with decreased head size from mid-pregnancy to
childhood. Acta Paediatrica, 105(7), 817-822. doi: 10.1111/apa.13416
Leong, F. T., & Kalibatseva, Z. (2011). Cross-cultural barriers to mental health services
in the United States. Cerebrum, 2011, 5.
Liu, C. H., & Tronick, E. (2012). Do patient characteristics, prenatal care setting, and
method of payment matter when it comes to provider-patient conversations on
perinatal mood? Maternal and Child Health Journal, 16(5), 1102-1112.
Lokuge, S., Frey, B. N., Foster, J. A., Soares, C. N., & Steiner, M. (2011). Depression in
women: Windows of vulnerability and new insights into the link between
estrogen and serotonin. Journal of Clinical Psychiatry, 72(11), e1563-1569. doi:
10.4088/JCP.11com07089
Maeda, A., Bateman, B. T., Clancy, C. R., Creanga, A. A., & Leffert, L. R. (2014).
Opioid abuse and dependence during pregnancy: Temporal trends and obstetrical
outcomes. The Journal of the American Society of Anesthesiologists, 121(6),
1158-1165.
Magee, T., Lee, S. M., Giuliano, K. K., & Munro, B. (2006). Generating new knowledge
from existing data: The use of large data sets for nursing research. Nursing
Research, 55(2), S50-S56.

167

Marais, S., Jordaan, E., Viljoen, D., Olivier, L., de Waal, J., & Poole, C. (2011). The
effect of brief interventions on the drinking behavior of pregnant women in a
high-risk rural South African community: A cluster randomized trial. Early Child
Development and Care, 181(4), 463-474.
Martin, C. E., Longinaker, N., Mark, K., Chisolm, M. S., & Terplan, M. (2015). Recent
trends in treatment admissions for marijuana use during pregnancy. Journal of
Addiction Medicine, 9(2), 99-104. doi: 10.1097/adm.0000000000000095
Martin, C. E., Longinaker, N., & Terplan, M. (2015). Recent trends in treatment
admissions for prescription opioid abuse during pregnancy. Journal of Substance
Abuse Treatment, 48(1), 37-42. doi: 10.1016/j.jsat.2014.07.007
May, P. A., Marais, A. S., Gossage, J. P., Barnard, R., Joubert, B., Cloete, M., . . .
Blankenship, J. (2013). Case management reduces drinking during pregnancy
among high risk women. International Journal of Alcohol and Drug Research,
2(3), 61-70. doi: 10.7895/ijadr.v2i3.79
McCabe, J. E., & Arndt, S. (2012). Demographic and substance abuse trends among
pregnant and non-pregnant women: Eleven years of treatment admission data.
Maternal and Child Health Journal, 16(8), 1696-1702. doi: 10.1007/s10995-0110872-z
Melville, J. L., Gavin, A., Guo, Y., Fan, M.-Y., & Katon, W. J. (2010). Depressive
disorders during pregnancy: Prevalence and risk factors in a large urban sample.
Obstetrics and Gynecology, 116(5), 1064.
Mental Health Parity and Addiction Equity Act, Pub. L. No. 110-343, 122 Stat. 3765,
H.R. 1424, 110th Cong. (2008). Retrieved from

168

https://www.cms.gov/CCIIO/Programs-and-Initiatives/Other-InsuranceProtections/mhpaea_factsheet.html#Key changes made by MHPAEA
Messer, K., Clark, K. A., & Martin, S. L. (1996). Characteristics associated with pregnant
women's utilization of substance abuse treatment services. American Journal of
Drug and Alcohol Abuse, 22(3), 403-422.
Metz, T. D., & Stickrath, E. H. (2015). Marijuana use in pregnancy and lactation: A
review of the evidence. American Journal of Obstetrics and Gynecology, 213(6),
761-778.
Meunier, M. R., Bennett, I. M., & Coco, A. S. (2013). Use of antidepressant medication
in the United States during pregnancy, 2002–2010. Psychiatric Services, 64(11),
1157-1160.
Meyer, M. C., Johnston, A. M., Crocker, A. M., & Heil, S. H. (2015). Methadone and
buprenorphine for opioid dependence during pregnancy: A retrospective cohort
study. Journal of Addiction Medicine, 9(2), 81-86. doi:
10.1097/adm.0000000000000092
Ming, K., & Rosenbaum, P. R. (2000). Substantial gains in bias reduction from matching
with a variable number of controls. Biometrics, 56(1), 118-124.
Mitchell, M. M., Severtson, S. G., & Latimer, W. W. (2008). Pregnancy and
race/ethnicity as predictors of motivation for drug treatment. American Journal of
Drug and Alcohol Abuse, 34(4), 397-404. doi: 10.1080/00952990802082172
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Group, P. (2009). Preferred
reporting items for systematic reviews and meta-analyses: The PRISMA
statement. PLoS Medicine, 6(7), e1000097.

169

Mojtabai, R., & Jorm, A. F. (2015). Trends in psychological distress, depressive episodes
and mental health treatment-seeking in the United States: 2001-2012. Journal of
Affective Disorders, 174, 556-561. doi: 10.1016/j.jad.2014.12.039
Mojtabai, R., Olfson, M., Sampson, N. A., Jin, R., Druss, B., Wang, P. S., . . . Kessler, R.
C. (2011). Barriers to mental health treatment: Results from the National
Comorbidity Survey Replication. Psychological Medicine, 41(8), 1751-1761. doi:
10.1017/s0033291710002291
Mota, N., Cox, B. J., Enns, M. W., Calhoun, L., & Sareen, J. (2008). The relationship
between mental disorders, quality of life, and pregnancy: Findings from a
nationally representative sample. Journal of Affective Disorders, 109(3), 300-304.
doi: 10.1016/j.jad.2007.12.002
Mukherjee, S., Trepka, M. J., Pierre-Victor, D., Bahelah, R., & Avent, T. (2016).
Racial/ethnic disparities in antenatal depression in the United States: A systematic
review. Maternal and Child Health Journal, 20(9), 1780-1797. doi:
10.1007/s10995-016-1989-x
Narkowicz, S., Plotka, J., Polkowska, Z., Biziuk, M., & Namiesnik, J. (2013). Prenatal
exposure to substance of abuse: A worldwide problem. Environment
International, 54, 141-163. doi: 10.1016/j.envint.2013.01.011
Norhayati, M., Hazlina, N. N., Asrenee, A., & Emilin, W. W. (2015). Magnitude and risk
factors for postpartum symptoms: A literature review. Journal of Affective
Disorders, 175, 34-52.
National Perinatal Association. (2012). Substance use among pregnant women. Retrieved
from

170

http://www.nationalperinatal.org/resources/Documents/Substance%20Abuse%20
Among%20Pregnant%20Women%20Position%20Paper%2010-1-15.pdf
National Survey on Drug Use and Health. (2016). About the survey. Retrieved from
https://nsduhweb.rti.org/respweb/project_description.html
O’connor, E., Rossom, R. C., Henninger, M., Groom, H. C., & Burda, B. U. (2016).
Primary care screening for and treatment of depression in pregnant and
postpartum women: Evidence report and systematic review for the US Preventive
Services Task Force. Journal of the American Medical Association, 315(4), 388406.
O'Mahen, H. A., & Flynn, H. A. (2008). Preferences and perceived barriers to treatment
for depression during the perinatal period. Journal of Women's Health (Larchmt),
17(8), 1301-1309. doi: 10.1089/jwh.2007.0631
O'Mahen, H. A., Henshaw, E., Jones, J. M., & Flynn, H. A. (2011). Stigma and
depression during pregnancy: Does race matter? Journal of Nervous and Mental
Disease, 199(4), 257-262. doi: 10.1097/NMD.0b013e3182125b82
Ondersma, S. J., Simpson, S. M., Brestan, E. V., & Ward, M. (2000). Prenatal drug
exposure and social policy: The search for an appropriate response. Child
Maltreatment, 5(2), 93-108. doi: 10.1177/1077559500005002002
Ondersma, S. J., Winhusen, T., & Lewis, D. F. (2010). External pressure, motivation, and
treatment outcome among pregnant substance-using women. Drug and Alcohol
Dependence, 107(2-3), 149-153. doi: 10.1016/j.drugalcdep.2009.10.004
Otiashvili, D., Kirtadze, I., O’Grady, K. E., Zule, W., Krupitsky, E., Wechsberg, W. M.,
& Jones, H. E. (2013). Access to treatment for substance-using women in the

171

Republic of Georgia: Socio-cultural and structural barriers. International Journal
of Drug Policy, 24(6), 566-572.
Palladino, C. L., Fedock, G. L., Forman, J. H., Davis, M. M., Henshaw, E., & Flynn, H.
A. (2011). OB CARES—the obstetric clinics and resources study: Providers'
perceptions of addressing perinatal depression—a qualitative study. General
Hospital Psychiatry, 33(3), 267-278.
Pan, I.-J., & Yi, H.-y. (2013). Prevalence of hospitalized live births affected by alcohol
and drugs and parturient women diagnosed with substance abuse at liveborn
delivery: United States, 1999–2008. Maternal and Child Health Journal, 17(4),
667-676.
Patient Protection and Affordable Care Act, 42 U.S.C. § 1800 (2010). Retrieved from
https://www.gpo.gov/fdsys/pkg/PLAW-111publ148/html/PLAW-111publ148.htm
Patrick, S. W., Davis, M. M., Lehmann, C. U., & Cooper, W. O. (2015). Increasing
incidence and geographic distribution of neonatal abstinence syndrome: United
States 2009 to 2012. Journal of Perinatology, 35(8), 650-655. doi:
10.1038/jp.2015.36
Patrick, S. W., Schumacher, R. E., Benneyworth, B. D., Krans, E. E., McAllister, J. M.,
& Davis, M. M. (2012). Neonatal abstinence syndrome and associated health care
expenditures: United States, 2000-2009. Journal of the American Medical
Association, 307(18), 1934-1940. doi: 10.1001/jama.2012.3951
Price, S. K., Corder-Mabe, J., & Austin, K. (2012). Perinatal depression screening and
intervention: Enhancing health provider involvement. Journal of Women's Health,
21(4), 447-455.

172

Qiu, C., Gelaye, B., Fida, N., & Williams, M. A. (2012). Short sleep duration, complaints
of vital exhaustion and perceived stress are prevalent among pregnant women
with mood and anxiety disorders. BioMed Central Pregnancy and Childbirth,
12(1), 104.
Rade, C. B., Desmarais, S. L., Van Dorn, R. A., Lutnick, A., Kral, A. H., & Lorvick, J.
(2015). Mental health correlates of drug treatment among women who use
methamphetamine. American Journal on Addictions, 24(7), 646-653. doi:
10.1111/ajad.12279
Rehm, J., Üstün, T. B., Saxena, S., Nelson, C. B., Chatterji, S., Ivis, F., & Adlaf, E.
(1999). On the development and psychometric testing of the WHO screening
instrument to assess disablement in the general population. International Journal
of Methods in Psychiatric Research, 8(2), 110-122.
Riesenberg, L. A., & Justice, E. M. (2014). Conducting a successful systematic review of
the literature, part 2. Nursing2016, 44(6), 23-26.
Roberson, E. K., Hurwitz, E. L., Li, D., Cooney, R. V., Katz, A. R., & Collier, A. C.
(2016). Depression, anxiety, and pharmacotherapy around the time of pregnancy
in Hawaii. International Journal of Behavioral Medicine, 23(4), 515-526.
Rosen, D., Tolman, R. M., & Warner, L. A. (2004). Low-income women's use of
substance abuse and mental health services. Journal of Health Care for the Poor
and Underserved, 15(2), 206-219.
Rossen, L., Hutchinson, D., Wilson, J., Burns, L., C, A. O., Allsop, S., . . . Mattick, R. P.
(2016). Predictors of postnatal mother-infant bonding: The role of antenatal

173

bonding, maternal substance use and mental health. Archives of Women's Mental
Health, 19(4), 609-622. doi: 10.1007/s00737-016-0602-z
Salganicoff, A., Ranji, U., Beamesderfer, A., & Jurani, N. (2014). Women and health
care in the early years of the Affordable Care Act. Retrieved from
https://kaiserfamilyfoundation.files.wordpress.com/2014/05/8590-women-andhealth-care-in-the-early-years-of-the-affordable-care-act.pdf
Shartzer, A., Garro, N., Pellegrini, C., & Long, S. (2015). Changes in insurance
coverage, access to care, and health care affordability for women of childbearing
age. Retrieved from http://hrms.urban.org/briefs/Changes-in-Insurance-CoverageAccess-to-Care-and-Health-Care-Affordability-for-Women-of-ChildbearingAge.pdf
Smith, M. V., Shao, L., Howell, H., Wang, H., Poschman, K., & Yonkers, K. A. (2009).
Success of mental health referral among pregnant and postpartum women with
psychiatric distress. General Hospital Psychiatry, 31(2), 155-162. doi:
10.1016/j.genhosppsych.2008.10.002
Snowden, L. R. (2001). Barriers to effective mental health services for African
Americans. Mental Health Services Research, 3(4), 181-187.
Snowden, L. R. (2012). Health and mental health policies' role in better understanding
and closing African American-White American disparities in treatment access and
quality of care. American Psychologist, 67(7), 524-531. doi: 10.1037/a0030054
Song, D., Sands, R. G., & Wong, Y. L. (2004). Utilization of mental health services by
low-income pregnant and postpartum women on medical assistance. Women
Health, 39(1), 1-24. doi: 10.1300/J013v39n01_01

174

Steverson, J. W., & Rieckmann, T. (2009). Legislating for the provision of
comprehensive substance abuse treatment programs for pregnant and mothering
women. Duke Journal of Gender Law and Policy, 16, 315.
Substance Abuse and Mental Health Services Administration. (2010). Reliability of Key
Measures in the National Survey on Drug Use and Health (Office of Applied
Studies, Methodology Series M-8, HHS Publication No. SMA 09-4425).
Rockville, MD: Substance Abuse and Mental Health Services Administration.
Substance Abuse and Mental Health Services Administration. (2011a). Addressing the
needs of women and girls: Developing core competencies for mental health and
substance abuse service professionals. Retrieved from
https://store.samhsa.gov/shin/content/SMA11-4657/SMA11-4657.pdf
Substance Abuse and Mental Health Services Administration. (2011b). National Survey
of Substance Abuse Treatment Services (N-SSATS): 2010. Data on Substance
Abuse Treatment Facilities. Retrieved from
https://wwwdasis.samhsa.gov/10nssats/NSSATS2010Web.pdf
Substance Abuse and Mental Health Services Administration. (2013). Trends in
substances of abuse among pregnant women and women of childbearing age in
treatment. Retrieved from http://www.samhsa.gov/data/sites/default/files/spot110trends-pregnant-women-2013.pdf
Substance Abuse and Mental Health Services Administration. (2014a). Projections of
National Expenditures for Treatment of Mental and Substance Use Disorders,
2010–2020. Retrieved from http://store.samhsa.gov/shin/content/SMA144883/SMA14-4883.pdf

175

Substance Abuse and Mental Health Services Administration. (2014b). Results from the
2013 National Survey on Drug Use and Health: Summary of national findings.
Retrieved from
http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/
Web/NSDUHresults2013.pdf
Substance Abuse and Mental Health Services Administration. (2014c). SAMHSA’s
concept of trauma and guidance for a trauma-informed approach. Retrieved from
http://store.samhsa.gov/shin/content/SMA14-4884/SMA14-4884.pdf
Substance Abuse and Mental Health Services Administration. (2015). National Survey of
Substance Abuse Treatment Services (N-SSATS): 2014. Data on substance abuse
treatment facilities. Retrieved from
https://wwwdasis.samhsa.gov/dasis2/nssats/2014_nssats_rpt.pdf
Substance Abuse and Mental Health Services Administration, Center for Behavioral
Health Statistics and Quality. (2017). Treatment Episode Data Set -Admissions
(TEDS-A) Series. Retrieved from
https://www.icpsr.umich.edu/icpsrweb/ICPSR/series/56
Terplan, M., Longinaker, N., & Appel, L. (2015). Women-centered drug treatment
services and need in the United States, 2002–2009. Journal Information, 105(11).
Terplan, M., McNamara, E. J., & Chisolm, M. S. (2012). Pregnant and non-pregnant
women with substance use disorders: The gap between treatment need and
receipt. Journal of Addictive Diseases, 31(4), 342-349. doi:
10.1080/10550887.2012.735566

176

Terplan, M., Smith, E. J., Kozloski, M. J., & Pollack, H. A. (2010). "Compassionate
coercion": Factors associated with court-mandated drug and alcohol treatment in
pregnancy 1994-2005. Journal of Addiction Medicine, 4(3), 147-152. doi:
10.1097/ADM.0b013e3181b562dc
Thoemmes, F. (2012). Propensity Score Matching in SPSS [Computer software].
Retrieved from https://sourceforge.net/projects/psmspss/
Thombs, B. D., Arthurs, E., Coronado-Montoya, S., Roseman, M., Delisle, V. C.,
Leavens, A., . . . Ciofani, L. (2014). Depression screening and patient outcomes in
pregnancy or postpartum: A systematic review. Journal of Psychosomatic
Research, 76(6), 433-446.
Toh, S., Li, Q., Cheetham, T. C., Cooper, W. O., Davis, R. L., Dublin, S., . . . Andrade, S.
E. (2013). Prevalence and trends in the use of antipsychotic medications during
pregnancy in the U.S., 2001-2007: A population-based study of 585,615
deliveries. Archives of Women's Mental Health, 16(2), 149-157. doi:
10.1007/s00737-013-0330-6
Tolia, V. N., Patrick, S. W., Bennett, M. M., Murthy, K., Sousa, J., Smith, P. B., . . .
Spitzer, A. R. (2015). Increasing incidence of the neonatal abstinence syndrome
in US neonatal ICUs. New England Journal of Medicine, 372(22), 2118-2126.
Tuchman, E. (2010). Women and addiction: The importance of gender issues in
substance abuse research. Journal of Addictive Diseases, 29(2), 127-138.
Unites States Department of Health and Human Services. (2003). Rural mental health in
the WICHE West: Meeting workforce demands through regional partnership.
Retrieved from http://ruralhealth.hrsa.gov/pub/WicheMH.asp#Ib.

177

United States Department of Health and Human Services. (2009). Actions steps for
improving women’s mental health. Retrieved from
https://store.samhsa.gov/shin/content/OWH09-PROFESSIONAL/OWH09PROFESSIONAL.pdf
United States Department of Health and Human Services, Substance Abuse and Mental
Health Services Administration, Office of Applied Studies. (2013). 2012 National
Survey on Drug Use and Health: Public use file codebook. Rockville, MD:
Substance Abuse and Mental Health Services Administration.
United States Department of Health and Human Services, Substance Abuse and Mental
Health Services Administration, Office of Applied Studies. (2014a). 2008
National Survey on Drug Use and Health: Public use file codebook. Rockville,
MD: Substance Abuse and Mental Health Services Administration.
United States Department of Health and Human Services, Substance Abuse and Mental
Health Services Administration, Office of Applied Studies. (2014b). 2009
National Survey on Drug Use and Health: Public use file codebook. Rockville,
MD: Substance Abuse and Mental Health Services Administration.
United States Department of Health and Human Services, Substance Abuse and Mental
Health Services Administration, Office of Applied Studies. (2014c). 2010
National Survey on Drug Use and Health: Public use file codebook. Rockville,
MD: Substance Abuse and Mental Health Services Administration.
United States Department of Health and Human Services, Substance Abuse and Mental
Health Services Administration, Office of Applied Studies. (2014d). 2011

178

National Survey on Drug Use and Health: Public use file codebook. Rockville,
MD: Substance Abuse and Mental Health Services Administration.
United States Department of Health and Human Services, Substance Abuse and Mental
Health Services Administration, Office of Applied Studies. (2014e). 2013
National Survey on Drug Use and Health: Public use file codebook. Rockville,
MD: Substance Abuse and Mental Health Services Administration.
United States Department of Health and Human Services, Substance Abuse and Mental
Health Services Administration, Office of Applied Studies. (2015). 2014 National
Survey on Drug Use and Health: Public use file codebook. Rockville, MD:
Substance Abuse and Mental Health Services Administration.
United States Department of Justice, National Drug Intelligence center. (2011). National
drug threat assessment. Retrieved from
https://www.justice.gov/archive/ndic/pubs44/44849/44849p.pdf
van der Zee-van den Berg, A. I., Boere-Boonekamp, M. M., IJzerman, M.J., HaasnootSmallegange, R. M., & Reijneveld, S. A. (2017). Screening for postpartum
depression in well-baby care settings: A systematic review. Maternal and Child
Health Journal, 21(1), 9-20. doi: 10.1007/s10995-016-2088-8
Vesga-Lopez, O., Blanco, C., Keyes, K., Olfson, M., Grant, B. F., & Hasin, D. S. (2008).
Psychiatric disorders in pregnant and postpartum women in the United States.
Archives of General Psychiatry, 65(7), 805-815. doi: 10.1001/archpsyc.65.7.805
Vittinghoff, E., Glidden, D., Shiboski, S., & McCulloch, C. (2012). Regression methods
in biostatistics: Linear, logistic, survival, and repeated measures models (2nd
ed.). New York: Springer.

179

Walton-Moss, B., & McCaul, M. E. (2006). Factors associated with lifetime history of
drug treatment among substance dependent women. Addictive Behaviors, 31(2),
246-253. doi: 10.1016/j.addbeh.2005.05.006
Weinreb, L., Byatt, N., Moore Simas, T. A., Tenner, K., & Savageau, J. A. (2014). What
happens to mental health treatment during pregnancy? Women's experience with
prescribing providers. Psychiatric Quarterly, 85(3), 349-355. doi:
10.1007/s11126-014-9293-7
Wendell, A. D. (2013). Overview and epidemiology of substance abuse in pregnancy.
Clinical Obstetrics and Gynecology, 56(1), 91-96. doi:
10.1097/GRF.0b013e31827feeb9
World Health Organization. (2014). Guidelines for the identification and management of
substance use and substance use disorders in pregnancy. Retrieved from
http://apps.who.int/iris/bitstream/10665/107130/1/9789241548731_eng.pdf
Witt, W. P., DeLeire, T., Hagen, E. W., Wichmann, M. A., Wisk, L. E., Spear, H. A., . . .
Hampton, J. (2010). The prevalence and determinants of antepartum mental
health problems among women in the USA: A nationally representative
population-based study. Archives of Women's Mental Health, 13(5), 425-437.
Wu, J., & Davis-Ajami, M. L. (2014). Antidepressant treatment persistence in lowincome, insured pregnant women. Journal of Managed Care Pharmacy, 20(6),
631-637.
Yamamoto, A., McCormick, M. C., & Burris, H. H. (2015). Disparities in antidepressant
use in pregnancy. Journal of Perinatology, 35(4), 246-251.

180

Yonkers, K. A., Wisner, K. L., Stewart, D. E., Oberlander, T. F., Dell, D. L., Stotland, N.,
. . . Lockwood, C. (2009). The management of depression during pregnancy: A
report from the American Psychiatric Association and the American College of
Obstetricians and Gynecologists. General Hospital Psychiatry, 31(5), 403-413.

181

CURRICULUM VITAE
Taghreed N. Salameh, MSN, RN, PhD Candidate
GENERAL INFORMATION
OFFICE:

Research Office/School of
Nursing
555 South Floyd Street
University of Louisville
Louisville, KY 40202

PHONE:

(502) 852-5129

FAX:

(502) 852-0704

E-mail:

tnsala02@louisville.edu
tagsalameh192@gmail.com

Jordan RN License #8040
************************************************************************
EDUCATION
Date

Degree or Course

Institution

1999-2003

BS in Nursing

The Hashemite University, Jordan

2004-2006

MSN/Maternal-newborn
Nursing

Jordan University of Science and
Technology, Jordan

PROFESSIONAL EXPERIENCE
Date

Title

Institution

2003–2004

Staff Nurse/CCU

Islamic Hospital, Jordan

1/6/–
10/3/2004

Clinical Instructor

The Hashemite University, Jordan

ACADEMIC APPOINTMENTS
Date

Title

Institution

2006-2008

Teaching & Research
Assistant

Maternal, Child and Family Department,
Hashemite University, Jordan

182

2008-2011

Full-time Lecturer

Maternal, Child and Family Department,
Hashemite University, Jordan

2011-2014

Full-time Lecturer

Nursing Department, Taif University,
Saudi Arabia

HONORS AND AWARDS
2003

Academic Excellence Honor Award by Princess Mona Al-Hussein,
Jordan

2004-2006

Full scholarship to Jordan University of Science and Technology/ MSN
Degree

2006

Academic Excellence Honor Award by Jordan University of Science and
Technology, Jordan

2015

Invitation for lifetime membership into Tau Sigma National Honor
Society

2015

Graduate Student Poster Award for Research!Louisville.
Salameh, T., & Smith, S. (2015, October). Maternal-Preterm infant
attachment in the NICU: A concept clarification. Poster presentation,
Research!Louisville, Louisville, KY, USA

2016

Top Ten Students Poster Award for 2016 Southern Nursing Research
Society (2nd place).
Salameh, T., Oweis, A., & Amarneh, B. (2016, February). Predictors of
postpartum depression in Jordanian mothers. Poster presentation,
Southern Nursing Research Society, Williamsburg, Virginia, USA

2016

Invitation for a lifetime membership into Golden Key International
Honor Society

RESEARCH AND CREATIVE PRODUCTIVITY
Funded Research Projects
1. Integration of Family Centered Care in NICU in Jordan (Co-investigator with
Mohammad Metleq, PI), Hashemite University, 2011-2013
2. Jordanian Parents Lived Experience of NICU: Phenomenological Study (Coinvestigator with Jamila Abudhail, PI), Hashemite University, 2011-2013
3. Impact of Psychosocial Status and Disease Knowledge on Deferoxamine Adherence
among Thalassemia Major Adolescents (Co-investigator with Manal Kloub, PI),
Hashemite University, 2010-2012
4. Impact of Educational Program on Protein Balance among Hemodialysis Patients
(Co-investigator with Mageda Mansour, PI), Taif University, 2013-2014

183

Peer-reviewed Publications
Al-Kloub, M.I., Salameh, T.N., & Froelicher, E.S. (2014). Nursing students’ evaluation
of problem based learning and the impact of culture on the learning process and
outcomes: A pilot project. Nurse Education in Practice, 14(2), 142-147.
Al-Kloub, M.I., Salameh, T.N., & Froelicher, E.S. (2014). Impact of psychosocial status
and disease knowledge on Deferoxamine adherence among Thalassemia major
adolescents. International Journal of Nursing Practice, 20(3), 265-274.
Mansour, M., Yousef, H., Salameh, T., & Yaseen, R. (2014). Impact of education
program on protein balance among hemodialysis patients. World Journal of Medical
Sciences, 11(1), 69-77.
Al-Motlaq, M., Abuidhail, J., Salameh, T., & Awwad, W. (2016). Development and
validation of an instrument to assess the implementation of family-centered care in
traditional open bay Neonatal Intensive Care Units. Early Child Development and
Care, [Published Online]. doi.http://dx.doi.org/10.1080/03004430.2016.1154050
Abuidhail, J., Al-Motlaq, M., Mrayan, L., & Salameh, T. (2017). The lived experience of
Jordanian parents in a neonatal intensive care unit: A phenomenological study. The
Journal of Nursing Research, 25(2), 156-162.
Presentations
Salameh, T., & Smith, S. (2015, October). Maternal-Preterm infant attachment in the
NICU: A concept clarification. Poster presentation, Research!Louisville, Louisville,
KY, USA
Salameh, T., Oweis, A., & Amarneh, B. (2016, February). Predictors of postpartum
depression in Jordanian mothers. Poster presentation, Southern Nursing Research
Society, Williamsburg, Virginia, USA
Salameh, T., Hall, L., & Crawford, T. (2017, February 24). Determinants of parenting
stress in Jordanian mothers. Southern Nursing Research Society. Dallas, TX.
(Presenter)
TEACHING AND ADVISING
Courses Taught at Taif University





Pediatric Nursing (Theory & Clinical)
Maternity Nursing (Clinical)
Community Nursing (Clinical)
Nursing Administration (Clinical)

Courses Taught at the Hashemite University


Nursing Ethics
184






Pediatric Nursing (Theory & Clinical)
Maternity Nursing (Theory & Clinical)
Fundamental of Nursing (Clinical)
Health Assessment (Clinical)
UNIVERSITY SERVICE

Hashemite University
2006-2011

Academic Advising Committee

2009-2011

Simulation Lab Committee

Taif University
2011-2014

Academic Advising Committee

2011-2014

Simulation Lab Committee

2011-2013

File Subject Committee

2013-2014

Head Deputy of Quality Unit

PROFESSIONAL ACTIVITY AND PUBLIC SERVICE
Memberships
Jordanian Nurses and Midwives Council
Southern Nursing Research Society
Sigma Theta Tau International Honor Society
Tau Sigma National Honor Society
Golden Key International Honor Society
Conferences /Workshops/Training Courses
Training course of SPSS for teaching staff, 2012, Taif University (Coordinator)
Innovation in Teaching Health Sciences: From Words to Action, 2012, Purdue University
& Taif University
Adobe Photoshop, 2012, Training and Continuous Education/Taif University
Symposium on International Nurses’ Day/Closing the Gap from Evidence to Action,
2012 (Speaker: Role of National Nurses' Association)
Nursing Process Application: From Theory to Practice, 2013, Taif University, (Speaker
& Facilitator)
Nursing Management Workshop, 2014, Taif University (Facilitator)

185

Public Service
2002

Volunteer at Islamic Hospital/ Critical Care Unit and Medical Surgical Floor
from April 1 to Aug

2007

Volunteer at Maternal and Child Health Center-Zarqa-UNRWA (Education for
staff)
International Diabetes Day Education and Prevention (Education at Secondary
School in Taif)

2011
2012

First Aid Training Course--Taif (Trainer)

2013
2013

The Current Paradigm of Diabetes Prevention and Education: A Vital
Investment (Facilitator)
Volunteer at Maternal and Child Health Center-Taif (Education for staff)

2014

First Aid Training Course--Taif (Trainer)

2014

A promise is a promise: Stop violence against women--Taif (Facilitator)

186

